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SUMMARY 
(Uhe stress response is an integral part of an adaptive biological system for 
homeostasis and survival; however, the negative impact of persistent and prolonged 
stress initiates,as well as accelerates psychosomatic disease processes including 
depression. 
Physical and psychological stress also alters the pro-oxidant:antioxidant 
balance, increasing oxidative stress and consequently damaging cellular 
macromolecules (lipids, proteins and DNA). Reactive oxygen species (ROS)-
mediated damage to proteins can lead to a loss of both free radical scavenging 
enzyme activity and structural integrity, resulting in compromised endogenous 
antioxidant defense mechanisms and cell membrane structure, respectively. 
Oxidative homeostasis is a major determinant of the ability to cope with stress, 
whereas deficits in the antioxidant defenses and the resultant oxidative damage play 
a critical contributory role in stress-induced pathophysiology and mediate the 
associations between psychiatric and non-psychiatric conditions, particularly cancers 
and cardiovascular disease. Clinical investigators have also found increased 
oxidative stress in major depression, as evidenced by defective antioxidant defenses 
in conjunction with enhanced lipid peroxidation in these patients. 
Prolonged exposure to glucocorticoid (GC) stress hormones, the central 
effectors of the stress response, induces depression and contributes towards chronic 
disease processes. They have damaging consequences, especially in the brain, 
evidenced by neuronal loss and neurodegeneration, features which are linked to an 
increase in the generation of ROS. However, less is known regarding the direct 
contribution of stress hormones to oxidative damage, and the consequent response of 
the endogenous antioxidant defenses towards chronic exposure to GCs. 
Despite the association of stress disorders with oxidative stress, the effect of 
antidepressant drugs on in vivo antioxidant status has been relatively imderstudied, 
although they are widely prescribed for the treatment of stress and stress-related 
depression and anxiety. In vitro studies implicate the important neuroprotective 
antioxidant enzyme superoxide dismutase (SOD) as a target of some antidepressant 
drugs. Though several antioxidant mechanisms serve to counterbalance the potential 
deleterious effects of ROS, the protective effects of antidepressants on these crucial 
and inter-related antioxidant systems have not been well investigated. Discrepancies 
exist among the few available clinical data. 
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Given this, an attempt was made in the present study towards a broad analysis 
of different therapeutic agents in terms of their antioxidant potential. Standard known 
herbal therapeutic agents having anti-stress and antioxidant properties were also used 
to compare the antioxidant potential of other less-studied herbal and anti-stress drugs. 
Studies examining an association between the pro-oxidant effects of chronic stress and 
stress-induced behavioral aberrations are also lacking. This was investigated by 
studying the modulation of restraint-induced oxidative stress and a simultaneous 
restoration of behavioural deficits using antidepressants. 
Dietary constituents (like vitamin B12, folic acid, selenium, zinc, essential 
fatty acids, etc.) and nutritional status are found to play important role in mental 
health and normal brain function including enzymatic activity, cellular and oxidative 
processes, maintenance of neuronal tissue, and synthesis of neurotransmitters and 
catecholamines. Recognizing the importance of nutritional status in stress and 
depression, the present study also attempted to investigate the role of pyridoxine 
(vitamin B6) and folic acid (vitamin B9) in reducing or reversing restraint stress-
induced oxidative damage, as compared to the well-characterized antioxidant 
potential of ascorbic acid (vitamin C). In the concluding portion of the thesis, 
possible influence of above micronutrients on behavioural parameters of stress and 
depression was also investigated. Behaviour was assessed in the forced swimming 
test, an animal model of depression, which is used to screen the antidepressant effect 
of drugs and also in determining the development of a depressive phenotype in 
rodents after exposure to other stressors. Moreover, weekly sucrose preference tests 
were also carried out as a model of stress-induced anhedonia with monitoring of 
body weight as an index of stress. 
Restraint or immobilization combines both emotional and physical 
components of stress, without any painful stimulation, and is an animal paradigm of 
psychological stress, major depression and post-traumatic stress disorder. Restraint 
stress, besides being widely employed to exert oxidative damage, is also used 
extensively to study the effects of drugs in stress-related pathology in animals. It 
was thus elected as the animal model in context of the study design followed 
throughout the present work. A wide range of key in vivo endogenous antioxidant 
defense components, comprising the primary and secondary free radical scavenging 
enzymes, superoxide dismutase (SOD), catalase (CAT), glutathione S-transferase 
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(GST) and glutathione reductase (GR), as well as non-enzymatic antioxidants, 
glutathione (GSH), glucose and uric acid, were studied. Oxidative stress markers, 
malondialdehyde levels (lipid peroxidation product) and protein carbonyl contents 
were also determined. To describe the physiological state of peripheral target organs 
of stress like liver and heart, relevant marker enzymes were evaluated, for example, 
glutamate oxaloacetate transaminase (GOT), glutamate pyruvate transaminase 
(GPT), alkaline phosphatase (ALP) and lactate dehydrogenase (LDH), both in 
tissues and circulation. Membrane damage exerted by the production of free radicals 
in response to stress is characterized by a rise in these marker enzymes. 
Chronic subjection of rats to uncontrollable physical, emotional and 
psychological stress exerted by restraint was found to decrease the protective 
antioxidant defenses, leading to oxidative stress and damage. The activities of SOD, 
CAT, GST and GR were significantly reduced in the brain, liver, heart and serum of 
restraint stressed animals in comparison to unstressed control animals. GSH in 
tissues, and uric acid as well as glucose in circulation, were also markedly 
decreased. In consequence, oxidative stress markers were found elevated, as 
evidenced by a significant rise in malondialdehyde (MDA), the product of lipid 
peroxidation, and increase in protein carbonyl contents. Loss of structural integrity 
at the cellular level due to stress-induced oxidative damage was demonstrated by 
significant increases in the tissue and serum levels of intracellular marker enzymes 
of the liver and heart, such as GOT, GPT, ALP and LDH. 
The impact of repetitive prolonged stress on the development of behavioural 
abnormalities characterizing depression-like symptoms was also demonstrated. 
Restraint stressed animals subjected to the forced swimming test manifested 
behavioural passivity and despair as evidenced by reduced time spent swimming and 
consequent increase in the time spent immobile, as compared to unstressed controls 
which displayed more active escape-oriented swimming behaviour. Restraint stress 
also produced a hedonic deficit in rodents as evidenced by a diminished preference 
for sucrose solution in contrast to controls which responded adequately when 
presented with this rewarding stimulus. Behavioural anomalies were associated with 
loss in total body weight in stressed animals over the experimental period of 21 
days. The induction of experimental depression and reduction in weight was found 
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associated with reduced antioxidant defenses leading to a prominent increase in 
oxidative stress and damage. 
The thesis is organized into five sections. Section 1 investigates the effect of 
exogenously administered corticosterone in chronic doses on the antioxidant defense 
system of rats, in isolation of other applied stressors. Chronic corticosterone 
administration was foimd to cause dose-dependent oxidative damage by significantly 
decreasing endogenous antioxidant defenses, both enzymatic and non-enzymatic, in 
the brain and other vulnerable organs like liver and heart, similar to a pro-oxidant 
status produced by chronic restraint stress. Thus, a corticosterone-induced deficit in 
overall antioxidant status strongly implicates oxidative damage as a putative 
mechanism for stress-induced psychopathological disorders like depression as well 
as general somatic diseases, and supports the ciurent clinical reports of dysregulated 
oxidant homeostasis in stress-induced depression. Given this, the following studies 
investigated the modulation of oxidative biology in restraint stress as a possible 
target of different therapeutic agents including herbal drugs, broad spectrum 
standard antidepressants and dietary micronutrients. Section 2: the anti-stress 
therapeutic efficacy of Withania somnifera and Raitwolfia serpentina were evaluated 
in terms of antioxidant parameters. Both the herbs were found to be almost equally 
effective in restoring restraint stress-induced oxidative damage and loss in body 
weight. Therefore, in general, protection from oxidative stress during chronic stress 
may possibly avert the precipitation of stress-induced degenerative diseases 
affecting various organs and their physiological functions. Section 3 investigates the 
antioxidant potential of fluoxetine (selective serotonin reuptake inhibitor) in 
comparison to Curcuma longa, a well known antioxidant Fluoxetine was foimd to 
inhibit the effects of stress by enhancing the activities of SOD, CAT, GST and GR, 
thereby replenishing GSH levels as well. Uric acid and glucose concentrations were 
also increased, while the downstream effects of oxidative stress, lipid peroxidation 
and protein oxidation, were markedly reduced. Fluoxetine treatment could exert 
sufficient antioxidant activity in vivo to reverse stress-induced oxidative damage 
with an efficacy at par witli Curcuma longa. This finding further demonstrated the 
importance of antioxidant status in stress disorders and provided a strong basis to 
evaluate other classes of antidepressant drugs in terms of their antioxidant/pro-
oxidant ability. Section 4 deals with a comparative evaluation of standard 
antidepressants from different classes with respect to their antioxidant potential. 
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Apart from normalizing restraint stress-evoked behavioural aberrations, the tricyclic 
antidepressant, imipramine, and the newer dual reuptake inhibitor, venlafaxine, 
inhibited stress-induced alterations in the antioxidant defenses and oxidative stress 
markers. Since treatment with these drugs was found to ameliorate stress-induced 
oxidative damage in association with abolishing the depressive symptoms, the 
present data thus demonstrated that improvement in cellular antioxidant status may 
be an important mechanism underlying the protective pharmacological effects for 
multiple classes of antidepressants observed clinically in the treatment of various 
stress disorders. Section 5 deals with an analysis of dietary micronutrients as 
prospective anti-stress antioxidative therapeutic agents. Treatment with pyridoxine 
and folic acid exerted significant antioxidant action which had a beneficial impact 
during stress by preventing oxidative damage, with an efficacy similar to ascorbic 
acid. The finding that treatment with pyridoxine, folic acid and ascorbic acid, 
attenuated both stress-induced behavioral suppression as well as oxidative stress in a 
consistent manner suggested that alteration of pro-oxidant:antioxidant balance might 
be associated to the stress-induced neurobehavioural changes. Besides preventing 
stress-induced oxidative damage to the brain, all the drugs investigated also had a 
significant hepatoprotective and cardioprotective action, evidenced by normalization 
of tissue and serum levels of marker enzymes. They also inhibited loss of body 
weight in restraint stressed animals. 
The study strengthens the detrimental role of oxidative damage diiring 
prolonged repetitive physical, emotional and psychological stress and demonstrates the 
opposing actions of various anti-stress therapeutic interventions. The sections 
constituting this thesis illustrate a consistent and recurring observation for the role of 
endogenous antioxidants in response to pharmacological modulation by multiple classes 
of antidepressants, both standard as well as herbal. The biochemical findings are well 
authenticated by histological examinations of tissues as detailed in the thesis. 
To conclude, the close integration of antioxidant and antidepressant activities 
of these vitamins and the antidepressant agents investigated endorses the view that 
modulation of endogenous antioxidant systems to balance oxidant status has 
potential therapeutic benefit as a possible stress-management approach in all kinds 
of stress-induced psychiatric and non-psychiatric conditions. 
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INTRODUCTION 
>tress is defined as a state of threatened homeostasis; the organism reacts 
to it with an array of adaptive responses to preserve its internal equilibrium. The 
paradox of stress lies in the simultaneity of its adaptive nature and its possible 
maladaptive consequences. While the acute stress response is essential for 
maintenance of homeostasis and survival, the negative impact of persistent and 
prolonged stress eventually leads to the onset of disease. It is well-documented that 
chronic stress can also induce several psychiatric conditions, including depression. 
Therefore, an essential component of adaptation is the protection of the organism 
against overreaction of the system. 
Oxidative homeostasis is a major determinant of the stress response (Pardon, 
2007). Emerging evidence supports an early and major role of mechanisms able to 
cope with oxidative stress and to protect against oxidative damage in the response to 
stress. Physical and psychological stress alters the pro-oxidant:antioxidant balance, 
adding to the oxidant burden associated with normal aerobic metabolism, and 
consequently damaging cellular macromolecules (lipids, proteins and DNA) (Liu 
and Mori, 1999). Deficits in the antioxidant defenses and the resultant oxidative 
damage play a critical contributory role in stress-induced pathophysiology and 
mediate the associations between psychiatric and non-psychiatric conditions, 
particularly cancers and cardiovascular disease. In stress disorders, oxidative stress 
initiates or aggravates various routes of damage including mitochondrial 
dysfunction, disruption of energy pathways, impairment of neurogenesis and 
stimulation of signalling events for apoptosis. These processes make a significant 
contribution towards the resultant disease pathophysiology, as evidenced by 
morphological changes in the brain characteristic in stress-induced depression. A 
growing number of clinical investigators have also found increased oxidative stress 
to occur in major depression, as evidenced by defective antioxidant defenses in 
conjunction with enhanced lipid peroxidation in these patients. 
Glucocorticoid stress hormones (GCs; corticosterone in rodents, Cortisol in 
humans) are the central effectors of the stress response and promote adaptation to 
acute stress. Conversely, persistently elevated levels of GCs during chronic stress 
have damaging consequences, especially in the brain, evidenced by neuronal loss 
and neurodegeneration. These features have been linked to an increase in the 
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generation of reactive oxygen species (ROS). However, less is known regarding the 
direct contribution of stress hormones to oxidative damage, and the consequent 
response of the endogenous antioxidant defenses towards chronic exposure to GCs. 
This was investigated in the initial part of this thesis by studying the effect of 
exogenously administered corticosterone in chronic doses on the antioxidant defense 
system, and comparing it with the pro-oxidant status present in rats submitted to 
restraint stress. Restraint or immobilization combines both emotional and physical 
components of stress, \\ithout any painful stimulation, and is an animal paradigm of 
psychological stress, major depression and post-traumatic stress disorder (Bremner 
et al., 1991; Singh et al., 1993). Robust increases in basal oxidative stress have been 
consistently reported by investigators using this model, besides neurotoxic damage. 
Restraint has been used extensively to study the impact of stress on disease process 
and the effects of drugs in stress-related pathology in animals (Glavin et al., 1994). It 
was thus elected as the animal model in context of the study design followed 
throughout the present work. 
A wide range of key in vivo endogenous antioxidant defense components, 
comprising the free radical scavenging enzymes, superoxide dismutase (SOD), 
catalase (CAT), glutathione S-transferase (GST) and glutathione reductase (GR), as 
well as non-enzymatic antioxidants, glutathione (GSH), glucose and uric acid, were 
studied. Oxidative stress markers, malondialdehyde levels (lipid peroxidation 
product) and protein carbonyl contents were also determined. To describe the 
physiological state of peripheral target organs of stress like liver and heart, relevant 
marker enzymes were evaluated, for example, glutamate oxaloacetate transaminase 
(GOT), glutamate pyruvate transaminase (GPT), alkaline phosphatase (ALP) and 
lactate dehydrogenase (LDH), both in tissues and circulation. Membrane damage 
exerted by the production of free radicals in response to stress is characterized by a 
rise in these marker enzymes. 
In spite of the connection between stress disorders and oxidative stress, the 
effect of antidepressant drugs on endogenous antioxidants has been relatively 
understudied, although they are widely prescribed for the treatment of stress and 
stress-related depression and anxiety. Recent in vitro studies implicate the important 
neuroprotective antioxidant enzyme SOD as a common target of some 
antidepressant drugs (Kolla et al., 2005). However, their effect on important 
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enzymes which function in conjunction with SOD, such as CAT, was not 
determined. In fact, several antioxidant mechanisms serve to counterbalance the 
potential deleterious effects of ROS; but the protective effects of antidepressants on 
these crucial and inter-related antioxidant systems have not been well investigated. 
Discrepancies exist among the few available clinical data. Accordingly, the present 
study examined the in vivo antioxidant modulating effects of antidepressants in 
restraint stress-induced oxidative damage, as a possible component underlying their 
therapeutic actions observed clinically in the treatment of various stress disorders. 
Standard known herbal therapeutic agents having anti-stress and antioxidant 
properties were also used to compare the antioxidant potential of other less-studied 
herbal and anti-stress drugs. Studies examining an association between the pro-
oxidant effects of chronic stress and stress-induced behavioral aberrations are also 
lacking. This was investigated by studying the modulation of restraint-induced 
oxidative stress and a simultaneous restoration of behavioural deficits using 
antidepressants. 
Dietary constituents (like vitamin B12, folic acid, selenium, zinc, essential 
fatty acids, etc.) and nutritional status are found to play important role in mental 
health and normal brain function including enzymatic activity, cellular and 
oxidative processes, maintenance of neuronal tissue, and synthesis of 
neurotransmitters and catecholamines (Bodnar and Wisner, 2005). Recognizing the 
importance of nutritional status in stress and depression, the present study also 
attempted to investigate the role of pyridoxine (vitamin B6) and folic acid (vitamin 
39) in reducing or reversing restraint stress-induced oxidative damage, as compared 
to the well-characterized antioxidant potential of ascorbic acid (vitamin C). In the 
concluding portion of the thesis, possible influence of above micronutrients on 
behavioural parameters of stress and depression was also investigated. Behaviour 
was assessed in the forced swimming test, an animal model of depression, which is 
used to screen the antidepressant effect of drugs and also in determining the 
development of a depressive phenotype in rodents after exposure to other stressors. 
Moreover, weekly sucrose preference tests were also carried out as a model of 
stress-induced anhedonia with monitoring of body weight as an index of stress. 
IV 
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The thesis is organized into five sections as follows: 
Section 1: A study of dose-dependent oxidative damage by exogenous 
corticosterone 
Section 2: An evaluation of anti-stress therapeutic efficacy of Withania somnifera 
and Rauwolfia serpentina herbs in terms of antioxidant parameters 
Section 3: An investigation of the antioxidant potential of fluoxetine in comparison 
to Curcuma longa 
Section 4: A comparative evaluation of different standard antidepressants with 
respect to their antioxidant potential 
• Imipramine (tricyclic antidepressant) 
• Venlafaxine (new dual serotonin/norepinephrine reuptake inhibitor) 
• Fluoxetine (selective serotonin reuptake inhibitor) 
Section 5: An analysis of dietary micronutrients as prospective anti-stress 
antioxidative therapeutic agents 
• Vitamin B6; pyridoxine 
• Vitamin B9; folic acid 
• Vitamin C; ascorbic acid 
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>tability in the internal environment of a living organism is the result of a 
complex equilibrium, which is constantly challenged by intrinsic or extrinsic forces, 
physical or psychological stimuli, known as stressors, which can endanger the 
survival of an individual. This tendency towards stability is called homeostasis 
(Caimon, 1932), and therefore stress is defined as a state of threatened homeostasis, 
to which the organism, to preserve its internal equilibrium, reacts with an array of 
adaptive responses (Chrousos and Gold, 1992; Akil and Morano, 1995). 
The stressors can be grouped into three broad categories: (a) psychological 
stressors based on a learned response to the threat of an impending adverse condition 
(fear, anxiety, exposure to a novel or uncontrollable envirormient); (b) physical 
stimulus which have a strong psychological component (pain, foot shock, 
immobilization/restraint); (c) stressors which challenge cardiovascular homeostasis 
(hemorrhage, exercise, heat exposure) (Van de Kar and Blair, 1999). 
The organism reacts to a stressor by mobilising energy stores in preparation 
for a response designed to efficiently terminate the stress. This response leads to 
central and peripheral changes coordinated by the central nervous system (Pardon, 
2007) and increases the probability of survival by improving the ability of the 
individual to adjust homeostasis. These synchronized responses, referred to as 
"stress responses," include alterations in behavior, autonomic function and the 
secretion of many hormones including adrenocorticotropin hormone and 
cortisol/corticosterone, adrenal catecholamines, oxytocin, prolactin and renin (Van 
de Kar and Blair, 1999). The stress response enables an organism to cope with 
potentially harmful or demanding stimuli and adapt to changes in its internal or 
external envirormient (McEwen and Sapolsky, 1995). 
Persistent stress can have maladaptive consequences on the body, 
particularly when stress responses are elicited too often or are inefficiently managed 
(McEwen, 1998; Korte et al., 2005). Chronic activation of this system due to 
interisive or prolonged exposure to stress, in combination with a perceived difficulty 
to cope with it, or even loss of controllability, will result in an impaired negative 
feed-back of the hypothalamus-pituitary-adrenal (HPA) axis, with the consequent 
increase of circulating Cortisol (Henry, 1992; Croes et al., 1993). Thus, an essential 
feature of adaptation is the protection of the organism against chronicity and 
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overreaction of the stress system, described as the general adaptation or stress 
syndrome (Selye, 1936, 1946), leading eventually to a spectrum of emotional and 
somatic diseases (Tsigos and Chrousos, 1994). 
1. Oxidant production during stress and the role of oxidative stress in 
the adaptive stress response 
Stress consumes energy and increases the metabolic rate, which is an 
important adaptive response to stress (Liu and Mori, 1999; Fehm et al., 2006). The 
high energy is provided by the release of glucocorticoids, neurotransmitters, 
oxidants and other mediators from the HPA axis and other systems (such as the 
sympathetic nervous system), stimulating catabolism, while simultaneously 
suppressing unessential anabolic processes, including growth, digestion, 
reproduction, and immime function (Liu and Mori, 1999). The inhibition of these 
vegetative functions allows the preservation of energy resources for efficient use by 
the effectors of the stress response (Chrousos and Gold, 1992). However, extended 
action of adaptive mechanisms has adverse effects on the body since so much energy 
is expended that not enough is left for other vital functions; this is a major factor 
contributing to the development of pathological conditions and the ageing process 
(Selye, 1976). Recent studies have associated oxidative stress with the adaptive 
stress response. A high metabolic rate during stress produces highly reactive free 
radicals (Figure A), which in excess (oxidative sfress) are chemically damaging and 
toxic to cells (Pardon, 2007). Chronic activation of the catabolic processes induced 
by stress may be ultimately destructive and damaging. Increased metabolism leads 
to an increased production of oxidants through nimierous pathways including the N-
methyl-D-aspartate receptors, monoamine oxidase activity and second messenger 
syntheses. The oxidants may ultimately act as stress responses or cause oxidative 
damage to cells (Liu and Mori, 1999). In addition, chronic exposure to the mediators 
of the stress response, such as catecholamines and glucocorticoids, has damaging 
effects, in which oxidative stress plays a major role (Simmons et al., 1991; P6rez-
Nievas et al, 2007). 
Accumulating evidence points to an early and major role of protective 
mechanisms against oxidative damage in response to stress (Parsons, 1995; Jazwinski, 
1996). This hypothesis initially origmated from studies on invertebrate models, 
the fruit-fly Drosophila melanogaster and the nematode Caenorhabditis elegans, 
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F^ure A. Excess free radicals from stress create imbalance and free radical pathology 
but several recent investigations on rodents also report an increase in oxidative 
mediators and associated damage to the brain (Liu et al., 1996; Madrigal et al, 2001, 
2003; Abidin et al., 2004; Zaidi and Banu, 2004; Lee et al., 2006) and other organs 
(Davydov and Shvets, 2003; Zaidi et al., 2005) after acute and chronic stress. 
Studies in animal models of stress have shown that chronic stress exposure causes 
alterations in oxidative status in body areas important to the stress response, such as 
the cardiopulmonary, nervous and muscle systems (Kaushik and Kaur, 2003; Sahin 
and Gumuslu, 2004). Marked changes were reported in erythrocyte antioxidant 
enzymes and lipid peroxidation levels of rats exposed to acute and chronic restraint 
stress (Sahin et al, 2004). Although different stress models were found to have 
different degrees of influence on enzymatic and non-enzymatic defense systems, 
protein oxidation and lipid peroxidation (Sahin and Gumuslii, 2004), however, 
increased oxidative stress has been consistently demonstrated to occur by the 
application of different stress procedures for variable durations of time. Rats 
subjected to 30 min cold-immobilization stress were found to have increased lipid 
peroxides and conjugated dienes in the liver, heart and stomach (Kovacs et al. 
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1996), whereas the study of Pajovic et al. (2005) in rats showed that 2 h exposure to 
cold or immobilization stress led to an increase in oxidative mediators in the brain. 
Emotional stress in rats induced by 24 h immobilization caused an increase in lipid 
peroxidation in different organs, such as the brain, liver and heart (Sosnovskii et al., 
1992; Sosnovskii and Kozlov, 1992). The potentiation of lipid peroxidation by stress 
may be due to insufficiency of the protective systems (Aydin et al., 2005) as 
depletion of antioxidants and antioxidant enzymes by stress have been observed in 
different tissues of rats (Al-Qirim et al., 2002; Zaidi et al., 2005). Thus experimental 
evidence strongly suggests that free radicals and imbalance in oxidative processes 
play an aberrant role in the mechanism of stress (Shaheen et al., 1993; Kovacs et al., 
1996; Olivenza et al., 2000). 
2. Role of oxidative processes in stress-induced disease 
Based on the experimental data of stress-associated oxidative damage it is 
evident that stress may add to the oxidant burden associated with normal aerobic 
metabolism and its consequent damage to cellular macromolecules (lipids, proteins 
and DNA) (Liu and Mori, 1999). Oxidative stress has been implicated in a large 
number of himian degenerative diseases affecting a wide variety of physiological 
functions, such as atherosclerosis, diabetes, ischemia/reperfusion injury, 
inflammatory diseases (rheiraiatoid arthritis, pancreatitis), cancer, neurological 
diseases, hypertension, ocular diseases (cataract, senile muscular degeneration), 
pulmonary diseases, and hematological diseases (Halliwell and Gutteridge, 1989; 
Maxwell, 1995; Opara, 2004). Aging and age-related loss of physiological fitness 
have also been attributed to the chronic effects of reactive oxygen species (ROS) on 
various biological macromolecules (Droge, 2003). 
Chronic exposure to stress alters the pro-oxidant:antioxidant balance, which 
might lead to the development of various human pathological states (Stojilkovic et 
al., 2005). By impairing antioxidant defenses, stress exerts a damaging influence on 
cellular functions, causing oxidative damage which is fundamental in many disease 
pathologies (Torres et al., 2004). Exposure to chronic stress has thus been found to 
be detrimental to health. Psychosocial stress and repeated chronic stress have been 
widely recognized as important triggers in the expression of various clinical 
syndromes, particularly anxiety and mood disorders (Post, 1992; Checkley, 1996). 
Stress, especially of a psychological nature, has long been associated with gastric 
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and duodenal ulcers, hypertension, cardiovascular and cerebrovascular diseases, 
cancer and aging (Cooper, 1984; Chrousos et al., 1995; Csermely, 1998). This 
progressive change in physiology, due to prolonged or repetitive stress, has been 
recently termed allostatic overload (McEwen and Wingfield, 2003). Thus, sustained 
adaptive responses may lead to pathophysiological changes produced by 
dysregulation of the stress syndrome. These changes could be perceived as different 
symptoms, or combinations of them, and may lead to a wide variety of disorders, 
including different psychosomatic diseases, chronic anxiety disorders, and 
depression. 
3. Oxygen homeostasis and oxidative stress 
Pro-oxidants are defined as endogenous or exogenous substances having the 
capacity to cause the oxidation of target molecules, either directly by abstraction of 
electrons, or indirectly through the production of highly reactive intermediate 
chemical entities (Cui et al., 2004). Free radicals represent a category of such 
entities whose reactivity is due to unpaired electrons in their atomic structure, and 
are capable of independent existence for very brief intervals of time (Halliwell, 
1997; Halliwell and Gutteridge, 1999). Reactive oxygen species (ROS) is a 
collective term for all reactive forms of oxygen, including both the radical and non-
radical species that take part in the initiation and/or propagation of radical chain 
reactions. Radicals derived from oxygen represent the most important class of 
radical species generated in living systems (Miller et al., 1990). 
ROS are formed as a normal product of aerobic metabolism and are integral 
for maintaining tissue oxygen homeostasis (Castro and Freeman, 2001). Since 
oxygen is a strong oxidant, it is impossible to avoid secondary oxidations not 
involved in physiological metabolism. Partial reduction of molecular oxygen, 
instead of the proteins of the respiratory chain, produces superoxide and various 
reactive oxidant intermediates, leading to secondary oxidations (Liu, 1997; Sorg, 
2004). 
When oxygen homeostasis is not maintained, the cellular enviromnent 
becomes oxidatively stressed (Seifried et al., 2007). Oxidative stress corresponds to 
an imbalance between the rate of oxidant production and their degradation (Sies, 
1991). As defined by Helmut Sies, oxidative stress is a process in which the natural 
balance between pro-oxidants and antioxidants is shifted toward the oxidant side to 
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cause biological damage (Sies, 1985). Approximately 1-3% of oxygen consumed by 
the body is converted into ROS (Sohal and Weindruch, 1996). Excess ROS can 
generate potentially damaging oxidative stress, thus they are kept in check or 
eliminated by endogenous cellular antioxidant mechanisms (McCord, 2000). 
i. Sources of ROS 
ROS can be generated by both endogenous and exogenous substances. 
Potential endogenous sources include mitochondria, microsomes (cytochrome P450 
metabolism), peroxisomes (enzymes mvolved in fatty acid metabolism), and 
inflanunatory cell activation (Castro and Freeman, 2001; Inoue et al., 2003; Klaunig 
and Kamendulis, 2004). Three of the major ROS — superoxide radical, hydrogen 
peroxide and hydroxyl radical — are normal metabolic byproducts generated 
continuously by mitochondria (Lopaczynski and Zeisel, 2004) and by flavoprotein 
oxidases such as xanthine oxidase which catalyzes the hydroxylation of purines to 
uric acid (Valko et al., 2004). 
Besides these physiological oxidations and their unavoidable secondary 
reactions, many dietary compounds are either oxidants by themselves or oxidant 
precursors (Sahu, 2002). ROS can be produced by multiple exogenous processes. 
Environmental agents such as non-genotoxic carcinogens can directly or indirectly 
induce ROS in cells. The induction of oxidative stress and damage also occurs 
following exposure to various xenobiotics such as chlorinated compounds, metal 
ions, different types of radiation and barbiturates (Klaunig et al., 1997). 
ii. Chemistry and biochemistry of ROS 
Molecular oxygen (dioxygen) has a imique electronic configuration and is 
itself a diradical containing two unpaired electrons. The intermediate steps of 
oxygen reduction to water in the electron transport chain, by the addition of four 
electrons, results in the formation of several hydrogen-containing ROS, such as 
hydroperoxyl radical, superoxide radical, hydrogen peroxide, and the hydroxyl 
radical (Cui et al., 2004). 
The addition of one electron to dioxygen forms the superoxide anion radical 
(02'~) (Miller et al., 1990), which is implicated in the pathophysiology of several 
diseases (Valko et al., 2004; Kovacic et al., 2005). In vivo, it is mainly produced by 
the electron transport chains in the mitochondria (Complexes I and III) and 
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microsomes (McCord and Ormar, 1993; Cadenas and Sies, 1998) through electron 
leakage, a phenomenon that increases with an increase in oxygen utilization. This is 
especially relevant in metabolic processes of the brain which utilize elevated 
quantities of oxygen (Reiter, 1995). Superoxide radicals are also formed by metal 
ion-dependent oxidation of epinephrine and norepinephrine, and enzymes such as 
tryptophane hydroxylase, indoleamine dioxygenase, and xanthine oxygenase. 
Superoxide and hydrogen peroxide are also enzymatically formed by NADPH 
oxidase in activated neutrophils or macrophages during inflammatory processes 
(Segal and Abo, 1993; Babior et al., 2002): 
NADPH+ 2O2 • NADP* + H* + 202" 
Generally speaking, all endogenous oxidases - enzymes that transfer two electrons 
from a substrate (AH2) to molecular oxygen - produce superoxide and hydrogen 
peroxide: 
oxidase 
AH2 + 2O2 ^ A + 2H* + 202*" 
Superoxide is depleted undergoing a dismutation reaction (Desideri and Falconi, 
2003) into oxygen (O2) and hydrogen peroxide (H2O2), either spontaneously at 
acidic pH or in a reaction catalysed by superoxide dismutase (SOD) (Halliwell and 
Gutteridge, 1999): 
SOD 
202*" +2H^ • O2 + H2O2 
SOD enzymes work in conjunction with H202-removing enzymes, such as catalases 
and glutathione peroxidases (Michiels et al., 1994). The hydrogen peroxide molecule 
does not contain an unpaired electron and thus is not a radical species (Valko et al., 
2006). The superoxide anion is too strongly charged to readily cross the iimer 
mitochondrial membrane (Valko et al., 2007) and, by itself, is not very reactive 
towards cell constituents (Cui et al., 2004). Hydrogen peroxide is also a 
comparatively inactive molecule, but can easily cross cell membranes. 
Superoxide anion is considered the "primary" ROS and can further interact 
v^th other molecules to generate "secondary" ROS, either directly or through 
enzyme- or metal-catalysed processes (Valko et al., 2005). Hydrogen peroxide and 
superoxide react with and undergo further transformations in the presence of 
transition metals, in particular iron and copper to give rise to the highly reactive 
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hydroxyl radicals, by the Haber-Weiss or Fenton reactions (Halliwell and 
Gutteridege, 1990). This property, combined with the membrane permeability of 
hydrogen peroxide, gives superoxide and hydrogen peroxide the ability to affect the 
integrity of distant molecules within the cell (Halliwell and Gutteridge, 1989; 
Cochrane, 1991). 
Fe^ ^ + H202 • Fe^ ^ + OH" + OH* 
(Fenton reaction) 
FeflliyCufli; 
O2'" + H2O2 • O2 + OH" + OH' 
(metal ion-catalysed Haber-Weiss reaction) 
The hydroxyl radical (OH*) is the neutral form of the hydroxide ion. It has a high 
reactivity, making it a very dangerous radical with a very short in vivo half-life of 
approximately 10"' s (Pastor et al., 2000). Thus its reactions are dififusion-limited 
and take place at the site of generation. Being the most aggressive member of the 
ROS family, the strong oxidant hydroxyl radical (Winterboum, 1995) can bring 
about extensive damage to various biomolecules, including proteins, nucleic acids, 
and lipids (Cui et al., 2004). It can be generated through a variety of mechanisms, 
including ionising radiation, photolytic decomposition of alkylhydroperoxides 
(Valko et al., 2006), enzymes such as L-amino acid oxidase, glycolate oxidase, 
xanthine oxidase, and monoamine oxidase-B (Masini-Repiso et al., 2004). 
Additional reactive radicals derived from oxygen that can be formed in living 
systems are peroxyl radicals (ROO*). The simplest peroxyl radical is the dioxyl 
(hydroperoxyl or perhydroxyl) radical HOO', which is the protonated form 
(conjugate acid; pKa 4.8) of superoxide (02*~). With this pKa value, only 0.3% of 
any superoxide present in the cytosol of a typical cell is in the protonated form (De 
Grey, 2002). The hydroperoxyl radical is imstable at physiological pH and 
dissociates to superoxide (Cui et al., 2004). Peroxyl radicals participate in lipid 
peroxidation (Gutteridge, 1995; Cadenas and Sies, 1998) and are involved in DNA 
cleavage and protein backbone modification. Lipid radicals are formed by hydrogen 
abstraction, a process elicited by UV irradiation or the hydroxyl radical (Taira et al, 
1992; Tyrrell, 1995). 
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iii. Oxidative damage to biomolecules 
Because of high chemical reactivity, excessive ROS may damage the 
structural and functional integrity of the cell; either by directly modifying cellular 
DNA (Halliwell and Gutteridge, 1999; Amici et al., 2003), proteins, and lipids or by 
initiating chain reactions that can bring about extensive oxidative damage to these 
critical molecules as discussed below. 
a. Oxidative modification of proteins 
The action of hydroxyl radicals on proteins leads to extensive protein-protein 
cross-linking (Stadtman, 1992). In metalloproteins and metalloenzymes, transition 
metals may also induce the formation of hydroxyl radicals, causing site-specific 
destruction of critical regions of the molecule (Cui et al., 2004). Metal-catalyzed 
damage to proteins involves oxidative scission, loss of histidine residues, bityrosine 
crosslinks, introduction of carbonyl groups, and the formation of protein derivatives 
of alkyl (R'), alkoxyl (RO*) and alkylperoxyl (ROO') radicals which are susceptible 
to peptide bond cleavage (Stadtman, 1990). Peptide bond cleavage can also occur by 
hydroxyl radical-initiated attack of the glutamic acid and proline residues of proteins 
to form a mixture of various products (Stadtman, 2004). The side chains of all amino 
acid residues of proteins, in particular cysteine and methionine residues are 
susceptible to oxidation by ROS (Levine et al., 1996). Oxidation of cysteine residues 
may lead to the reversible formation of mixed disulphides between protein thiol 
groups (-SH) and low molecular weight thiols, in particular GSH (Valko et al., 
2007). 
Protein oxidation has an important role in aging and multiple diseases 
(Davies, 2000; Sohal, 2002; Stadtman and Levine, 2003; Grune et al., 2004). 
Proteins serve vital roles in regulating cell structure, signaling, and various 
enzymatic processes, thus their oxidation can contribute to oxidative stress by 
directly affecting these processes and cellular metabolism. The accumulation of 
oxidised proteins in living systems may be: (i) due to an increase in the steady state 
level of ROS and a decrease in the antioxidant capacity; (ii) a decrease in the ability 
to degrade oxidised proteins (Valko et al., 2006). ROS-mediated protein oxidation 
can be measured in terms of the protein carbonyl content through highly sensitive 
methods available (Levine et al., 1990). 
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b. Lipid peroxidation 
The peroxidation of polyunsatiirated fatty acid residues (PUFAs) by 
hydroxyl radicals constitutes one of tlie most severe attaclcs on cellular integrity 
(Gutteridge, 1995). Peroxidation of membrane PUFAs may adversely affect 
functionally important parameters, such as membrane fluidity, permeability, 
electrical potential, and controlled transport of metabolites across the membrane 
(Mattson, 1998; Del Rio et al., 2005). 
The overall process of ROS-induced lipid peroxidation generally consists of 
three stages (Niki et al., 1993): (1) initiation, in which the free radical attacks a 
methylene group in the PUFAs, leading to rearrangement of double bonds to the 
conjugated diene form, and simultaneously producing a carbon-centered alkyl 
radical, which reacts with molecular oxygen to give rise to a peroxyl radical (ROO*); 
(2) propagation, in which the peroxyl radical starts a self-perpetuating cyclisation 
chain reaction that converts most of the membrane lipids to a variety of 
endoperoxides (precursors of malondialdehyde) with the final product of the 
peroxidation process being malondialdehyde (MDA) (Mamett, 1999). The 
degradation products of hydroperoxides are hydrocarbons, alcohols, ether, epoxides, 
and aldehydes. The aldehydic products, MDA and 4-hydroxy-2-nonenal (HNE), can 
inactivate phospholipids, proteins, and DNA by bringing about cross-linking 
between these molecules (Esterbrauer et al., 1990); and (3) termination, in which the 
chain reaction is stopped by interactions between the radicals themselves, or 
between the radicals and antioxidants, givmg rise to non-radical products or 
unreactive radicals (Pinchuk et al., 1998; Nyska and Kohen, 2002). 
4. Stress and depression 
The link between stress and depression has long been observed at the clinical 
level, since chronic exposure to stressful life events has been associated with the 
development of depressive symptoms, depending on the characteristics of the stress 
experienced and the psychological resources of each individual to cope with them 
(Tafet and Bemardini, 2003). In humans, adaptation principally denotes adjustment 
to psychosocial challenges, especially those with relevant emotional implications. 
Psychosocial stress is widely recognized as an important trigger in the expression of 
various psychiatric syndromes, including major depression and anxiety disorders 
(Gold et al., 1988; Post, 1992). Depressive reaction is one of the major responses to 
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psychological stress (Leonard, 2001) and depressive episodes occur frequently after 
chronic or very intense stress exposure (Bhagwagar et al., 2002; Wang, 2005; 
Bockting et al., 2006; Iny et al., 2006). The syndrome of major depression also 
seems to reflect alterations in the adaptive response to stress (Chrousos and Gold, 
1992, 1998). HPA axis abnormalities in major depression are one of the most 
consistent findings in biological psychiatry (Nemeroff, 1996; Pariante and Miller, 
2001; Pariante, 2003). Although the underlying mechanisms are still unclear 
(Pariante, 2006) studies have suggested that psychological stress stimulates the HPA 
axis, simultaneously increasing the formation of ROS (MoUer et al., 1996; Busciglio 
et al., 1998). Recent clinical studies suggest that enhanced oxidative stress or 
defective antioxidant defenses may be related to the pathogenesis of depression 
(Tsuboi et al., 2006). If psychological factors actually promote oxidative damage in 
human subjects, these factors could also be relevant to the enhancement of 
susceptibility to various other diseases (Tsuboi et al., 2004). 
5. Oxidative stress in the pathophysioiogy of depression 
A large number of neurological and psychiatric diseases such as Parkinson's, 
dementia, schizophrenia, and also affective (depressive) disorders show an enhanced 
production of ROS (Matsuo et al., 1994; Sayre et al., 2005; Schmidt et al., 2005). A 
relationship between depression and some illnesses, which are associated with over-
production of ROS, has also been proposed, namely, Alzheimer's disease, 
Parkinson's disease, dementia, rheumatoid arthritis, systemic lupus erythematosus 
(Davies, 1995), atherosclerosis (Krishnan and McDonald, 1995), coronary artery 
disease (Barefoot et al., 1996; Friedman, 2000) and cancer (Bodurka-Bevers et al., 
2000). The pivotal link with oxidative stress has been extensively studied for three 
major neurodegenerative diseases: Alzheimer's, Parkinson's and amyotrophic lateral 
sclerosis (Rao and Balachandran, 2002; Emerit et al., 2004). Evidence for the role of 
oxidative stress in depression is outlined below. 
i. Lipid peroxidation 
Various clinical studies have reported increased lipid peroxidation to occur 
in patients with major depression and affective disorders (Khanzode et al., 2003; 
Ozcan et al., 2004). Significant correlations were found between MDA levels and 
the severity and duration of depressive illness (Bilici et al., 2001). Serum lipid 
hydroperoxide as a marker of lipid peroxidation was also foimd increased in 
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depression (Tsuboi et al., 2004). Abnormalities in certain lipids may play a role in 
depression (Horrobin, 1990) by causing overproduction of ROS (Maes et al., 2000). 
Depression may also affect the intensification of lipid peroxidation and oxidative 
modification of plasma lipoproteins (Tsuboi et al., 2006). A combined dysregulation 
of lipid metabolism, antioxidant defenses, activation of inflammatory processes and 
increase of monoamine neurotransmitter catabolism (oxidation), may be an integral 
component associated to the pathophysiology of major depression (Bilici et al., 
2001; Mazzaetal., 2007). 
ii. Other antioxidants 
Few reports of alterations in other indicators of antioxidant status have been 
docimiented firom clinical studies. For example, plasma tryptophan and tyrosine, 
which have antioxidant activity (Meucci and Mele, 1997), and serum albumin, a 
major contributor to the oxygen radical absorbing capacity, were found to be 
significantly decreased in depression (Van Hxmsel et al., 1996). Psychological stress 
may reduce the plasma levels of a-tocopherol and P-carotene (Tsuboi et al., 2006). A 
study on elderly patients has showed preventive effects of a-tocopherol on the 
progression of depressive status (Shibata et al., 1999), whereas such an association 
was not found significant in another study after adjusting factors such as age, 
cognitive fimctions, serum cholesterol concentration, smoking and living situations 
(Tiemeier et al., 2002). Depression was found to be accompanied by significantly 
lower serum vitamin E concentrations, suggesting lower antioxidant defenses 
against lipid peroxidation (Maes et al., 2000). A significant depletion of brain 
glutathione, another antioxidant, has been reported to occur in mice imder stress-
induced depression (Gutteridge and Halliwell, 1994; Pal and Dandiya, 1994). 
iii. Antioxidant enzymes 
A susceptibility to increased oxidative stress or impaired antioxidant 
activity may occur in cases of major depression. Studies on patients with affective 
disorder showed lower levels of superoxide dismutase (SOD), catalase (CAT) and 
glutathione peroxidase (GPx) (Ozcan et al., 2004; (Herken et.al., 2007) in 
erythrocytes in comparison with healthy controls. In addition, it has been reported 
that low levels of erythrocyte CAT activities correspond to higher levels of MDA in 
patients with affective disorders (Ozcan et al., 2004). Contradictory to this report, in 
certain age- and sex-matched case-control studies, major depressive patients 
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exhibited an increase in semm/RBC SOD activity (Bilici et al., 2001; Khanzode et 
al., 2003) as compared with a normal healthy control group. Significant correlations 
were found between SOD levels and the length of index episode as well as duration 
of ilbess. On the other hand, an accompanying increase in GPx activity was not 
observed in several studies (Bilici et al., 2001; Sarandol et al., 2007) which nught be 
one of the contributors of the increased lipid peroxidation seen in depression, 
represented by elevated MDA levels. Srivastava et al. (2002) found no alterations in 
the activities of SOD and GPx in polymorphonuclear leukocytes from patients with 
depression. Thus, while the data for antioxidant enzymes is variable and 
contradictory, however, alterations or imbalances in their activities are clearly 
indicative of enhanced oxidative stress in this disorder. 
The altered SOD activity in depressive disorder is found associated with 
morphological changes in the brain (Michel et al., 2007). Postmortem studies have 
revealed reductions in glial cell number and density in brain regions as well as more 
subtle changes in neuronal density and size (Rajkowska et al., 2001; Cotter et al., 
2002). At present, no specific pathophysiological process has been linked with these 
morphological changes. Oxidative stress is well known to contribute to neuronal 
degeneration in the central nervous system (CNS) in the process of aging as well as 
in neurodegenerative diseases (Cantuti-Castelvetri et al., 2000; Koutsillieri et al., 
2002). Enzymatic activity has been shown to be significantly positively correlated 
with enzyme protein levels (Gnienblatt et al., 2005) and an increase in the 
concentration of antioxidants such as SOD in atrophied brain regions in depression 
compared to those of matched controls (Michel et al., 2007) can be considered as a 
compensatory response to oxidative stress (Michel et al., 2004). These findings 
provide evidence for an oxidative stress hypothesis of depression. 
In view of the crucial role of oxidative stress in the pathophysiology of 
stress-induced depression, it has been suggested that antioxidants might therefore be 
consumed against increased oxidative stress induced by psychological stress, 
whereas some antioxidants may be consumed for adapting oneself to stress 
conditions (Tsuboi et al., 2006). Thus, the oxidative stress hypothesis of depression 
was suggested to be an important lead with implications for the etiology and 
treatment of depressive disorders that requires fiirther investigation. 
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Depressive symptoms have been widely investigated in relation to various 
diseases, such as cardiovascular diseases (Ketterer et al., 2000), cancer (Spiegel, 
1996; Newport and Nemeroff, 1998), allergic responses (Bell et al., 1991; Cufell et 
al., 1999), and in terms of correlation to immune responses (Irwin, 1999; Maddock 
and Pariante, 2001). Despite the association of oxidative stress with depressive 
symptoms, the modulation of endogenous antioxidant status by antidepressant drugs 
has not been fully clarified. Discrepancies exist among the available in vitro studies 
and in vivo clinical reports. There are very few comprehensive animal studies in 
relevant models of stress and depression pertaining to stress-induced oxidative 
damage in relation to the treatment/management of stress-induced depression. 
Although other processes and mechanisms have also been postulated for both stress 
and depression, this thesis has attempted to focus on the possibly opposing effects of 
stress and therapeutic interventions on critical oxidative processes implicated in both 
chronic stress and depression. 
6. Depression and behaviour 
Depression is a stress disorder with a wide spectrum of syndromes 
(depressed mood, anhedonia, weight and sleep distvirbances, negative thinking and 
suicidality) and unclear pathogenesis (Insel and Chamey, 2003; Wong and Licinio, 
2004). There has been considerable interest in simulating and studying these 
phenomenology to identify the underlying constitutive factors that contribute to the 
vulnerability to clinical depression in humans. 
Chronic stress has been found to affect different behavioral variables. 
Valuable tools for researching affective disorders are methods inducing depressive-
like states in experimental animals. Animals are used in an attempt to (1) reproduce 
aspects of the behavioural disorder that can be studied, (2) to discover novel 
pharmaceuticals that may treat the disorder and (3) as procedures through which 
new molecular targets can be identified for subsequent drug discovery and 
development (McArthur and Borsini, 2006). 
The forced swimming test (FST) is an attractive behavioral test for 
antidepressant drugs because it is quick and simple to run, reliable across 
laboratories and sensitive and specific to the effects of all of the major classes of 
antidepressant drugs (Porsolt et al 1977, 1978; Borsini and Meli, 1988; Detke et al, 
1997). Responses measured include active behaviour thought to reflect adaptive 
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coping to the inescapable situation, and passive behaviour which reflects learned 
helplessness. Whether administered chronically or after brief subchronic 
administration, antidepressant drugs decrease the duration of immobility in the FST 
(Brotto et al., 2001). It is used as a screen to predict antidepressant activity of drugs 
(Redrobe and Bourin, 1999) and has validity as a procedure to detect the presence of 
depressive-like behaviours under the influence of depressogenic manipulations on 
rodents such as an inescapable stressful situation. Several established animal models 
of depression have noted increased levels of immobility in the FST (Heritch et al., 
1990; Velazquez-Moctezuma and Diaz Ruiz, 1992; Overstreet et al., 1995; Hansen 
et al., 1997). Since shortened immobility time in this test indicates anti-depressive 
activity, increase in this parameter per analogiam is considered the behavioural 
expression of a depressive-like symptom in rats (Rygula et al., 2005). 
An additional effect induced following stress exposure is reduced sensitivity 
to rewarding stimuli, an effect suggested to model human anhedonia, described as a 
marked diminished interest or pleasure in events that would normally be enjoyable, 
which is a core symptom of major depression episodes according to DSM-IV criteria 
(Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition; American 
Psychiatric Association, 1994). Following exposure to uncontrollable stressors, a 
reduced preference for naturally preferable solutions (such as sucrose and saccharin) 
over drinking water is produced and represents a disturbance in the ability to 
experience pleasure (Willner, 2005). Such behavioural passivity (in this test as well 
as the FST) may be considered a behavioural index of experimental depression, and 
a behavioural analogue of the psychomotor retardation symptom associated with 
human depression (Wilhier, 1991). Repeated antidepressant treatments antagonize 
stress-induced anhedonia (Zurita et al., 1996). 
7. Antidepressants 
Recurrent depressive disorder (International Statistical Classification of 
Diseases and Related Health Problems, Tenth Revision - ICD 10; WHO, 1992) has a 
lifetime prevalence of about 16% (Doris et al., 1999). Large-scale epidemiological 
studies have shown that depression and anxiety disorders together are the most 
prevalent clinical conditions worldwide (Holsboer, 2004). It has been estimated that 
by the year 2020 depressive disorder will be the second most significant contributor 
to global health impairment (Miuray and Lopez, 1997). 
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The biological changes leading to depressive symptoms are still not fully 
understood, and all the drugs that are currently available mediate their actions via a 
small family of neurotransmitters - the monoamines (Nash and Nutt, 2004). 
Perturbed monoaminergic transmission is causally implicated in depressive states 
(Manji et al., 2003), but definitive proof for this hypothesis is still unavailable and 
the precise nature of defects remains to be clarified (Millan, 2004). 
i. Reuptake inhibitors: monoamine reuptake inhibition 
Current treatments for depression rely primarily on modulation of serotonin 
(5-hydroxytryptamine, 5HT) and norepinephrine (NE) neurotransmitter systems 
(Hamon and Bourgoin, 2006). Blockade of monoamine uptake/clearance from the 
synaptic cleft is the principal known pharmacological action of most antidepressants, 
and increases the concentrations of 5HT and NE at postsynaptic monoamine 
receptors (Holsboer, 2004). 
a. Tricyclic antidepressants (TCAs): Imipramine 
This heterogeneous group consists of the earliest reuptake inhibitors acting 
by blocking the reuptake of 5HT and NE at nerve endings of the central nervous 
system (Kulkami and Dhir, 2007). In addition to reuptake inhibition of these 
biogenic amines, TCAs also antagonize postsynaptic a 1-adrenoceptors, histamine 
(Hi) receptors, muscarinic cholinergic receptors and 5HT2 receptors. These actions 
are responsible for the additional side-effects in comparison with more selective 
drugs such as the selective serotonin reuptake inhibitors (Hamon and Bourgoin, 
2006). 
b. Selective serotonin reuptake inhibitors (SSRIs): Fluoxetine 
The SSRIs are highly selective for the 5HT transporter. They are effective in 
most stress-related mood and anxiety disorders and are widely prescribed in 
depression owing to their improved safety and tolerability (Wilde and Benfield, 
1998). Fluoxetine is a racemate (Benfield et al., 1986). It undergoes extensive 
metabolic conversion leading to the active metabolite norfluoxetine. After oral 
administration, fluoxetine is almost completely absorbed; the oral bioavailability is 
< 90% (Vaswani et al., 2003). It is highly bound to plasma proteins and has an 
elimination half-life of 1-3 days. 
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c. Serotonin and noradrenaline reuptake inhibitors (SNRIs): Venlafaxine 
This class of drugs has additional inhibitory activity at NE reuptake sites. 
Venlafaxine, a novel antidepressant is a dual inhibitor of both 5HT and NE 
transporters (Redrobe et al., 1998). The clinical efficacy of venlafaxine was found 
equal to other antidepressants with some studies showing an advantage over 
fluoxetine and imipramine in some patients, particularly those with more severe 
depression (Anderson, 2000). Venlafaxine is a racemic mixture of R- and S-
enantiomers with the major metabolite 0-desmethyl venlafaxine (Holliday and 
Benfield, 1995). All of these are active as inhibitors of 5HT with a weaker effect on 
NE reuptake. It lacks significant effects on other receptors and has low toxicity in 
overdose. Venlafaxine is well-absorbed, has low plasma protein-binding (35%) and 
an elimination half-life of 5 h (11 h for the metabolite) (Anderson, 1999). 
ii. Relevance of downstream targets of antidepressant action 
The pharmacology of currently used antidepressants is known, but the 
actions responsible for their clinical efficacy remain poorly understood (Anderson, 
1999). Antidepressant agents induce rapid elevations in extracellular levels of 
monoamines within hours, yet they have a slow onset of action (weeks) (Manji et al., 
2003). This delay indicates that the therapeutic efficacy of these drugs must be 
related to phenomena occurring downstream from neurotransmitter reuptake 
inhibition, receptor blockade or enzyme inhibition (Hyman and Nestler, 1996). Such 
mechanisms include changes in gene regulation and in the amount of protein 
expressed by these genes (Jeste et al., 1988). Lately, SODl gene expression has been 
implicated as a potential target of antidepressant regulation (Li et al., 2000; KoUa et 
al., 2005). Increased levels of SOD activity may acco\mt, at least in part, for the 
observed clinical effects of certain antidepressant drugs used in the treatment of 
depression (KoUa et al., 2005). The potential modulation of other antioxidant 
enzymes by antidepressant agents is thus worthy of further exploration and these 
investigations may add to an imderstanding of a common mechanism of action for 
various antidepressant agents. 
Rationale for the possible clinical effectiveness of antioxidants in several 
degenerative conditions has risen out of the many years of basic science generally 
showing that ROS and oxidative damage are important factors in the process 
involved (Floyd, 1999). In contrast, although a convincing body of evidence now 
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implicates critical oxidative processes in both chronic stress and depression, 
however, the opposing effects of stress and anti-stress therapeutic interventions on 
antioxidant parameters have received strikingly less attention. A few variable reports 
exist regarding the modification of oxidative-antioxidative systems by 
antidepressant treatment (Khanzode et al., 2003; Sarandol et al., 2007). Emphasis on 
pharmacological modulation of stress-induced oxidative damage by antidepressants 
as a possible stress-management strategy may aid in reconciling the contradictory 
data generated by various clinical studies. An all-inclusive investigation of the 
involvement of major cellular antioxidants, both enzymatic and non-enzymatic, has 
not been carried out to date. Conversely, evaluation of the effectiveness of various 
antioxidants in comparison to antidepressant drugs has also not been targeted 
sufficiently. 
8. Antioxidants 
Exposure to fi"ee radicals fi-om a variety of sources has led organisms to 
develop a series of defense mechanisms (Cadenas, 1997). The excess of ROS is 
generally inactivated by endogenous or exogenous antioxidant molecules that have 
the ability, even at low concentrations, to delay or inhibit the oxidation of a substrate 
(Gutteridge, 1995). They may do so by removing or lowering the local 
concentrations of one or more of the participants m this reaction, such as oxygen, 
ROS, or metal ions which catalyze oxidation (Fe^ ,^ Cu^ "^ , etc.), or by interfering with 
the chain reactions that propagate oxidation to neighboring molecules. They may 
also act by enhancing the endogenous antioxidant defenses of the cell. Thus, 
antioxidants may intervene at any of the three major steps: initiation, propagation, or 
termination of the oxidative process and are classified accordmg to their chemical 
nature and mode of fimction. The most efficient antioxidants are enzymes that 
catalyse the reduction of specific ROS after they are formed and degrade them to 
less harmful products (Mates et al., 1999). They are of enormous importance in 
limiting ROS-mediated damages to biological macromolecules. Examples are 
superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GPx). 
They are considered the primary antioxidant enzymes, since they are involved in the 
direct elimination of ROS. SOD catalyses the dismutation of superoxide radical into 
hydiogen peroxide, which is not a free radical by itself, but is a precursor of the 
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highly reactive hydroxyl radical. Detoxification of hydrogen peroxide is carried out 
by (i) CAT, which decomposes hydrogen peroxide to water and oxygen, or by (ii) 
GPx, which reduces hydrogen peroxide to water in the presence of GSH. The 
oxidised glutathione cofactor (GSSG) is then reduced (GSH) by glutathione 
reductase (GR). Besides being an antioxidant by itself, glutathione (GSH) is also the 
cofactor for GPx and GR. Glutathione-S-transferase (GST), GR and glucose-6-
phosphate dehydrogenase (G6PD) are secondary antioxidants which aid the 
detoxification of ROS and secondary products generated by the interaction of ROS 
with macromolecules to prevent further intracellular damage, degradation of cell 
components and eventual cell death, by decreasing peroxide levels or by maintaining 
a steady supply of metabolic intermediates like GSH and NADPH for the primary 
antioxidant enzymes. NADPH is regenerated by one of the pathways of glucose 
oxidation; thus glucose appears as a key component of the antioxidant reaction 
cascade (Figure B; Sorg, 2004). The non-en2ymatic antioxidant small molecules 
include sulphydryl compoimds such as glutathione (GSH), uric acid, flavonoids and 
other antioxidants. Under normal conditions there is a balance between both the 
activities and the intracellular levels of these antioxidants. 
i. Enzymatic antioxidants 
The major intracellular enzymatic antioxidants that provide the first line of 
defense against superoxide and hydrogen peroxide include superoxide dismutase, 
catalase and glutathione peroxidase (GPx). 
a. Superoxide dismutase (SOD) (EC 1.15.1.1) 
Superoxide is depleted undergoing a dismutation reaction. SOD catalyses the 
dismutation of 62*" to O2 and to the less-reactive species H2O2. 
SOD 
202'~ + 2H^ • H2O2 + O2 
SOD enzymes accelerate this reaction in biological systems by about four orders of 
magnitude. SOD destroys 02*' with remarkably high reaction rates, by successive 
oxidation and reduction of the transition metal ion at the active site in a "Ping-Pong" 
type mechanism (Mates et al., 1999). While this enzyme was isolated as early as 
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Figure B. Overview of free radical and ROS formation and elimination. 
1939, it was only in 1969 that McCord and Fridovich proved the antioxidant activity 
of SOD (McCord and Fridovich, 1969). SOD exists in several isoforms, differing in 
the nature of the active metal centre and amino acid constituency, as well as their 
number of subunits, cofactors and other features. In humans there are three forms of 
SOD: cytosolic Cu/Zn-SOD, mitochondrial Mn-SOD, and extracellular SOD (EC-
SOD) (Landis and Tower, 2005). 
b. Catalase (CAT) (EC 1.11.1.6) 
This enzyme very efficiently promotes the conversion of hydrogen peroxide 
to water and molecular oxygen. Catalase has one of the highest turnover rates for all 
enzymes: one molecule of CAT can convert approximately 6 million molecules of 
hydrogen peroxide to water and oxygen each minute: 
CAT 
2H2O2 • 2H2O + O2 
In animals, CAT is present in all major body organs, being especially concentrated 
in liver and erythrocytes. Most purified catalases have been shown to consist of four 
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protein subunits, each of which contains a haem group bound to its active site 
(Halliwell and Gutteridge, 1990). 
c. Glutathione S-transferase (GST) (EC 2.5.1.18) 
GST is the selenium-independent form of the enzyme glutathione 
peroxidase. GSTs are a multigene family of isoenzymes that catalyze the 
conjugation of electrophilic compounds to glutathione (GSH). The diversity of 
substrates accommodated by GST is a result of both the relatively non-specific 
nature of the binding site for the hydrophobic substrate and the existence of 
numerous isoforms of GST (Salinas and Wong, 1999). GST exist as dimeric proteins 
comprised of two subimits. Each of the subunits possesses a glutathione binding site 
as well as an adjacent relatively hydrophobic site for the binding of the electrophilic 
substrate. GST metabolizes carcinogens, environmental pollutants, drugs and a 
broad spectrum of other xenobiotics. GST participates in the defense against 
oxidative stress as these enzymes are able to detoxify endogenous harmful 
compounds like hydroxyalkenals and base propenals (breakdown products of lipid 
peroxidation) or DNA hydroperoxides, and also electrophilic xenobiotics and/or 
reactive intermediates formed during their biotransformation like epoxides and 
quinones (Tew, 1994; Hayes and Pulford, 1995). Although microsomal forms of 
GST have been detected (Morgenstein and DePierre, 1988), GST activity is mainly 
located in the cytosol. 
c. Glutathione reductase (GR) (EC 1.6.4.2) 
This enzyme catalyses the reaction: 
GSSG + NADPH + H^ ^ 2GSH + NADP^ 
At normal physiological ckcumstances, the oxidized glutathione disulphide (GSSG) 
is reduced to GSH by the action of glutathione reductase (GR) at the expense of 
NADPH as a reductant, thereby forming a redox cycle (Lu, 2000). GR can also 
catalyse reduction of certain mixed disulphides, such as that between GSH and 
coenzyme A. GR is a flavoenzyme found in cytosol and mitochondria, and is 
represented by a single-copy gene in humans. It has been observed that exposure to 
agents that lead to increased oxidative stress also leads to an increase in its mRNA 
content. Further experimental data have shown the importance of GR activity in 
GSH metabolism, demonstrating that the enzymatic activity is regulated in response 
21 
REVIEW OF LITERATURE 
to Stress, and that mutations affecting GR activity would have deleterious 
consequences. The recycling pathway for GSH formation is thus fundamental in the 
metabolism of GSH-dependent defense reactions (Rogers et al., 2004). The presence 
of GSH is essential, but not in itself sufficient, to prevent the cytotoxicity of ROS, 
being of fundamental importance the functionality of the glutathione-dependent 
enzymes, which participate in the first and second lines of defense. 
ii. Non-enzymatic antioxidants 
Chemical small molecule antioxidant compounds including vitamins, dietary 
flavonoids, carotenoids, uric acid and glutathione (Gate et al., 1999) provide a 
second line of antioxidant defense. 
a. Thiol antioxidants - Glutathione (GSH) 
The major thiol antioxidant is the tripeptide, glutathione (L-y-glutamyl-L-
cysteinylglycine). Glutathione metabolism is one of the most essential of antioxidative 
defense mechanisms (Masella et al., 2005). Glutathione (GSH) represents the most 
prominent low molecular weight thiol (up to 5-10 mM) present in cells (Hayes and 
Pulford, 1995). It is a multifiinctional intracellular non-enzymatic antioxidant and is 
considered to be the major thiol-disulphide redox buffer of the cell. The reduced form 
of glutathione is GSH and the oxidised form is GSSG, glutathione disulphide (Valko 
et al., 2006). Under oxidative stress conditions, ROS are reduced by GSH with 
concomitant formation of the oxidized disulphide, GSSG. Although relatively 
resistant to 'spontaneous oxidation', GSH reacts rapidly and non-enzymatically with 
hydroxyl radicals, and with N2O3 and peroxynitrite (Griffith, 1999). GSH also acts in 
the enzymatic first line antioxidant defense as a co-factor in GPx mediated reduction 
of peroxides, also resulting in GSSG formation. At normal physiological 
circumstances, GSSG is reduced to GSH by GR at the expense of NADPH, thereby 
forming a redox cycle (Lu, 2000). Thus, GSH is also the cofactor for GR. Generally, 
the antioxidant capacity of thiol compounds is due to the sulphur atom which can 
easily accommodate the loss of a single electron (Karoui et al., 1996). The lifetime of 
the sulphur radical species thus generated, i.e., a thiyl radical (GS*), may be 
significantly longer than many other radicals generated during stress. The reaction of 
GSH with the radical R' can be described as follows: 
GSH + R' • GS' + RH 
22 
REVIEW OF LITERATURE 
Thiyl radicals generated may dimerise to form the non-radical product, oxidised 
glutathione (GSSG): 
GS* + GS' • GSSG 
GSSG is accumulated inside cells and can react with protein sulphydryl groups to 
produce protein-glutathione mixed disulphides: 
GSSG + protem-SH < • protein-SSG + GSH 
The mixed disulphides (protein-SSG) have a longer half-life than GSSG, most 
probably due to protein folding. The main protective roles of glutathione against 
oxidative stress are as follows (Masella et al., 2005): (i) GSH is a cofactor of several 
detoxifying enzymes against oxidative stress, for example, GPx, GST and others; (ii) 
GSH scavenges hydroxyl radical and singlet oxygen directly, detoxifying hydrogen 
peroxide and lipid peroxides by the catalytic action of GPx. Thus, GSH and GSH-
related processes play a central role in this second line of antioxidant defense by 
contributing to a number of processes, such as free radical scavenging, reduction of 
peroxides, detoxification of electrophilic compounds to less toxic and more 
hydrophilic thioether compounds, modulation of the cellular redox status and thiol-
disulphide status of proteins, the action of ATP-dependent transport proteins and 
regulation of cell signalling and repair pathways (Sen and Packer, 1996; Palmer and 
Paulson, 1997; McLellan and Wolf, 1999). All these multiple functions of GSH 
point to a central and critical role of GSH in the complex cellular defense against 
oxidative stress. 
b. Uric acid 
Lipid-soluble and water-soluble scavengers act in cellular environments that 
are either hydrophobic or hydrophilic, respectively. Uric acid, the end product of 
purine metabolism in humans, provides a second line of antioxidant defense (Gate et 
al., 1999). It functions in the aqueous milieu (Frei et al., 1988) as a scavenging or 
chain-breaking antioxidant, by presenting itself for oxidation at an early stage in the 
free radical chain reaction and giving rise to low energy products that are unable to 
propagate the chain fiirther. It may function both as a classic suicidal antioxidant and 
as a chelator of transition metals. By binding iron and/or copper, uric acid may 
inhibit metal-catalyzed oxidation reactions without itself becoming oxidized 
(Davies, 2000). 
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9. Vulnerability of the brain to oxidative stress 
The brain is a target of stress along with the metabolic systems of the body, 
of which the liver is the central organ (McEwen, 2000). The brain is particularly 
vulnerable to oxidative stress and sensitive to oxidative damage. Some of the most 
important of these are summarized below: 
i. High oxygen utilization 
The brain accounts for only 2% of body weight, but consumes 20% of the 
total oxygen inspired and carries out the turnover of large quantities of ATP at a 
high rate, indicating the potential generation of a high quantity of ROS during 
oxidative phosphorylation in the brain as compared to other tissues that use less 
oxygen (Cui et al., 2004). 
ii. High content of oxidisable polyunsaturated fatty acids (PUFAs) 
The brain is rich in lipids with unsaturated fatty acids, which are particularly 
susceptible to ROS damage through peroxidation (Porter, 1984; Halliwell, 1992). 
iii. Modest antioxidant defenses 
The brain contains only low to moderate activities of SOD, CAT and GPx 
compared to the liver or kidney (Cooper, 1997; Ho et al., 1997). Since neurons are 
non-replicating cells any damage to brain tissues by the ROS tends to be ciraiulative 
over time. 
iv. Presence of redox-active metals (Cu, Fe) 
Additionally, the human brain has higher levels of iron (Fe) in certain 
regions as well as of ascorbate. Thus, if tissue organizational disruption occurs, the 
iron-ascorbate mixture may act as a potent pro-oxidant for bram membranes (Mazza 
et al., 2000). A high content of iron can catalyze the generation of ROS. 
10. Role of antioxidants in mental health 
Oxidative stress is integral to neurodegenerative processes in many stress 
disorders, therefore, the detoxification of ROS is essential within the brain and the 
involvement of glutathione as an antioxidant is very important (Dringen, 2000). 
Recent reports indicate that lower antioxidant defenses against lipid peroxidation are 
involved in the biochemical mechanisms underlying neuropsychiatric disorders in 
humans and in chronic mild stress model of depression. Since elevations in ROS 
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may, in part, also mediate the associations observed between major depressive 
disorder, cardiovascular disease, and cancer, it is of therapeutic and mechanistic 
relevance to assess antidepressant agents in comparison to antioxidants, both from 
herbal sources and dietary micronutrients. 
i. Herbal medicines as anti-stress therapeutic agents 
The disease preventive and health promotive treatment in the Indian systems 
of medicine of Ayurveda is a holistic approach finding increasing acceptability in 
many regions of the world. Ayurvedic pharmacology classifies medicinal plants into 
different groups according to then- actions, one of which is the 'Rasayana' group. 
Studies on these plants used as 'Rasyana' drugs constitute an active field of research 
in order to reason them in the modem context. It has been reported that the 
'Rasayanas' are rejuvenators, nutritional supplements and possess strong antioxidant 
activity, 1000 times more potent than ascorbic acid, a-tocopherol and probucol 
(Sharma et al., 1992). Emerging adaptogenic drugs exhibit a wide range of 
regulatory activity eliciting non-specific resistance to harmful influences of an 
extremely wide spectrum of factors causing stress. The exact mechanism of such 
adaptation is unknown, but may be due to induction of antioxidant enzymes. The 
therapeutic efficacy of the 'Rasayana' drugs in many free radical-implicated 
physiological disorders coiild be due to their antioxidant potential (Hanna et al., 
1994; Arivazhagan et al., 2004) 
a. Withania somnifera Dunal (family: Solanaceae, Ayurvedic name: 
'Ashwagandha') 
It has been in use for more than 2500 years. The roots of the plant are 
categorized as 'Rasayanas', a group of plant-derived drugs reputed to promote 
health and longevity by augmenting defense against disease, arresting the aging 
process, revitalizing the body in debilitated conditions, increasing the capability of 
the mdividual to resist adverse envirormiental factors and creating a sense of mental 
well-being (Weiner and Weiner, 1994). Ashwagandha root powder and its active 
principles such as glycov^thanolides, sitoindosides VII-X and withaferin A possess 
significant free radical scavenging activity (Bhattacharya et al., 1997; Panda and 
Kar, 1997). WS was found to be effective against lowered antioxidant defenses and 
lipid peroxidation induced by chronic doses of lead acetate (Chaurasia et al., 2000). 
The answer to the cure of depressive disorders probably lies in the Ayurvedic 
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'Rasayana', the most promising of which is Withania somnifera, which merits 
further investigation. 
b. Rauwolfia serpentina Benth. Ex Kurz. (L.) Dunal (family: Apocynacea, 
common name: Indian snakeroot) 
Rauwolfia serpentina (RS) is referred to as a miracle medicinal plant in 
various texts of the indigenous systems of medicine Ayurveda, Siddha and Unani. 
RS has been used in Africa for hxmdreds of years and in India for at least 3000 years. 
It was used as an antidote to snake bite, to remove white spots in the eyes, against 
stomach pains, fever, vomiting and headache and to treat insanity (Dewick, 2002). 
The roots of the plant contain several alkaloids; ajmalicine, chandrine, rauwolfme, 
renoxidine, rescin-namine, reserpiline, reserpinine, sarpagine, serpentine, 
serpentinine, tetraphyllicine, yohimbine, 3-epi-a-yohimbine and reserpine. 
Serpentine is not used as such, but first converted into ajmalicine through 
hydrogenation. Ajmalicine is used in hypertension and obstruction of cerebral blood 
flow, and also for treatment of liver disorders. Although RS has been used 
traditionally as an antipsychotic and antidepressant (Mamedov, 2005), and in 
modem medicine as an antihypertensive agent (Frishman et al., 2004), however, no 
detailed biochemical studies have been carried out regarding its action on chronic 
stress-induced pro-oxidant status. Its effect on endogenous antioxidant status per se 
has also been relatively understudied. 
c. Curcuma longa L. (family: Zingiberaceae) 
Curcuma longa, commonly called turmeric, has been described in traditional 
Chinese medicine and in Ayurveda for thousands of years (Xi et al., 2007). The 
rhizomes of turmeric are widely used in food and medicine. Timneric extracts have 
powerful antioxidant, anti-inflammatory, lipid-reducing, chemopreventive, and 
immunodulatory actions (Miquel et al., 2002; Joe et al., 2004). The phenolic yellow 
curry pigment curcumin has potent anti-inflammatory and antioxidant activities that 
can function to reduce oxidative damage and cognitive deficits associated with aging 
(Wu et al., 2006). Its ability to protect the brain from free radical-induced damage is 
thought to be several times stronger than that of vitamin E (Martin-Aragon et al., 
1997). Recent reports indicate that curcumin may be useful as a powerful, natural 
antidepressant agent and these effects may be mediated by the central 
monoaminergic neurotransmitter systems (Xu et al., 2005). The behavioral effects of 
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curcumin in chronically stressed animals, and by extension in humans, may be 
related to their modulating effects on the HPA axis and neurotrophin factor 
expressions (Xu et al., 2006). Of significance, it has been demonstrated that the 
powerful antioxidant effects of curcumin were sufficient to reduce the action of 
oxidative stress on brain derived neurotrophic factor (BDNF), synaptic plasticity, 
and cognitive function (Wu et al., 2006). 
Aqueous extracts of C. longa were recently demonstrated to be active in 
preclinical models of behavioral depression, the tail suspension test and the forced 
swimming test in mice, with effects comparable to those of known antidepressants 
(Yu et al., 2002). Oral administration of ethanolic extracts was also found to reduce 
the duration of immobility in the mouse forced swimming test, as well as to 
markedly attenuate swim stress-induced decreases in monoamine neurotransmitter 
levels, and significantly reverse swim stress-induced increases in serum 
corticotropin-releasing factor and Cortisol levels. The antidepressant properties of 
the ethanolic extract were suggested to be mediated through regulations of 
neurochemical and neuroendocrine systems, indicating it to be beneficial in stress-
related psychiatric disorders associated with an overactivity of the HPA axis system. 
However, unlike aqueous extracts, the effects of ethanolic extracts were found partly 
different from fluoxetine and amitriptyline. 
Thus, recent evidence indicates that turmeric effectively incorporates both 
antioxidant and antidepressant properties. Though the antidepressant activity of 
turmeric has been evalioated to some extent against standard drugs, those 
antidepressants have not been systematically examined for antioxidant potential in 
comparison to turmeric. These lacunae further strengthen the need to carry out a 
comprehensive comparative study between antidepressants and antioxidants. 
ii. Nutritional factors as anti-stress therapeutic agents: focus on 
antioxidant properties 
Although depression is a complex disorder, yet a key to its prevention and 
treatment may be a factor so fundamental that it has been broadly overlooked: 
dietary intake and overall nutritional status. Evidence for a role of nutrition in 
mental health originates from research docimienting neurological and psychological 
effects of nutrient deficiencies and demonstrating the important role of various 
dietary constituents (such as vitamin B12, folic acid, selenium, zinc, essential fatty 
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acids, etc.) in various aspects of nomial brain functioning, including enzymatic 
activity cellular and oxidative processes, maintenance of neuronal tissue, and 
synthesis and function of neurotransmitters and catecholamines (Bodnar and Wisner, 
2005). Investigations on a possible role of nutritional factors in depressive 
symptoms are becoming more numerous. The fact that oxidative stress is an intrinsic 
component of stress-induced depression indicates that dietary antioxidant therapy is 
a realistic approach to promote protective mechanisms and may represent a potential 
therapeutic approach to ameliorate the progression of stress disorders. This 
represents an important avenue for research targetting the evaluation of the 
effectiveness of various dietary antioxidants in stress management strategies 
a. Vitamin C (ascorbic acid) 
Vitamin C (ascorbic acid) is a very important and potent water-soluble low 
molecular weight antioxidant (Aruoma, 1998). It has two ionisable hydroxyl groups 
and is, therefore, a di-acid (ASCH2). At physiological pH, 99.9% of Vitamin C is 
present as AscH", thus the antioxidant chemistry of Vitamin C is that of AscH", 
which is a donor antioxidant and reacts with radicals to produce the resonance 
stabilised tricarbonyl ascorbate free radical (AscH"). Thus during its antioxidant 
action, ascorbate imdergoes a two-electron reduction to the semidehydroascorbate 
radical (Asc""), a poorly reactive radical that is considered to be a terminal, small 
molecule antioxidant (Cuzzorcrea et al., 2004; Kasparova et al., 2005). A majority of 
in vivo studies showed a reduction in markers of oxidative DNA, lipid and protein 
damage after supplementation with Vitamin C. Vitamin C reacts rapidly with 
hydroxyl radicals (Lynch et al., 1996), readily scavenges nitric oxide and 
hypochlorous acid (Noroozi et al., 1998), spares or increases intracellular GSH 
concentration (Meister, 1994) and protects lipids and lipoproteins against oxidative 
damage (Das et al., 2005). It is also an essential co-factor in hydroxylation reactions 
and the biosynthesis of collagen, carnitine and neurotransmitters (Burri and Jacob, 
1997). Vitamin C also protects against cell death triggered by various stimuli and a 
major proportion of this protection has been linked with its antioxidant ability. 
Several studies reported the mechanisms by which Vitamin C regulates the AP-1 
complex, including the Fos and Jun superfamilies. Ascorbate-treated cells exposed 
to UV-B irradiation led to a 50% decrease in JNK phosphorylation (which activated 
AP-1), therefore inhibiting the JNK/AP-1 signalling pathways (Valko et al, 2006). 
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Although situations of stress are capable of inducing depression and 
oxidative stress in the brain, vitamin C has not been investigated sufficiently in this 
context. 
b. Vitamin B9 (folic acid) 
Folic acid (pteroyl-L-glutamic acid, vitamin B9) belongs to the class of 
compoimds denoted as folates. It is composed of a 2-amino-4-hydroxypteridine 
moiety that is linked to the side-chain containing p-aminobenzoic acid and L-
glutamic acid (Gregory, 1998). In vivo folic acid (FA) is reduced initially to 7, 8-
dihydrofolate (DHF), and subsequently to 5,6,7, 8-tertahydrofolate (THF), which is 
enzymatically converted into 5-methyltetrahydrofolate (5-MTHF). The biochemical 
role of these reduced forms of FA is well-established in the transfer and utilisation 
of one-carbon groups for DNA synthesis (Stanger, 2002). Folate is also an essential 
co-factor in the generation of endogenous methionine as the source of methyl groups 
in important brain processes such as the synthesis of neuroactive substances and the 
formation of membrane phospholipids (Henning et al., 1997). Folate also appears to 
influence the biosynthesis of biopterin-dependent neurotransmitters (Alpert et al., 
2000). 5-MTHF may have a neuromodulatory role at presynaptic sites by binding to 
glutamate receptors (Bjelland et al., 2003). In some patients of depressive disorders 
methylation processes involving folate have been found impaired (Reynolds, 2007). 
Elevated levels of homocysteine, resulting from folate deficiency, may play a role in 
mediating some of the neiiropsychiatric complications (Alpert et al., 2000; 
Bjelland et al., 2003). FA was reported to have antioxidative behaviour towards 
superoxide, hydroxyl radical and peroxynitrite (Huang et al., 2001). Its free radical 
scavenging activity expressed as trolox equivalent antioxidant capacity (TEAC) 
and ferric reducing antioxidant power (FRAP) values was found comparable to 
those of some natiu-al polyphenolic antioxidants like soyabean isoflavones and 
citrus flavonones (Rice-Evans et al., 1995, 1996) and carotenoids (Miller et al., 
1996). Activity of FA against oxidative damage in human whole blood was also 
reported (Stocker et al., 2003). The scavenging of radicals by folic acid 
independent of any indirect effects through lowering of homocysteine levels makes 
it a potential vitamin to be considered as an antioxidant, which requires further 
research into this important aspect. 
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Although earlier studies of FA generated attention because of its role in the 
pathogenesis of cardiovascular disease and neural tube defects (MRC Vitamin Study 
Research Group, 1991; Welch and Loscalzo, 1998), lately, the antioxidant role of 
FA has come into focus and it has been proposed that the presumed protective 
effects of folic acid in the pathogenesis of several degenerative diseases could be 
associated with its antioxidant activity (Nakano et al., 2001). Altogether, results 
show that the antioxidant role of FA could become important in vivo for nutritional 
supplementation and fortification of food Thus, the modulation of cellular 
antioxidant defenses by FA in relation to stress management is certainly worthy of 
further study. 
c. Vitamin B6 (pyridoxine) 
Natural vitamin B6 consists of six interconvertible compounds, pyridoxine, 
pyridoxal, pyridoxamine, pyridoxine 5'-phosphate, pyridoxal 5'-phosphate, and 
pyridoxamine 5'-phosphate. Pyridoxal 5'-phosphate (PLP) is the major active 
coenzyme form and plays essential roles in many aspects of amino acid and cellular 
metabolism (John, 1995). Nutritionally, the application of pyridoxine may be 
adequate because it is converted to natural vitamin B6 compounds in vivo 
(Chumnantana et al., 2005). 
Modulation of homocysteine levels is a likely contributor to the apparent 
health benefits of pyridoxine intake (Ellis and McCully, 1995); however, some 
epidemiology suggests that at least part of the protection associated with good 
pyridoxine status is independent of homocysteine (Folsom et al., 1998; Robinson et 
al., 1998). Pyridoxine nutritional status selectively modulates the synthesis of 
serotonin and y-aminobutyric acid (GABA) - neurotransmitters which control 
depression, pain perception, and anxiety - since the decarboxylases which produce 
these neurotransmitters have a relatively low affinity for PLP. High tissue levels of 
PLP may act both centrally and peripherally to alleviate the physiological 
consequences of stress. In vivo, evidence that high-dose pyridoxine prevents stress-
mediated immune suppression (Lettko and Meuer, 1990) and also restraint-induced 
gastric ulceration in rats, may reflect decreased activity of glucocorticoid receptors 
in pyridoxine-treated animals (McCarty, 2000). 
The coenzyme forms of vitamin B6 are involved in transaminations, 
decarboxylations, racemizations and numerous modifications of amino acid side 
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chains (Stocker et al., 2003). In vitro pyridoxine was demonstrated to inhibit 
superoxide radical formation and protein glycosylation (Jain and Lim, 2001). 
Vitamin B6-deficient diets were found to cause excessive free radical production 
and lipid peroxidation in hepatic tissues of rats, while reducing their GSH levels 
significantly (Cabrini et al., 1998; Taysi, 2005). Thus the role of pyridoxine as a 
strong antioxidant can be evaluated in alleviating stress-induced oxidative damage. 
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Pyrogallol 
Rauwolfia serpentina 
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A. Subjects 
Swiss Albino rats weighing 100-150 g were housed in group cages under 
standard laboratory conditions (temperature: 25±5°C; humidity: 50-60%) and 12 h 
light/dark cycle (lights on 0700 h, lights off 1900 h) with free access to standard 
pellet chow (Ashirwad Industries, Chandigarh, India) and drinking water ad libitum. 
All experimental procedures were carried out within the light period of the light/dark 
cycle. The experimental protocol was in strict accordance with regulations and 
prescribed animal ethical procedures outlined by the Institutional Research and 
Ethics Conmiittee. All efforts were made to minimize animal suffering and to reduce 
the number of animals used in the experiments 
B. Restraint stress 
Animals were exposed to this stress regimen for 4 h each day at random 
times during the light period of the light/dark cycle to avoid habituation during the 
experimental period of 21 days. Restraint stress was accomplished by individually 
immobilizing animals in body-size wire mesh restrainers (Singh et. al., 1993). This 
restricted all physical movement without subjection to pain. The animals were deprived 
of food and water during the entire period of exposure to stress. Subsequently the 
animals were released from their enclosure and provided access to water. 
C. Experimental protocol 
All animals were acclimated to laboratory conditions and handled daily for 7 
days preceding the 21-day treatment period. During this time, animals were 
randomly assigned to weight-matched groups of six animals each, receiving either 
restraint stress and/or the test drug under study, according to the experimental 
regimen presented in each section. Drug administration was via oral route, through 
gastric intubation with the use of a catheter. Unstressed, untreated animals 
constituted the control group and were accustomed to daily handling during the 
experimental period. At the end of the experimental period all animals were 
sacrificed imder deep ether anesthesia in the light phase (between 0800 to 1000 h), 
24 h after the last restraint session or drug treatment, for biochemical studies. 
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D. Collection of serum and preparation of tissue homogenates 
Blood samples were collected by cardiac puncture for separation of serum. Brain, 
liver and heart tissues were rapidly removed and washed in ice-cold sterile 
physiological saline (0.9%). A 10% (w/v) homogenate was prepared in 0.1 M 
sodiimi phosphate buffer, pH 7.4, and centrifuged at 10,000 g (4°C, 15 min) to 
remove cellular debris. The supematants were stored at -20 °C until utiUzed for 
analysis. 
E. Biochemical parameters 
1. Enzymatic antioxidants 
The following antioxidant enzyme activities were assayed according to the 
standardized, sensitive and rapid procedures specific for the substrate used in the 
assay medium under optimal conditions of temperature, pH and wavelength 
measurement during the time in which the reaction rate is linearly enhanced: 
u Superoxide dismutase (SOD: E. C. 1.15.1.1) 
The assay method was based on monitoring the inhibition of auto-oxidation 
of pyrogallol by SOD (Marklund and Marklund, 1974). The assay medium in a final 
volume of 3 ml consisted of 0.05 ml sample (tissue homogenate supernatant/serum) 
and 0.05 M tiis succinate buffer, pH 8.2 (2.85 ml). After incubation at 25°C for 20 
min, the reaction was initiated by the addition of 8 nM pyrogallol. The change in 
absorbance was recorded spectrophotometrically at 420 nm for 3 min. Blanks devoid 
of sample were worked up in the same manner and run simultaneously. One enzyme 
unit is defined as the amount of enzyme required to cause 50% inhibition of the rate 
of pyrogallol auto-oxidation. Enzyme activity was expressed as units per mg of 
protein. 
ii. Catalase (CAT: E.C. 1.11.1.6) 
The assay principle is summarized in the reaction scheme below: 
Catalase 
: H : 0 : • : H ; 0 - ( > 
Absorbance at 240 nm No Absorbance at 240 nm 
CAT activity was measured by following the decrease in absorbance at 240 
nm due to decomposition of hydrogen peroxide (H2O2) (Aebi, 1984). The reaction 
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was allowed to proceed in 0.05 M phosphate buffer (pH 7.0) containing 1 ml H2O2 
(30 mM) and 0.05 ml sample. One enzyme unit is defined as the amount of enzyme 
decomposing 1 \iM H2O2 per min at 25 °C. Enzyme activity was expressed as units 
per mg of protein. 
iii. Glutathione S-transferase (GST: E.G. 2.5.1.18) 
GST activity was assayed after adding 1 mM 1-chIoro 2, 4 dinitrobenzene 
(CDNB) and 1 mM GSH in the reaction medium, consisting of 0.2 M phosphate 
buffer, pH 6.5 and 0.1 ml sample. The increase in absorbance due to formation of 
the CDNB-GSH conjugate was recorded at 340 nm (Habig et al., 1974). One unit of 
enzyme activity is defined as the amount of enzyme catalyzing the formation of 1 
\iM product per min under the specific assay conditions. Enzyme activity was 
expressed as units per mg of protein (molar extinction coefficient = 9.6 x 10^  M/cm). 
iv. Glutathione reductase (GR: E.G. 1.8.1.7) 
GR activity was assayed by monitoring the oxidation of 0.1 mM NADPH as 
a decrease in absorbance at 340 nm due to NADPH-dependent reduction of 1.0 mM 
oxidized glutathione disulphide (GSSG) to glutathione (GSH) by the catalytic action 
of GR (0.1 M phosphate biiffer, pH 7.6) as shown below: 
GSSG + NADPH + H' ^ ^ >2GSH +NADP' 
One unit of enzyme activity is defined as the amount of enzyme catalyzing the 
conversion of 1 nM NADPH per min under assay conditions (Carlberg and 
Mannervik, 1975). Enzyme activity was calculated using a molar extinction 
coefficient of 6.22 x 10'^  M/cm and expressed as units per mg of protein. 
2. Non-enzymatic antioxidants 
The following non-enzymatic antioxidants were estimated: 
i. Glutathione (GSH) 
GSH was determined by the method of Jollow et al. (1974), using the general 
thiol reagent 5, 5' - dithiobis - 2 - nitrobenzoic acid (DTNB). An aliquot of 1 ml of 
tissue homogenate supernatant was precipitated with equal volume of 4% (w/v) 
sulphosalicylic acid. The samples were incubated for 1 h at 4°C and subsequently 
centrifuged at 1,200 g for 15 min. The reaction medium in a final volume of 3 ml 
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consisted of 0.1 ml filtered aliquot, 0.1 M phosphate buffer, pH 7.4 (2.7 ml) and 0.2 
ml DTNB (40 mg/10 ml). The yellow colour developed by the reaction of GSH with 
DTNB was read at 412 imi. Assay mixtures without sample were used as blanks. 
ii. Uric acid 
Circulating levels of uric acid were estimated using a specific commercial kit 
(Span Diagnostics Ltd., Surat, India), based on the prmciple that in alkaline medium uric 
acid reduces phosphotungstic acid to a blue coloured complex, 'tungsten blue' detected 
spectrophotometrically at 710 nm. 0.5 ml sample was deproteinized with 2/3 N 
sulphuric acid (0.25 ml) and 10% sodium tungstate (0.25 ml), and centrifuged after 10 
min to obtain a clear supernatant. Colour development was initiated by addition of 14% 
sodium carbonate (0.5 ml) and phosphotungstate (0.5 ml) to the clear supernatant (1.5 
ml), followed by incubation in dark for 15 min. A reaction mixture devoid of sample 
was used as blank, A working reagent was prepared from 100 mg% stock uric acid 
standard for quantification. Serum uric acid was reported in mg/100 ml. 
iii. Glucose 
Quantitative determination of glucose was performed using a specific 
commercial kit (Span Diagnostics Ltd., Surat, India). The assay principle is based on 
oxidation of the aldehyde group of glucose by glucose oxidase to form gluconic acid 
and hydrogen peroxide. In the presence of peroxidase, hydrogen peroxide is coupled 
with phenol and 4-aminoantipyrine to form the coloured quinoneimine dye, 
detectable at 505 rmi, and directly proportional to glucose concentration in the 
sample. 0.02 ml serum was mixed with the reagents and incubated at 37 °C for 10 
min, following which absorbance at 505 nm was recorded against a reagent blank. 
Serum glucose concentration was expressed as mg/dL. 
3. Oxidative stress markers 
The following markers of oxidative stress were determined: 
i. Lipid peroxidation 
Lipid peroxidation was assessed by spectrophotometrically determining its 
aldehydic product, malondialdehyde (MDA), a thiobarbituric acid reactive species 
(TBARS) (Beuge and Aust, 1978). Quantitative measurement of lipid peroxidation 
was performed following the thiobarbituric acid (TBA) test for the formation of 
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TBARS during an acid-heating reaction. Samples were mixed with 1 ml of 10% 
trichloroacetic acid (TCA) and 1 ml of 0.67% TBA, then heated in a boiling water 
bath for 15 min. The pink chromogen formed by MDA-TBA complex was detected 
at 535 nm and quantified using an extinction coefficient of 1.56 x 10^  M/cm. Results 
were expressed as nanomoles of MDA per milligram of protein 
ii. Protein carbonyl content 
Oxidative damage to proteins was determined spectrophotometrically at 360 
nm by quantification of carbonyl groups based on their reaction with the labelling 
agent 2, 4-dinitrophenylhydrazine (DNPH) (Levine et al., 1990). 0.5 ml sample was 
incubated with 0.1% DNPH for 1 h at room temperature, following which 10% TCA 
was added. The precipitate, consisting of protein hydrazone derivatives, was extracted 
three times with ethanol/ethyl acetate reagent (1:1) and dissolved in 6M guanidine 
hydrochloride. Carbonyl content was calculated using an extinction coefficient of 
22,000 M/cm (for aliphatic hydrazones) and expressed in nmol/mg protein. 
4. Marker eniymes 
i. Glutamate pyruvate transaminase (GPT) or Alanine transaminase 
(ALT) (E.C. 2.6.1.2) 
GPT was estimated using a specific commercial kit (Span Diagnostics Ltd., 
Surat, India) based on the method of Reitman and Frankel (1957). The assay 
principle is based on the GPT-catalysed formation of pyruvate, which is coupled 
with DNPH vmder alkaline conditions to yield the corresponding hyydrazone that is 
measured spectrophotometrically at 505 nm. 0.25 ml of pre-incubated buffered L-
alanine-a-ketoglutarate (substrate) was incubated with 0.05 ml sample for 30 min at 
37T, following which DNPH colour reagent was added. After 20 min (15-30°C), 
2.5 ml (4N) sodium hydroxide (NaOH), diluted 1:10 with distilled water, was 
included in the reaction mixture and absorbance at 505 nm recorded against distilled 
water. GPT activity was calculated from a standard calibration curve of a 2mM 
working pyruvate standard and reported in Units/ml. 
ii. Glutamate oxaloacetate transaminase (GOT) or Aspartate 
transaminase (AST) (E.C.2.6.1.1) 
GOT was estimated using a specific commercial kit (Span Diagnostics Ltd., 
Surat, India) based on the method of Reitman and Frankel (1957). The assay 
principle is based on the GOT-catalysed formation of oxaloacetate, which is coupled 
37 
METHODS 
with DNPH under alkaline conditions to yield the corresponding hyydrazone that is 
measured spectrophotometrically at 505 rnn. 0.25 ml of pre-incubated buffered L-
aspartate-a-ketoglutarate (substrate) was incubated with 0.05 ml sample for 60 min 
at 37 °C, following which DNPH reagent was added. After 20 min (15-30°C), 2.5 ml 
(4N) NaOH, diluted 1:10 with distilled water, was included in the reaction mixture 
and absorbance at 505 nm recorded against distilled water. GOT activity was 
calculated from a standard calibration curve of a 2mM working pyruvate standard 
and reported in Units/ml. 
iii. Alkaline phosphatase (ALP: E.C.3.1.3.) 
ALP activity was assayed by the method of Shah et al. (1979). 0.1 ml of 
sample was dispensed in 1.4 ml assay buffer (50 mM glycine, 36 mM NaCl and 45 
mM NaOH, pH 10.5) and the reaction initiated by the addition of 0.6 M p-
nitrophenol phosphate. Following incubation at 37 °C for 15 min, the reaction was 
stopped with 0.05 ml of 5N NaOH. The yellow colour developed was measurable at 
405 nm against a reagent blank. ALP activity was calculated from a standard 
calibration curve of p-nitrophenol and expressed as mg/ml. 
iv. Lactate dehydrogenase (LDH: E.C.LLL27) 
LDH activity was assayed according to the method of Wroblewski and 
LaDue (1955). The reaction medium in a final volume of 3 ml contained 0.1 ml of 
sample in 0.1 M phosphate buffer, pH 7.4, 10 mM magnesium chloride (MgCb), 0.5 
M sodium pyruvate, 0.2% (w/v) NADH and distilled water. The conversion of 
NADH to NAD"^  was monitored at 340 nm by the change in absorbance over a 5 min 
period, against a blank devoid of the sample. The rate of NADH oxidation is 
proportional to LDH activity and specific activity was expressed as Units/mg 
protein. 
5. Protein estimation 
Protein content was estimated by the method described by Lowry et al. 
(1951), using bovine serum albumin as standard. The method depends on the 
conversion of Cu^ "*" to Cu"^  under alkaline conditions. The Cu"^  is detected by reaction 
with Folin reagent (a mixture of sodium tungstate, molybdate and phosphate) to 
produce a blue colour which can be quantified by its absorbance at 660 nm. After 
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appropriate dilution, 1 ml of protein solution was mixed with 5 ml of alkaline copper 
reagent (0.5% copper sulphate solution and 1% sodium potassium tartarate in 2% 
sodium carbonate prepared in 0.1 M NaOH). Colour development was initiated after 
10 min incubation at room temperature, by the addition of Folin reagent. 
Absorbance was recorded after 30 min and protein concentration was reported in 
mg/ml. 
F. Behavioural Parameters 
1. Forced swimming test 
This test included modifications of the Porsolt's procedure (Porsolt et al., 
1977; Porsolt et al., 1978) and was performed at Interdisciplinary Brain Research 
Centre, J.N. Medical College, AMU. Animals were individually dropped into a glass 
cylindrical tank (height 40 cm, diameter 20 cm) containing firesh water (25 ± 2°C) up 
to a depth of 30 cm and forced to swim for 10 min. This depth of water prevented 
subjects firom supporting themselves by touching the base of the swim tank with 
their hind paws. After each swim session the tank was thoroughly rinsed in order to 
remove the presence of any potential alarm substances and the water changed. After 
testing, each animal was towel-dried and retiimed to its home cage. Active 
components of forced-swim behaviour were assessed based on descriptions by Lucki 
(Lucki, 1997; Cryan et al., 2002). The behavioural measures scored according to 
these criteria were: time spent climbing, time spent swimming, time spent immobile 
and latency to assimie immobility. Climbing was defined as vigorous upward-
directed movements of the forepaws, usually against the walls of the tank. 
Swimming comprised active horizontal motions throughout the tank. Parameters of 
immobility were absence of directed motions of the head and body resulting in 
floating behaviour and only enough motion required to keep the nose above water. 
Depressive behaviour was inferred from "despair" as indicated by increased duration 
of immobility during the test (Lucki, 1997). 
2. Sucrose preference test 
The preference for sucrose over water was used as a hedonic measure 
(Willner, 2005). Prior to testing, animals were habituated to two water bottles for 
three days in their home cages, with standard pellet chow available continuously. No 
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previous food or water deprivation was applied before the test. Following this, two-
bottle preference tests were conducted by offering simultaneous access to tap water 
and a 1% sucrose solution for 24 h. To prevent possible effects of positional 
habituation or side preference in drinking behaviour, a variable sequence of bottle 
positioning was followed, alternating after 12 h. Fluid intake was determined ifrom 
the weight difference by weighing the pre-weighed bottles at the end of the test. The 
sum of water and sucrose intake was defined as total intake and the sucrose 
preference was expressed as the percentage of sucrose intake fi-om the total intake 
following the formula: 
% sucrose preference = sucrose intake x 100/ total intake 
G. Histopathological observations 
Liver and brain tissues were fixed with 10% phosphate-buffered neutral 
formalin and dehydrated in graded (50-100%) alcohol. The collected specimens 
were sent to Department of Pathology, J.N. Medical College, AMU, for histological 
studies. The fixed tissues were embedded in paraffin and serial sections were cut and 
stained with hematoxylin and eosin (H&E) stain. The sections were examined under 
light microscope (Nikon, Tokyo, Japan) and photomicrographs were taken. The 
examination was qualitative, with the aim of determining histopathological lesions. 
The parameters related to microarchitecture configuration (disorganization of 
structure) and parameters related to injury (necrosis) were analyzed. 
H. Statistical evaluation 
Data was expressed as group mean ± S.E.M. (n = number of animals in each 
group). Comparisons between control and experimental groups were performed by 
Student's t-test and analysis of variance by one-way ANOVA. P<0.05 was 
considered statistically significant. 
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A Study of Dose-Dependent 
Oxidative Damage by 
Exogenous Corticosterone 
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1. Introduction 
Several studies have now examined the impact of oxidative biochemistry in 
the adaptive response to stress (Melov, 2002; Pardon, 2007). It has been 
demonstrated that increased protection from oxidative stress plays a key role in 
maintaining homeostasis and enhancing resistance to environmental stress in animal 
models (both invertebrate and rodent), with a resultant increase in their longevity as 
observed following antioxidant treatment (Winter, 1998; Bonilla et al., 2002; Wu et 
al., 2002). Furthermore, evidence for the role of oxidative processes in physical and 
psychological stress comes from an accumulating number of rodent studies 
demonstrating increased oxidative tissue damage following acute and chronic 
exposure to a variety of stressors (Kaushik and Kaur, 2003; Singal et al., 2005). 
Robust increase in basal oxidative stress has been consistently reported by 
investigators employing restraint or immobilization stress, as evidenced by a rise in 
oxidant species, such as nitric oxide over a 21-day period (Madrigal et al., 2001), 
with a resultant accumulation of the oxidative stress marker, lipid peroxidation (Liu 
et al., 1996; Hu et al., 2000; Olivenza et al., 2000; Madrigal et al., 2001; Abidin et 
al., 2004; Fontella et al., 2005; Perez-Nievas et al., 2007). Studies in our laboratory 
have also demonstrated a restraint stress-induced decline in the primary endogenous 
antioxidant defenses, both enzymatic and non-enzymatic, in the brain and other 
target organs of stress such as liver (Zaidi et al., 2005; Zafir and Banu, 2007) with a 
consequent increase of oxidative stress. Together, all these investigations 
corroborate the emerging association of oxidative stress in the maladaptive 
consequences of chronic stress. This may hold considerable relevance to the 
pathophysiological changes produced by prolonged stress, which may lead to a wide 
variety of disorders, including psychosomatic diseases, chronic anxiety disorders, 
and depression (Tafet and Bemardini, 2003). Therefore, protection from oxidative 
stress during chronic stress may possibly avert the precipitation of stress-induced 
degenerative diseases affecting various organs and their physiological functions. 
The restraint stress paradigm reliably induces elevations of the adrenal 
steroid hormone, corticosterone (CORT) due to HPA axis activation (Abidin et al., 
2004). Glucocorticoids (GCs; CORT in rodents) are the central effectors of this 
stress response and promote adaptation. Conversely, persistently elevated levels of 
GCs during chronic stress have damaging consequences, especially in the brain 
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(Joels et al., 2007). Exposure to 21 days of exogenous CORT or restraint stress is 
found to result in dendritic atrophy of hippocampal neurons, as well as impairment 
in related cognitive functions over the same time-period (Magarinos et al., 1998; 
Walesiuk et al., 2006). Administration of CORT has also been shown to exacerbate 
hippocampal neuron loss and associated degenerative markers in a dose-dependent 
manner (Stein-Behrens et al., 1994). These deleterious effects were similar to that of 
restraint stress and thus, in fact, CORT mediates neuronal loss and 
neurodegeneration during chronic stress exposure (Watanabe et al., 1992; 
Manikandan et al., 2006), and associated cognitive impairment. Neuronal 
remodeling in key brain regions associated with depressive illness (Woolley et al., 
1990; Watanabe et al., 1992; Wellman, 2001; Vyas et al., 2002; Cook and Welhnan, 
2004) was demonstrated to be reversible by antidepressant drug treatments 
(Magarinos et al., 1999). In addition, studies have demonstrated that rats chronically 
administered medium to high doses of exogenous CORT develop behavioural 
abnormalities that resemble several of the diagnostic symptoms of depression in 
humans, including reduced locomotor activity (Femandes et al., 1997) and cognitive 
deficits (Bardgett et al., 1994; Bodnofif et al., 1995). Thus, repeated stress in 
laboratory animals or exogenous CORT have been utilized as "depressogenic 
manipiilations" and repeated corticosterone administration paradigm provides a 
useful model within which to further study the role of stress and glucocorticoids in 
depressive illness (Johnson et al., 2006). 
Although the detrimental effects of high levels of corticosterone on cognitive 
function, behaviour and brain morphology are well established, however, little is 
known about the effect of chronically high levels of this hormone on oxidative 
processes. The study on chronic emotional stress in rodents could not conclusively 
draw whether GCs or other stress factors contribute to oxidative damage (Fontella et 
al., 2005), however, after acute immobilization stress it was found that CORT levels 
are specific predictors of oxidative damage to the brain (Perez-Nievas et al., 2007). 
Thus, in extension of these findings, the present work attempted to further 
investigate the contribution of chronic restraint stress and different oral doses of this 
hormone to oxidant production by evaluating the consequent response of 
endogenous antioxidant defenses toward chronic exposure to CORT. The doses of 
CORT treatment and the experimental regime were based on the available literature, 
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which showed that subcutaneous CORT doses at 40 mg/kg significantly enhanced in 
vivo circulating CORT levels, and caused significant physiological changes such as 
substantial weight loss. Furthermore, a dose-dependent induction of depressive 
behaviour in rodents was reported using these doses (Johnson et al., 2006). The oral 
route was found equally efficacious to chronic subcutaneous administration of 
CORT in causing neuronal damage after 21 days (Magarinos et al., 1998; Nacher et 
al., 2004) and reliably mimicked the effects of restraint stress on neuronal atrophy, 
and induction of weight loss. Oral administration was also proposed to be less 
stressful to laboratory animals than the injection regime (Magarinos et al., 1998). 
With the view that oxidative stress is a significant pathophysiological finding in 
major depression (Herken et al., 2007; Michel et al., 2007), the present study was 
undertaken to evaluate the effects of exogenous CORT on antioxidant status within 
the same time-frame as previous relevant studies. 
Among other causative factors, oxidative stress also accounts for stress-
induced brain damage and neuropathology in several neurological and psychiatric 
diseases such as stress-induced depression (Cantuti-Castelvetri et al., 2000; Michel 
et al., 2007). Thus, the effect of exogenous CORT was evaluated on brain 
antioxidant enzyme activities of SOD, CAT, GST and GR, and the non-enzymatic 
antioxidants such as GSH levels, serum glucose and serum uric acid, as well as the 
pathological markers of oxidative stress, lipid peroxidation and protein carbonyl 
production. Since the association of stress with several non-psychiatric conditions is 
well documented (notably in case of cardiovascular disease and cancers) (Kugaya et 
al., 2000; Black and Garbutt, 2002; Mazza et al., 2007), antioxidant defenses were 
also investigated in the liver and the heart, important peripheral target organs 
siisceptible to stress-induced pathologies. To determine the contributory role of 
stress hormones in oxidative processes, the effects of oral CORT administration 
were compared with a parallel group of animals subjected to restraint stress and 
untreated non-stressed controls. Moreover, to assess any possible dose-dependent 
effects, the different CORT doses were also compared with each other. 
2. Experimental Protocol 
Male Swiss Albino rats weighing 100-125 g were used in the present study. 
Animals were acclimated to laboratory conditions and handled daily for a week prior 
43 
SECTION 1 
to experimental manipulations, which occurred during the light phase of the natural 
cycle. Weight-matched groups of six animals each were constituted, receiving either 
restraint stress or corticosterone treatment. A solution of corticosterone (Himedia, 
India) was prepared in 0.9 % physiological saline (with absolute ethanol to the final 
concentration of 2.5%) and administered via oral route to three groups of animals as 
10, 20 and 40 mg corticosterone per kg of body weight per day for 21 days. Another 
group of animals were subjected to restraint stress at random times for 4 h each day 
during the experimental period of 21 days by immobilizing them in wire mesh 
restrainers. Unstressed, imtreated animals constituted the control group and were 
accustomed to daily handling. Thus, the following five groups were constituted: 
Group I Control 
Group II Restraint stress (4 h daily for 21 days) 
Group III Corticosterone Dose 1(10 mg/kg/day, p.o. for 21 days) 
Group rv Corticosterone Dose 2 (20 mg/kg/day, p.o. for 21 days) 
Group V Corticosterone Dose 3 (40 mg/kg/day, p.o. for 21 days) 
At the end of the experimental period all animals were sacrificed under ether 
anaesthesia 24 h after the last restraint or corticosterone treatment. Blood samples 
were collected for separation of serum. Brain, liver and heart tissues were rapidly 
removed, washed in ice-cold sterile physiological saline (0.9%) and a 10% 
homogenate (0.1 M sodium phosphate buffer, pH 7.4) was utilized for analysis of 
enzymatic (SOD, CAT, GST, GR) and non-enzymatic antioxidants (GSH, uric acid, 
glucose). Oxidative damage was assessed by determining lipid peroxidation marker 
MDA and protein carbonyl contents. Marker enzymes of liver and heart were also 
assayed. {Details given in Materials and Methods) 
3. Results 
i. Effect of restraint stress and different doses of corticosterone on 
antioxidant enzyme activities 
As shown in figures 1-4 and table 1, chronic exogenous administration of all 
doses of corticosterone and chronic exposure to restraint stress induced a significant 
decrease of SOD, CAT, GST and GR activities in brain, liver, heart and circulation 
in comparison to controls (Dose 1: SOD: P<0.01 in brain, heart, P<0.05 in liver, 
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serum; CAT: P<0.05 in brain, heart, serum, P<0.02 in liver; GST: P<0.01 in brain, 
liver, P<0.05 in heart, P<0.02 in serum; GR: P<0.05 in brain, heart, P<0.02 in liver. 
Dose 2: SOD: P<0.001 in brain, P<0.05 in liver, P<0.01 in heart, serum; CAT: 
P<0.05 in brain, heart, serum, P<0.01 in liver; GST: P<0.001 in brain, P<0.01 in 
liver, heart, serum; GR: P<0.01 in brain, liver, P<0.02 in heart. Dose 3: SOD: 
P<0.01 in brain, heart, serum, P<0.001 in liver; CAT: P<0.01 in brain, liver, heart, 
P<0.02 in serum; GST: P<0.01 in brain, liver, serum, P<0.001 in heart; GR: P<0.01 
in bram, liver, P<0.02 in heart. Restraint stress: SOD: P<0.001 in brain, P<0.02 in 
liver, P<0.01 in heart, serum; CAT: P<0.05 in brain, serum, P<0.02 in liver, P<0.01 
in heart; GST: P<0.01 in brain, liver, P<0.02 in heart, P<0.01 in serum; GR: P<0.01 
in brain, P<0.05 in liver, P<0.02 in heart). The restraint stress-induced decrease of 
enzyme activities was not different from the decrease caused by any dose of 
corticosterone. 
Comparison among the three corticosterone doses showed a significant dose-
dependent effect (P<0.05) of corticosterone in reducing antioxidant enzyme 
activities in the brain. Corticosterone at 40 mg/kg/day decreased enzyme activities to 
a significantly greater extent than 10 mg/kg/day. A similar dose-response was 
evident for all enzymes except GR in heart and for only CAT in liver. Circulating 
levels of these enzymes, which reflect in vivo cellular antioxidant status, showed 
conformity with the pattern described above for brain (P<0.05). 
ii. Effect of restraint stress and different doses of corticosterone on non-
enzymatic antioxidant levels 
a. GSH 
Alterations in GSH by corticosterone and following exposure to the stress 
paradigm are depicted in Figure 5. GSH content was significantly reduced versus 
controls by all doses of CORT in all tissues (Dose 1: P<0.05 in brain, heart, P<0.01 
in liver; Dose 2: P<0.01 in brain, Hver, P<0.02 in heart; Dose 3: P<0.01 in brain, 
heart, P<0.001 in liver). Following exposure to the stress paradigm, significantly 
lower levels of GSH were also observed in brain, liver and heart, relative to control 
animals (P<0.01 in brain, liver, P<0.05 in heart). There were no significant 
differences between restraint stress and corticosterone for decreased GSH levels. In 
the brain, significant differences in GSH were observed among CORT doses 
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(P<0.05). Animals receiving 40 mg/kg/day CORT showed significantly greater 
decline in GSH levels when compared to those administered 10 mg/kg/day. No such 
dose-related effects were found for other tissues. 
b. Uric acid 
In comparison to control animals, administration of corticosterone 
significantly decreased serum uric acid concentration (table 1; Dose 1: P<0.05; Dose 
2: P<0.02; Dose 3: P<0.01). Restraint stress induced a similar decrease (P<0.05) in 
circulating levels of uric acid to CORT administration. CORT had dose-dependent 
effects on serum uric acid concentration (P<0.05). 
c Glucose 
Circulating levels of glucose (table 1) were significantly decreased with 
increasing doses of corticosterone (Doses 1, 2: P<0.001; Dose 3: P<0.01). A similar 
significant decline in serum glucose was also evident in response to stress exposure 
(P<0.01). 
iii. Effect of restraint stress and different doses of corticosterone on 
oxidative stress markers 
a. Lipid peroxidation 
As depicted in figure 6 and table 1, a significant increase in the 
concentrations of the aldehydic product of lipid peroxidation, malondialdehyde 
(MDA) was induced by exogenous corticosterone and restraint stress in the brain of 
treated animals (Doses 1, 2, 3: P<0.01; Restraint stress: P<0.001), liver (Dose 1: 
P<0.01, Doses 2, 3: P<0.02; Restraint stress: P<0.01), heart (Dose 1: P<0.05, Doses 
2, 3: P<0.01 in heart; Restraint stress: P<0.05), as compared to controls. A similar 
rise was also reflected in circulation (Doses 1, 2, 3: P<0.01; Restraint stress: 
P<0.02). The increase in MDA levels by exposure to restraint stress was similar to 
that after corticosterone treatment. 
b. Protein carbonyl production 
Administration of exogenous corticosterone doses elicited significant 
increases in carbonyl groups compared to untreated controls (figure 7; Dose 1: 
P<0.01 in brain, heart, P<0.05 in liver; Dose 2: P<0.001 in brain, P<0.01 in liver, 
heart; Dose 3: P<0.001 in brain, P<0.01 in liver, heart). A significant elevation in 
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protein oxidation was also exerted by restraint stress (P<0.001 in brain, P<0.01 in 
liver, heart). The effect of corticosterone in decreasing protein carbonyl contents was 
significantly dose-related in brain, liver and heart (P<0.05). A significantly greater 
elevation in protein oxidation was exerted in these tissues by 40 mg/kg/day CORT 
as compared to 10 mg/kg/day. 
iv. Effect of restraint stress and different doses of corticosterone on 
marker enzymes of liver and heart 
Liver and heart function enzymes are presented in figure 8 and table 2. 
Circulating, hepatic and cardiac levels of the marker enzymes GOT, GPT, ALP and 
LDH were significantly increased (P<0.05) in response to exogenous corticosterone 
treatments, as compared to controls. Restraint stress also produced a significant rise 
(P<0.05) in the activities of all the above marker enzymes, similar to corticosterone 
administration, both in circulation and tissues. 
V. Effect of different doses of corticosterone on body weight of animals 
Figure 9 shows the effect of increasing doses of corticosterone on body 
weights of animals measured every seven days starting fi-om the day of experimental 
manipulations. Both restraint stress and all doses of exogenous CORT significantly 
decreased body weight over the treatment period of 21 days, as compared to 
controls. On day 1, the effects of none of the CORT doses or restraint on body 
weight were statistically different fi-om controls. Loss of weight due to all doses of 
CORT, similar to restraint, was evident from the first week onward and remained 
significantly decreased thereafter (P<0.05). 
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Figure 1. Dose response effect of chronic corticosterone administration on SOD 
activity in brain, liver and heart of experimental animals. Animals in treatment 
groups received exogenous corticosterone doses (p.o., for 21 successive days) indicated as 
follows: Dose 1: 10 mg/kg/day; Dose 2: 20 mg/kg/day; Dose 3: 40 mg/kg/day; or were 
subjected to chronic restraint stress (4 h/day for 21 successive days). Data represent group 
mean ± S.E.M. (n = 6). a, b, c, d: P<0.05, P<0.02, P<0.01, P<0.001 as compared with the 
control group. * P<0.05 as compared to Dose 1. 
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Figure 2. Dose response effect of chronic corticosterone administration on CAT 
activity in brain, liver and heart of experimental animals. Animals in treatment 
groups received exogenous corticosterone doses (p.o., for 21 successive days) indicated as 
follows: Dose 1: 10 mg/kg/day; Dose 2: 20 mg/kg/day; Dose 3: 40 mg/kg/day; or were 
subjected to chronic restraint stress (4 h/day for 21 successive days). Data represent group 
mean ± S.E.M. (n = 6). a, b, c, d: P<0.05, P<0.02, P<0.01, P<0.001 as compared with the 
control group. * P<0.05 as compared to Dose 1. 
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Figure 3. Dose response effect of chronic corticosterone administration on GST 
activity in brain, liver and heart of experimental animals. Animals in treatment 
groups received exogenous corticosterone doses (p.o., for 21 successive days) indicated as 
follows: Dose 1: 10 mg/kg/day; Dose 2: 20 mg/kg/day; Dose 3: 40 mg/kg/day; or were 
subjected to chronic restraint stress (4 h/day for 21 successive days). Data represent group 
mean ± S.E.M. (n = 6). a, b, c, d: P<0.05, P<0.02, P<0.01, P<0.001 as compared with the 
control group. • P<0.05 as compared to Dose 1. 
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Figure 4. Dose response effect of chronic corticosterone administration on GR 
activity in brain, liver and heart of experimental animals. Animals in treatment 
groups received exogenous corticosterone doses (p.o., for 21 successive days) indicated as 
follows: Dose 1: 10 mg/kg/day; Dose 2: 20 mg/kg/day; Dose 3: 40 mg/kg/day; or were 
subjected to chronic restraint stress (4 h/day for 21 successive days). Data represent group 
mean ± S.E.M. (n = 6). a, b, c, d: P<0.05, P<0.02, P<0.01, P<0.001 as compared with the 
control group. * P<0.05 as compared to Dose 1. 
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Figure 5. Dose response effect of chronic corticosterone administration on GSH levels 
in brain, liver and heart of experimental animals. Animals in treatment groups 
received exogenous corticosterone doses (p.o., for 21 successive days) indicated as 
follows: Dose 1: 10 mg/kg/day; Dose 2: 20 mg/kg/day; Dose 3: 40 mg/kg/day; or were 
subjected to chronic restraint stress (4 h/day for 21 successive days). Data represent group 
mean ± S.E.M, (n = 6). a, b, c, d: P<0.05, P<0.02, P<0.01, P<0.001 as compared with the 
control group. * P<0.05 as compared to Dose 1. 
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Figure 6. Dose response effect of chronic corticosterone administration on lipid 
peroxidation levels in brain, liver and heart of experimental animals. Animals 
in treatment groups received exogenous corticosterone doses (p.o., for 21 successive days) 
indicated as follows: Dose 1:10 mg/kg/day; Dose 2: 20 mg/kg/day; Dose 3:40 mg/kg/day; 
or were subjected to chronic restraint stress (4 h/day for 21 successive days). Data 
represent group mean ± S.E.M. (n = 6). a, b, c, d: P<0.05, P<0.02, P<0.01, P<0.001 as 
compared with the control group. 
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Figure 7. Dose response effect of chronic corticosterone administration on protein 
carbonyl contents in brain, liver and heart of experimental animals. Animals in 
treatment groups received exogenous corticosterone doses (p.o., for 21 successive days) 
indicated as follows: Dose 1:10 mg/kg/day; Dose 2: 20 mg/kg/day; Dose 3:40 mg/kg/day; 
or were subjected to chronic restraint stress (4 h/day for 21 successive days). Data 
represent group mean ± S.E.M. (n = 6). a, b, c, d: P<0.05, P<0.02, P<0.01, P<0.001 as 
compared with the control group. * P<0.05 as compared to Dose 1. 
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Figure 8. Circulating (SCOT, SGPT) and hepatic (GOT, GPT) levels of liver function 
enzymes in response to chronic corticosterone administration. Animals in 
treatment groups received exogenous corticosterone doses (p.o., for 21 successive days) 
indicated as follows: Dose 1:10 mg/kg/day; Dose 2: 20 mg/kg/day; Dose 3: 40 mg/kg/day; 
or were subjected to chronic restraint stress (4 h/day for 21 successive days). Data 
represent group mean ± S.E.M. (n = 6). * P<0.05 as compared with the control group. 
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Table 1. Dose response effect of chronic corticosterone administration on 
circulating levels of antioxidant defenses and oxidative stress markers. 
Group 
Control 
Restraint 
stress 
Dosel 
Dose 2 
Dose 3 
SOD 
(U/mg 
protein) 
22.80 
±0.23 
9.90' 
±0.71 
13.20* 
±1.08 
10.51' 
±0.45 
8.04'* 
±0.33 
CAT 
(U/mg 
protein) 
1.52 
±0.14 
0.53" 
±0.10 
0.66" 
±0.02 
0.61" 
±0.05 
0.38*'' 
±0.06 
GST 
(U/mg 
protein) 
0.30 
±0.06 
0.09' 
±0.02 
0.12'' 
±0.01 
0.10' 
±0.01 
0.06'* 
±0.01 
MDA 
(nmol/ 
mg 
protein) 
0.09 
±0.01 
0.37" 
±0.05 
0.34' 
±0.03 
0.41' 
±0.03 
0.43' 
±0.03 
Glucose 
(mg/dl) 
110.83 
±4.99 
72.44' 
±6.98 
81.55" 
±2.91 
70.22'* 
±3.14 
65.55' 
±7.60 
Uric 
acid 
(mg/dl) 
3.76 
±0.39 
1.76" 
±0.33 
2.14" 
.0.14 
1.69'' 
±0.17 
1.28'* 
±0.14 
Animals in treatment groups received exogenous corticosterone doses (p.o., for 21 
successive days) indicated as follows: Dose 1: 10 mg/kg/day; Dose 2: 20 mg/kg/day; Dose 
3: 40 mg/kg/day; or were subjected to chronic restraint stress (4 h/day for 21 successive 
days). Data represent group mean ± S.E.M. (n = 6). a, b, c, d: P<0.05, P<0.02, P<0.01, 
P<0.001 as compared with the control group.* P<0.05 as compared to Dose 1. 
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Table 2. Circulating, hepatic and cardiac levels of marker enzymes in 
response to chronic corticosterone administration. 
1 Group 
Control 
Restraint stress 
Dose 1 
Dose 2 
Dose 3 
ALP (mg/ml) 
Serum 
0.248 
± 0.024 
0.580* 
± 0.039 
0.485* 
±0.019 
0.603* 
± 0.035 
0.678* 
± 0.042 
Liver 
2.038 
±0.146 
4.308* 
± 0.259 
3.863* 
± 0.239 
4.830* 
±0.141 
5.058* 
± 0.252 
LDH (U/mg protein) 
Serum 
0.078 
±0.015 
0.184* 
±0.016 
0.161* 
±0.015 
0.221* 
± 0.035 
0.239* 
± 0.037 
Liver 
0.215 
±0.016 
0.473* 
± 0.024 
0.398* 
±0.019 
0.508* 
±0.018 
0.538* 
± 0.024 
Heart 
0.401 
±0.044 
0.621* 
± 0.039 
0.592* 
± 0.023 
0.685* 
±0.013 
0.704* 
± 0.033 
Animals in treatment groups received exogenous corticosterone doses (p.o., for 21 
successive days) indicated as follows: Dose 1:10 mg/kg/day; Dose 2: 20 mg/kg/day; Dose 
3: 40 mg/kg/day; or were subjected to chronic restraint stress (4 h/day for 21 successive 
days). Data represent group mean ± S.E.M. (n = 6). * P<0.05 as compared with the control 
group. 
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Figure 9. Dose response effect of chronic corticosterone administration on body 
weight of experimental animals. Body weight was recorded every 7 days. Animals in 
treatment groups received exogenous corticosterone doses (p.o., for 21 successive days) 
indicated as follows: Dose 1:10 mg/kg/day; Dose 2:20 mg/kg/day; Dose 3:40 mg/kg/day; 
or were subjected to chronic restraint stress (4 h/day for 21 successive days). Data 
represent group mean ± S.E.M. (n = 6). *: P<0.05 as compared with the control group. 
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4. Discussion 
Currently, few studies exist concerning direct correlations between induction 
of oxidative damage under stress and the magnitude of exposure to stress hormones. 
Important findings in the available literature come from the work of Perez-Nievas 
and coworkers (Perez-Nievas et al., 2007). They have demonstrated rise in the levels 
of circulating CORT after acute immobilization to be directly proportional to the 
increase in oxidative mediators, thereby predictive of the degree of stress-induced 
brain damage imder these conditions. Past studies have demonstrated that three days 
exposure to exogenous GCs decreased brain SOD and CAT activities (Mcintosh et 
al., 1998a, 1998b), and CORT reduces GPx activity in vitro (Patel et al., 2002). In 
the present work a possible direct contribution of stress hormones to oxidative 
processes is investigated by chronic administration of exogenous CORT in isolation 
of other applied stressors. In brief, the main outcome of this approach was a 
coordinate decline in a wide range of enzymatic and non-enzymatic antioxidant 
defense components in response to all doses of CORT employed, in a dose-
dependent manner. The results confirm that the effects of chronically administered 
CORT on induction of oxidative stress are similar to that induced by a severe 
physical and psychological stressor (restraint stress) (Fontella et al., 2005; Zafir and 
Banu, 2007). The diminished antioxidant status was evident not only in the brain of 
experimental animals, but also in the important peripheral target organs of stress 
such as liver and heart. In all organs, a dose-response was obtained for the most 
important antioxidant enzymes, SOD and CAT, between the high (40 mg/kg) and 
low (10 mg/kg) doses of CORT. The results obtained in the tissues were comparable 
with that of circulation. Similar dose-effect was observed for protein oxidation in all 
organs too. 
During the stress response, essential catabolism is increased by GCs, which 
are the principal effectors of these adaptive changes. However, continuous stress-
enhanced metabolism is associated with increased production of oxidant species that 
ultimately raises basal levels of oxidative stress to damaging proportions (Liu and 
Mori, 1999). A prolonged stress response mediated by GCs can also have negative 
effects on important cellular adaptations in the brain, thereby causing neuronal loss 
and suppressing neurogenesis during chronic exposure to stress (Joels et al., 2007). 
The importance of altered structure-ftmction relationships is evident from 
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behavioural aberrations such as impaired cognitive function related to neuronal 
atrophy in the relevant brain region (for e.g., hippocampus) (Manikandan et al., 
2006). Of further significance is the observation that increased oxidative stress has 
also been found to occur in these key areas of the brain after chronic stress, 
contributing to and exacerbating neurodegeneration in stress-related disorders, such 
as volume reduction in the brain of depressed patients due to morphological changes 
(Michel et al., 2007). The impact of stress hormones on brain function is thus 
significantly related to chronic stress-induced oxidative processes. In this context, it 
is also notable that accumulating evidence now implicates oxidative stress in the 
adaptive stress response. It is increasingly being established in various animal 
models that an inability to balance oxidant-antioxidant interactions is concomitant to 
greater susceptibility to various types of stress (Winter, 1998; Bonilla et al., 2002). 
Combating oxidative stress is thus relevant to maintaining homeostasis, and is linked 
to protection from the deleterious consequences of stress. Besides the brain, the 
stress response is also manifested in peripheral organ systems and is associated with 
oxidative stress in these organs as well (Hu et al., 2000; Kaushik and Kaur, 2003). 
Consistent with this view, and apparent in the present work, the restraint stress 
model has been shown to reliably produce robust increases in basal oxidative stress 
in different organs by various investigators as well as previous work in our 
laboratory (Liu et al. 1996; Madrigal et al., 2001; Zafir and Banu, 2007). To clarify 
the causal versus consequential role of stress hormones in stress-related oxidative 
processes, the effect of chronic administration of CORT was smdied in isolation of 
other applied stressors. Of significance, it was observed that the manner by which 
exogenous CORT compromised in vivo antioxidant status in experimental animals 
was strikingly analogous to the deleterious effects of restraint stress, indicating a 
direct effect of stress hormones on induction of oxidative stress during physical and 
psychological stress. Efficient cellular antioxidant mechanisms serve to 
counterbalance the potential deleterious effects of ROS and reduce oxidative stress. 
In spite of this, the brain is very sensitive to oxidative damage due to its much 
greater oxygen requirements that enhance oxidant production (Cui et al., 2004). A 
synchronized significant decline in the activities of the important antioxidant 
enzymes SOD and CAT by exogenous CORT signifies enhanced vulnerability 
toward the primary ROS, superoxide anion (dismutated by SOD) and hydrogen 
peroxide (metabolized by CAT). The damaging effects of both these species is 
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especially manifested in their interaction to generate hydroxyl radicals, the most 
destructive ROS to cellular integrity, causing widespread damage to all 
macromolecules, including proteins, nucleic acids, and lipids. Adding to this 
extensive cellular oxidative damage, CORT also significantly depleted uric acid, a 
major circulating non-enzymatic antioxidant molecule that functions in the aqueous 
phase as scavenging/chain-breaking antioxidant. Moreover, treatment with all doses 
of exogenous CORT was found to significantly reduce levels of the major non-
enzymatic thiol antioxidant GSH, concomitant to decreasing activities of the GSH-
metabolizing enzymes, GST and GR. This GSH system has multifunctional roles in 
combating oxidative stress via direct scavenging of free radicals, detoxification of 
electrophilic compounds and lipid hydroperoxides, modulation of cellular redox 
status and thiol-disulphide status of proteins, and regulation of cell signaling and 
repair pathways (Cnubben et al., 2001). Thus, an aberration in this critical second 
line of cellular defense against ROS further intensifies oxidative stress by CORT. 
This is supported by recent findings that 21 days of daily restraint stress 
significantly decreased the gene expression of Gstp2, which codes for GST (Cohen 
et al., 2006). This down regulation is related to increased oxidative stress observed 
upon chronic exposure to restraint, accounting, in part, for the structural and 
functional damage to the brain. Drawing a parallel from the present results, it may 
possibly be inferred that such stress-mduced oxidative and neurotoxic damage 
during physical and psychological stress could be directly mediated by stress 
hormones. Reduction in GSH is also a signaling event in apoptosis (Sato et al., 
1995), while a major neuronal defense mechanism against apoptotic cell death is 
upregulation of SOD (Greenlund et al., 1995). Thus, an overall CORT-induced 
decline in not only SOD activity and GSH, but also in the activities of other 
enzymes working in conjunction with them (CAT, GST and GR) may largely 
promote neurodegeneration via apoptotic mechanisms, as evidenced by atrophy of 
brain regions in stress-induced depression. A dose-response of all these endogenous 
antioxidants towards the high and low CORT doses in the brain may thus be related 
to the previously demonstrated dose-dependent effects of CORT in eliciting 
depressive behaviour in rodents (Johnson et al., 2006). Growing body of evidence 
supports oxidative stress as a major pathological finding in depression (Khanzode et 
al., 2003; Tsuboi et al., 2006). The results of the present study on the effect of 
exogenous CORT in decreasing antioxidant defenses correlates well with the earlier 
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finding where enhancement of oxidative stress in brain could be predicted by 
endogenous plasma CORT levels (Perez-Nievas et al., 2007). Therefore, the data 
presented here indicating a substantial decline in key components of the antioxidant 
defense system by corticosterone, parallel to the effects of restraint stress, points to a 
key role of stress hormones in initiating stress-induced oxidative damage. 
This is further corroborated by the observed amplification in markers of 
oxidative stress, lipid peroxidation and protein oxidation, by corticosterone 
treatments. These secondary effects of oxidative stress have particularly vast 
potential to affect several aspects of brain function, due to the high content of 
oxidisable polyunsaturated fatty acids in the brain. Peroxidation of lipids has 
disruptive potential to alter membrane viscosity, fluidity, permeability, as v^ ell as to 
impair the functions of membrane transport proteins and ion channels, thereby 
adversely affecting electrical potential and controlled transport of metabolites across 
the membrane (Mattson, 1998). Protein oxidation directly affects the structure of the 
cell, enzymatic processes such as free radical scavenging, metabolism, and also cell 
signaling pathways, as well as inducing the accumulation of oxidized proteins and 
enhancing cellular dysfunction (Stadtman and Levine, 2000). In the present study a 
significant dose-related effect of exogenous CORT on lipid peroxidation was not 
observed as reported by Perez-Nievas et al. (2007). However, a dose-dependent 
increase in another marker of oxidative stress, protein carbonyl content, was 
observed in all organs. This apparently signifies the impact of stress in disrupting 
homeostasis at the cellular level, due to the critical involvement of proteins in 
maintaining all vital intracellular functions. This finding is important because 
protein oxidation events are linked to the pathology of several diseases as well as 
aging processes (Stadtman and Levine, 2000). 
Thus the present study is also of interest in relation to the role of oxidative 
stress as a crucial link between stress and the development of disease, as well as 
associations found between psychiatric and non-psychiatric conditions, particularly 
cancers and cardiovascular disease (Mazza et al., 2007). For example, psychological 
stress is a recognized major risk factor for cardiovascular disease (Wittstein et al., 
2005). It is possible that insufficiencies in the antioxidant system imposed by stress 
hormones, as evidenced by the present results, may underlie stress-induced 
degenerative diseases affecting various organs and their physiological functions. The 
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present finding thus also corroborates the involvement of oxidative stress in 
physiological damage exerted on major organ systems during exposure to chronic 
stress, as a putative mechanism for stress-induced disease, hi this regard, a CORT 
dose-response was especially evident in the brain, denoting higher vulnerability to 
oxidative stress during chronic physical and psychological stress and supporting the 
contribution of oxidative processes in stress-induced psychiatric disorders, 
especially depression. The dose-effect of CORT in the heart was found for SOD, 
CAT and GST, while in the liver, only CAT activity was affected in this manner. 
This result could be interpreted in a general way to mean that the heart is more 
susceptible to the adverse effects of stress-induced oxidative damage than the liver, 
and thus partially account for the stress-induced onset of cardiovascular disease. 
Therefore, this finding may hold important implications for pharmacological 
interventions targeting cellular antioxidants as a promising stress management 
strategy for protecting against oxidative insults in all kinds of psychiatric and non-
psychiatric conditions induced by stress. This is supported by various animal studies 
demonstrating that negative consequences of stress are amenable to improvement by 
antioxidant intervention acting through various pathways to enhance resistance to 
stress (Winter et al., 1998; Bonilla et al., 2001, Pardon et al., 2004). 
Finally, oxidative damage induced by CORT was found to be associated with 
decreased body weight, an "organic correlate of stress effects" (Sapolsky et al., 
2000). The present study confirms previous reports of substantial weight loss during 
exposure to repeated stress, and decreased body weight gain due to administration of 
glucocorticoids (Magarinos et al., 1998; Johnson et al., 2006). 
In conclusion, to the best of our knowledge, this is the first comprehensive 
study that has evaluated and clearly demonstrated such oxidative damage to vital 
organs of experimental animals, including brain, liver and heart, due to exogenously 
administered stress hormone depicting clear similarities with the outcomes of 
chronic restraint stress, thus suggesting that stress hormones have a causal role in 
impacting oxidative processes induced during the adaptive response to physical and 
psychological stress. 
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1. Introduction 
Stress is a universal phenomenon in everyday life and is attracting increased 
focus. Stress-induced perturbations in the biological equilibriiun are effectively 
balanced by general stress responses. A large body of evidence concerning harmful 
consequences of stress indicates that chronic persistence of the stressor is required 
(Stein-Behrens et al., 1994; Magarinos and McEwen, 1995). A great number of 
human illnesses reflect the consequences of an inability to cope with excessively 
stressful situations, like environmental, physiological or psychological, all of which 
are known to finally precipitate several stress-related diseases (Chrousos and Gold, 
1992). Free radical-mediated pathology is an important mechanism by which stress 
causes widespread damage to health. Exposure to chronic stress disrupts the in vivo 
pro-oxidant:antioxidant balance to damaging proportions, a potential cause 
underlying the development of various diseases and pathological states in humans 
(Stojilkovic et al., 2005). Oxidative stress is critically associated with the etiology of 
several chronic diseases, including cancer and cardiovascular disease, which account 
for a major portion of deaths today (Willcox et al., 2004). 
Given the broad spectrum of damage by stress, the global trend is shiftmg 
towards traditional and integrative health sciences both in research and practice 
(Scartezzini and Speroni, 2000). The whole person concept of customized medicine 
is the therapeutic basis of Ayurvedic pharmacology, the traditional Indian medical 
system that aims at holistic management of health and disease, approved by the 
World Health Organization (Zaman, 1974; Singh, 1992). Medicinal plants of the 
'Rasayana' group act by modulatmg the neuro-endocrino-immune systems and have 
been found to be a rich source of antioxidants (Brahma and Debnath, 2003). These 
herbal drugs are used to treat diverse physiological disorders associated with 
oxidative stress, probably through their antioxidant potential. Their 
antistress/adaptogenic properties against diverse unrelated stressors have made them 
therapeutically far more important (Brahma and Debnath, 2003). 
Withania somnifera (WS) is not only a general herbal tonic (Sharma and 
Dandiya, 1991), but also an official drug included in the Indian Pharmacopeia 
(1985). Its traditional Ayurvedic use includes many diseases associated with 
oxidative damage, maybe due to a certain degree of its antioxidant activity (Mishra 
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et al., 2000). WS has also been therapeutically used for the treatment of several 
stress-induced diseases (Weiner and Weiner, 1994). Some of the biochemical 
parameters evaluated and normalized by WS were stress-induced increases in blood 
urea nitrogen, blood lactic acid (Dadkar et el, 1987) and plasma corticosterone 
(Archana and Namasivayan, 1999). Physiological indices included reversal of 
adrenal hypertrophy (Dadkar et el., 1987) and increase in body weight (Grandhi et 
al., 1994), while behavioiiral parameters improved by WS comprise stress-induced 
cognitive impairment and reduction in swimming time (Bhattacharya et al., 1995; 
Bhattacharya et al., 2000; Bhattacharya and Muruganandam, 2003). Although 
significant anti-stress activity of WS has also been documented in acute restraint 
stress-induced gastric ulceration, auto-analgesia and thermic response of morphine 
in rodents (Bhattacharya et al., 1987), however, the effects of WS on chronic 
restraint stress-induced oxidative damage were not determined. 
Very few experimental studies have been carried out to study the effects of 
another herbal adaptogen used in Ayurvedic medicine, Raitwolfia serpentina (RS). It 
has been described as an antipsychotic (Meimini, 2002) and antidepressant 
(Reynolds, 1993; Mamedov, 2005) for nervous and mental disorders in 
pharmacopeias and traditional systems of medicine. Its usage in modem medicine is 
for the treatment of cardiovascular disease and hypertension (Frishman et al., 2004). 
'Rasayana' drugs are good hepatoprotective agents and have antagonistic actions on 
oxidative stressors (Govindarajan et al., 2005). The hepatoprotective property of RS 
has also been documented against paracetamol-induced oxidative damage, 
attributable to its in vivo antioxidant activity (Gupta et al., 2006). Stress is known to 
be a cofactor in the aggravation of liver diseases (Lu et al., 2003), however, the 
effects of RS on stress-induced oxidative damage to the liver, the central metabolic 
target organ of stress, have not been mvestigated. 
Thus, the objective of the present study was to examine the effects of WS 
and RS on restraint stress-induced oxidative damage in rodents by assessing 
antioxidant status in vital target organs of stress like brain, liver and heart, as well as 
in circulation. 
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2. Experimental Protocol 
Swiss Albino rats weighing 125-150 g were used in this study after 
habituation to standard laboratory conditions for a week. Six weight-matched groups 
of five animals each were randomly constituted for stress and drug treatments over 
an experimental period of 21 days. Unstressed, untreated animals constituted the 
control group and were accustomed to daily handling. Stressed animals were 
exposed to 4 h restraint at random times each day. Standardized root extracts of 
Withania somnifera (1.5% withanolides, 1.0% alkaloids) (The Himalaya Drug Co., 
Bangalore, India) and Raitwolfia serpentina (2% alkaloids) (Hamdard Wakf 
Laboratories, New Delhi, India) were administered to animals orally in 
physiological saline, either alone or 30 min following restraint. The doses and 
treatment schedule are presented below: 
Group I Control 
Group II Withania somnifera root extract (WS: 250 mg/kg/day, p.o. for 
21 days) 
Group III Ravwolfia serpentina root extract (RS: 200 mg/kg/day, p.o. for 
21 days) 
Group rV Restraint stress (4 h daily for 21 days) 
Group V Restraint stress (4 h daily for 21 days) followed by WS extract 
(250 mg/kg/day, p.o. for 21 days) 
Group VI Restraint stress (4 h daily for 21 days) followed by RS extract 
(200 mg/kg/day, p.o. for 21 days) 
Animals were anesthetized and sacrificed 24 h after the last restraint session 
or drug treatment, upon completion of the 21 day experimental period. Blood 
samples were collected for separation of serum. Brain, liver and heart tissues were 
rapidly removed, washed in ice-cold sterile physiological saline (0.9%) and a 10% 
homogenate (0.1 M sodium phosphate buffer, pH 7.4) was utilized for analysis of 
enzymatic (SOD, CAT, GST, GR) and non-enzymatic antioxidants (GSH, uric acid). 
Oxidative damage was assessed by determining lipid peroxidation markers and 
protein carbonyl contents. Marker enzymes of liver and heart were also assayed. 
{Details given in Materials and Methods) 
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3. Results 
i. Effect of WS and RS on restraint stress-induced decline in 
antioxidant enzyme activities 
The results depicted in Figure 1 and Table 1 show that restraint stress 
significantly decreased (P<0.01) SOD activity in brain, liver and heart of 
experimental animals in comparison to untreated controls, which was also reflected 
in serum. However, compared to stressed animals, oral administration of WS 
following the restraint session could significantly increase (P<0.02) SOD activity in 
brain, liver and heart and also in serum. A significant enhancement (P<0.02) in SOD 
activity was also observed by RS treatment to stressed animals in all organs as well 
as in serum. 
As shown in Figure 2 and Table 1, CAT activity was also significantly 
reduced (P<0.01) by chronic stress in brain, liver, heart and serum as compared to 
control animals. Following stress, WS administration significantly enhanced 
(P<0.02) enzyme activity in all organs and serum, relative to stressed animals. RS 
was also observed to reverse stress-induced decline in CAT activity significantly 
(P<0.02) in all tissues, including serum. 
GST activity is presented in Figure 3 and Table 1. Restraint stress 
significantly decreased (P<0.01) GST activity in brain, liver, heart and serum in 
comparison to control levels. However, in comparison to stress alone-treated 
animals, oral treatment of stressed rats with WS resulted in a significant increase 
(P<0.02) in GST activity. Similarly, RS administration caused a significant rise 
(P<0.02) in GST activity following stress, in brain, liver, heart and serum. 
Evident in Figure 4, a similar result was obtained for GR activity, which was 
significantly declined (P<0.01) by restraint stress in all organs, but enhanced 
significantly following WS and RS treatments (for both, P<0.02). 
In non-stressed animals, both WS and RS did not cause any significant 
alteration in the basal activities of antioxidant enzymes (Figures 1-4, Table 1). 
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ii. Effect of WS and RS on restraint stress-induced decline in non-
enzymatic antioxidant levels 
a, GSH 
Chronic exposure to restraint stress significantly depleted (P<0.01) GSH 
levels in brain, liver and heart as compared to non-stressed controls (Figure 5). Both 
the drug treatments were foimd to have a comparable protective effect against stress-
induced alterations. WS significantly increased (P<0.02) GSH in brain, liver and 
heart. RS also caused a significant increase (P<0.02) of GSH in all these organs. 
Both the drugs administered to non-stressed animals did not alter the normal 
GSH levels from control values. 
b. Glucose 
A significant reduction (P<0.01) in circulating glucose concentrations was 
observed in stressed animals relative to the controls (Table 1). This was significantly 
increased by WS as well as by RS following the stress paradigm (for both, P<0.02). 
Both the drugs administered to non-stressed animals did not affect glucose 
levels significantly. 
iii. Effect of WS and RS on restraint stress-induced lipid peroxidation 
As depicted in Figure 6, restraint stress significantly elevated lipid 
peroxidation in all organs (P<0.01) in comparison to controls, and this rise was 
reflected in circulation as well. WS exerted a normalizing effect by significantly 
reducing (P<0.02) MDA levels in brain, liver, heart and serum. Similarly, RS 
administration also caused significant decrease (P<0.02) in lipid peroxidation 
relative to stressed animals in all organs and in serum. 
Lipid peroxidation was maintained near basal levels as in controls by both 
the drugs given to non-stressed animals. 
iv. Effect of WS and RS on marker enzymes of liver and heart 
While restraint stress exposure was characterized by a significant elevation 
(P<0.01) in all the marker enzymes of liver and heart, like GOT, GPT, ALP and 
LDH (Figure 7, Table 2), however, treatment with both the drugs to the stressed 
animals resulted in a substantial hepatoprotective and cardioprotective effect as 
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evidenced by a significant decline (P<0.01) in the levels of these enzymes, in tissues 
as well as in circulation, compared to stressed animals. 
Oral treatment alone of WS and RS maintained levels of marker enzymes 
near normal values. 
v. Effect of WS and RS on restraint stress-induced decline in body 
weight of animals 
Figure 8 depicts a declining trend for body weight upon exposure to chronic 
restraint stress which was significantly reduced (P<0.05) jfrom Day 14 onwards in 
comparison to control animals. Stress-induced weight loss was antagonized by both 
WS and RS in a comparable manner and body weights of these animals were 
significantly higher (P<0.05) than those of stressed animals on Days 14 and 21. WS 
and RS treatment to non-stressed animals maintained body weight close to that 
observed in control animals throughout the duration of the experiment, with no 
significant changes being produced. 
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Figure 1. Effect of Withania somnifera (WS) and Rauwolfia serpentina (RS) 
administration on SOD activity in brain, liver and heart of experimental 
animals. Animals in treatment groups received WS (250 mg/kg/day, p.o.) or RS (200 
mg/kg/day, p.o.) for 21 successive days, either alone or following 4 h of daily restramt 
stress (Stress + WS, Stress + RS). Data represent group mean ± S.E.M (n = 5). * P<0 01 
as compared with the control group; # P<0.02 as compared with stress alone. 
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Figure 2. Effect of Withania somnifera (WS) and Rauwolfia serpentina (RS) 
administration on CAT activity in brain, liver and Iieart of experimental 
animals. Animals in treatment groups received WS (250 mg/kg/day, p.o.) or RS (200 
mg/kg/day, p.o.) for 21 successive days, either alone or following 4 h of daily restraint 
stress (Stress + WS, Stress + RS). Data represent group mean ± S.E.M. (n = 5). * P<0 01 
as compared with the control group; # P<0.02 as compared with stress alone. 
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Figure 3. Effect of Withania somnifera (WS) and Rauwolfia serpentina (RS) 
administration on GST activity in brain, liver and heart of experimental 
animals. Animals in treatment groups received WS (250 mg/kg/day, p.o.) or R5 (200 
mg/kg/day, p.o.) for 21 successive days, either alone or following 4 h of daily restraint 
stress (Stress + WS, Stress + RS). Data represent group mean ± S.E.M. (n = 5). • P<0.01 
as compared with the control group; # P<0.02 as compared with stress alone. 
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Figure 4. Effect of Withania somnifera (WS) and Rauwolfia serpentina (RS) 
administration on GR activity in brain, liver and heart of experimental 
animals. Animals in treatment groups received WS (250 mg/kg/day, p.o.) or RS (200 
mg/kg/day, p.o.) for 21 successive days, either alone or following 4 h of daily restraint 
stress (Stress + WS, Stress + RS). Data represent group mean ± S.E.M. (n = 5). • P<0 01 
as compared with the control group; # P<0.02 as compared with stress alone 
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Figure 5. Effect of Withania somnifera (WS) and Rauwolfia serpentina (RS) 
administration on GSH levels in brain, liver and heart of experimental 
animals. Animals in treatment groups received WS (250 mg/kg/day, p.o.) or RS (200 
mg/kg/day, p.o.) for 21 successive days, either alone or following 4 h of daily restraint 
stress (Stress + WS, Stress + RS). Data represent group mean ± S.E.M. (n = 5). • P<0.01 
as compared with the control group; # P<0.02 as compared with stress alone. 
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Figure 6. Effect of Withania somnifera (WS) and Rauwolfia serpentina (RS) 
administration on lipid peroxidation levels in brain, liver and heart of 
experimental animals. Animals in treatment groups received WS (250 mg/kg/day, p.o.) 
or RS (200 mg/kg/day, p.o.) for 21 successive days, either alone or following 4 h of daily 
restraint stress (Stress + WS, Stress + RS). Data represent group mean ± S.E.M. (n = 5). 
*P<0.01 as compared with the control group; # P<0 02 as compared with stress alone. 
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Figure 7. Circulating (SGOT, SGPT) and hepatic (GOT, GPT) levels of Uver function 
enzymes in response to chronic administration of Withania somnifera (WS) 
and Rauwolfia serpentina (RS). Animals in treatment groups received WS (250 
mg/kg/day, p.o.) or RS (200 mg/kg/day, p.o.) for 21 successive days, either alone or 
following 4 h of daily restraint stress (Stress + WS, Stress + RS). Data represent group 
mean ± S.E.M. (n = 5). * P<0.01 as compared with the control group; # P<0.01 as 
compared with stress alone. 
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Table 1. Modulatory effects of chronic Withania somnifera (WS) and Rauwqlfia 
serpentina (RS) treatments on restraint stress-induced alterations 1h fc'irculatkig^'"• 
levels of antioxidant defenses and oxidative stress markers. 
Group 
Control 
WS 
RS 
Restraint 
stress 
Stress + WS 
Stress + RS 
SOD 
(U/mg 
protein) 
2.69 
±0.29 
3.06 
±0.32 
2.21 
±0.30 
0.78* 
±0.24 
2.30* 
±0.18 
1.84* 
±0.27 
CAT 
(U/mg 
protein) 
0.29 
±0.02 
0.33 
±0.03 
0.25 
±0.03 
0.09* 
±0.01 
0.22* 
±0.02 
0.19* 
±0.04 
GST 
(U/mg 
protein) 
1.00 
±0.14 
1.05 
±0.17 
0.87 
±0.09 
0.36* 
±0.08 
0.80* 
±0.12 
0.71* 
±0.20 
MDA 
(nmol/ 
mg 
protein) 
9.84 
±0.28 
9.10 
±0.30 
8.65 
±0.84 
15.26* 
±1.36 
7.81* 
±0.85 
10.34* 
±1.40 
Glucose 
(m^M^-
42.18 
±1.99 
44.01 
±3.73 
50.23 
±4.03 
13.65* 
±2.70 
39.70* 
±2.12 
42.42* 
±6.2 
: 
Animals in treatment groups received WS (250 mg/kg/day, p.o.) or RS (200 mg/kg/day, 
p.o.) for 21 successive days, either alone or following 4 h of daily restraint stress (Stress + 
WS, Stress + RS). Data represent group mean ± S.E.M. (n = 5). * P<0.01 as compared 
with the control group; # P<0.02 as compared with stress alone. 
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Table 2. Circulating, hepatic and cardiac levels of marker enzymes in 
response to chronic administration of Withania somnifera (WS) and Rauwoljia 
serpentina (RS). 
Group 
Control 
WS 
RS 
Restraint 
stress 
Stress + WS 
Stress + RS 
ALP (mg/ml) 
Serum 
0.281 
± 0.023 
0.276 
± 0.051 
0.292 
± 0.052 
0.515* 
± 0.033 
0.314* 
± 0.026 
0.321* 
± 0.042 
Liver 
1.750 
±0.410 
1.600 
± 0.220 
1.820 
± 0.209 
3.850* 
± 0.350 
2.100* 
±0.140 
2.350* 
± 0.300 
LDH (U/mg protein) 
Serum 
0.097 
±0.014 
0.106 
±0.016 
0.112 
± 0.022 
0.240* 
± 0.023 
0.120* 
±0.018 
0.133* 
±0.017 
Liver 
0.280 
±0.021 
0.250 
± 0.033 
0.300 
± 0.040 
0.520* 
±0.015 
0.320* 
± 0.025 
0.341* 
±0.031 
Heart 
0.381 
± 0.040 
0.402 
± 0.036 
0.410 
± 0.046 
0.618* 
± 0.028 
0.434* 
± 0.050 
0.460* 
± 0.029 
Animals in treatment groups received WS (250 mg/kg/day, p.o.) or RS (200 mg/kg/day, 
p.o.) for 21 successive days, either alone or following 4 h of daily restraint stress (Stress + 
WS, Stress + RS). Data represent group mean ± S.E.M. (n = 5). * P<0.01 as compared 
with the control group; # P<0.01 as compared with stress alone. 
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Figure 8. Effect of Withania somnifera (WS) and Rauwolfla serpentina (RS) 
administration on body weight of experimental animals. Body weight was 
recorded every 7 days. Animals in treatment groups received WS (250 mg/kg/day, p.o.) or 
RS (200 mg/kg/day, p.o.) for 21 successive days, either alone or following 4 h of daily 
restraint stress (Stress + WS, Stress + RS). Data represent group mean ± S.E.M. (n = 5). * 
P<0.05 as compared with the control group; # P<0.05 as compared with stress alone. 
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4. Discussion 
While the stress response is essential for maintenance of homeostasis and 
survival, the negative impact of persistent and prolonged stress is evident in that it 
accelerates disease processes (Nestler et al., 2002). Pathologically prolonged stress 
has immense potential to impair tlie general health of an individual by affecting 
several aspects of physiology (Liu and Mori, 1999) as evidenced by the clear 
association between stressful events and the onset of a broad range of diseases, 
mainly cardiovascular, neurologic and cancers (Baum and Posluszny, 1999). This 
great diversity of psychiatric, somatic and psychosomatic diseases and disorders 
precipitated by chronic exposure to stress is crucially linked with oxidative damage 
(Torres et al., 2004; WiUcox et al., 2004; Perez-Nievas et al., 2007). Holistic 
medicinal therapy to counter the increasing incidence of stress-related disorders is 
currently gaining ground. Adaptogenic (plant-based) drugs exhibit a wide range of 
regulatory activity eliciting non-specific resistance to the harmful influences of an 
extremely broad spectrum of stress-causing factors (Wagner, 1994; Govindarajan et 
al., 2005). Thus, the effectiveness of adaptogens as antistress drugs is immense, 
given their holistic property of exerting general protection against diverse 
detrimental effects of various chronic stressors with limited side-effects. 
Exposure of animals to repeated physical/psychological stress or prolonged 
emotional stress is known to induce the formation of ROS (Manoli et al., 2000; 
Fontella et al., 2005). Restramt is an extensively preferred stress model to induce 
such oxidative and neurotoxic damage and protective effects of antioxidants have 
been demonstrated in several such investigations (Fontella et al., 2005; Lee et al., 
2006). The neurotoxic damage exerted by chronic restraint stress (Bremner et al., 
1991; Singh et al., 1993) is associated with decreased expression of the antioxidant 
enzyme glutathione S-transferase (GST) (Cohen et al., 2006), supporting the role of 
oxidative stress in stress-induced neuropathology. Moreover, oxidative damage to 
peripheral target organs by restraint stress is also well-documented and reversible by 
antioxidants (Liu et al., 1996; Zaidi et al., 2005). In all these organ systems, it has 
been consistently reported that restraint stress decreases the activities of SOD and 
CAT (Zaidi and Banu, 2004) and markedly reduces the degree of protection offered 
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by the GSH system, thus aggravating oxidative damage (Madrigal et al., 2001; Zafir 
and Banu, 2007). The present results also demonstrate a significant stress-induced 
decline in the activities of GST and GR and in GSH levels. Primary circulating 
antioxidants such as glucose (Halliwell and Gutteridge, 1990) were also found 
reduced after chronic imcontrollable stress. Insufficiency in the antioxidant systems 
and consequent rise in free radical-mediated processes enhanced the rate of lipid 
peroxidation during restraint stress, which is a causative factor for necrotic mjury to 
organs and is evidenced by rise in the serum levels of relevant intracellular marker 
en2ymes, due to increased permeability through the damaged membrane (Al-Athar, 
2004). A significant increase in serum transaminases (SGOT and SGPT) were 
observed in response to restraint stress, as reported earlier (Nagaraja and Jeganathan, 
1999). A moderate activation of transaminases may be regarded as an indication of 
activation of intracellular energy metabolism (Dhuley, 1998) due to stress. In 
addition to these organs, significant lipid peroxidation was also evident in the brain, 
the prime target of stress and oxidative damage. Protein carbonyl contents were also 
found markedly elevated in the brain, as reported earlier (Liu et al., 1996), and also 
in liver and heart. 
While the anti-stress effects of WS have been reported following acute 
exposure to restraint stress (Bhattacharya et al., 1987), few studies have investigated 
modification of reduced antioxidant parameters imder chronic restraint stress by WS 
treatment. In the present investigation, WS is found to have a restorative action in 
normalizing several antioxidant parameters decreased by restraint stress. These 
observations are along the lines of previous research showing the antioxidant 
potential of WS in reversing foot-shock stress-induced oxidative damage 
(Bhattacharya et al., 2001). Oral administration of WS following restraint was found 
to significantly enhance tissue and serum SOD and CAT activities. The increase in 
CAT can be attributed to the modulatory action of active sitoindoside constituents 
present in WS (Bhattacharya et al., 2001). WS-induced increase in liver GST 
activity following restraint stress is in agreement with earlier reports showing its role 
in the detoxification pathway (Davis and Kuttan, 2001). The present study also 
demonstrated that GST activities in brain and heart of experimental arvimals treated 
81 
SECTION 2 
with WS reverted to their control values, along with parallel increases in GR activity 
and GSH levels in all organs. Similarly, circulating glucose levels were also 
enhanced by WS. The decrease in oxidative stress observed in this study is perhaps 
due to the counteracting effects of the key bioactive principles of Withania 
somnifera present in its aqueous extract, namely the sitoindosides VII-X, and the 
glycowithanolides and withaferins (withaferin-A) which are steroidal lactones 
reported earlier to increase the levels of major antioxidant enzymes in the brain 
comparable to that seen with deprenyl (a known antioxidant) administration 
(Bhattacharya et al., 1997). Thus, an overall improvement in endogenous antioxidant 
status may contribute towards the stress-attenuating action of WS, thereby protecting 
the functioning of major organ systems from the adverse pro-oxidant effects of 
stress. 
Oral treatments of WS were found to reduce lipid peroxidation. Similar 
reports have been documented earlier for WS and its active principles (Panda and 
Kar, 1997; Dhuley, 1998), indicating that at least part of chronic stress-induced 
pathology may be due to oxidative stress, lending support to the clinical use of the 
plant as an antistress adaptogen (Bhattacharya et al., 2001). As a result, WS 
treatment either alone or during stress treatment maintained serum transaminase 
levels to values near controls. Oral WS administration was also found to normalize 
other hepatic and cardiac marker enzymes, such as ALP and LDH elevated by stress, 
demonstrating its significant protective effect on the physiological status of these 
organs by maintaining membrane integrity. The beneficial effect of WS in 
maintaining oxidant homeostasis in liver and heart is thus related to reduced 
membrane damage as a possible protective mechanism of adaptogenic activity to 
counter the opposing effects of stress. This finding also verifies previous reports that 
have demonstrated positive effects of WS on myocardial structure and flmction, 
correlating it with the known protective effect of the major lipid-phase antioxidant, 
vitamin E (Mohanty et al, 2004). By restoring the antioxidant status of the 
myocardium following isoprenaline-induced oxidative stress, WS was found to exert 
functional recovery of the myocardium as evidenced by favourable modulation of 
haemodynamic variables and reversal of histopathological alterations (Mohanty et 
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al., 2004). WS was also found to prevent lipid peroxidation in the brain, perhaps by 
augmenting antioxidant defenses against oxidative stressr. Similar to the present 
results, it has been suggested previously that WS has an antioxidant effect in the 
rodent brain which may be responsible for its diverse pharmacological properties 
(Bhattacharya et al., 1997). Inhibition of cognitive deficits (Bhattacharya et al., 
1995) as well as the antidepressant and mood stabilizing effects of WS and its major 
active principles have been documented (Bhattacharya et al., 2000). Since these 
processes are associated with oxidative stress it is likely that the antioxidant action 
of WS may contribute, at least in part, to their improvement. 
It was evident from the results obtained that administration of RS extract to 
chronically stressed animals antagonized stress-induced effects such as decline in 
total body weight and oxidative damage to vital organ systems. A substantial 
antioxidant effect of RS was noted in the present study in terms of enhancement of 
stress-induced decreases in enzymatic and non-enzymatic antioxidant parameters. 
Activities of SOD, CAT, GST, GR, intracellular thiol status and circulating levels of 
glucose were augmented by RS after chronic stress, whereas RS alone did not alter 
the basal levels of these parameters in non-stressed animals from control values. 
Thus, RS administration exerts overall protection from oxidative stress in brain, liver 
and heart in response to physical and psychological stress induced by restraint. 
Prevention of stress-induced oxidative damage was evident by reduced lipid 
peroxidation and protein carbonyl production in all three organs of restraint stressed-
animals treated with RS. It has been reported earlier that acute injections of 
reserpine, one of the constituents of RS, elevates basal oxidative stress in the rodent 
brain, as evidenced by lower levels of antioxidants (Abilio et al., 2003). However, 
the present results obtained clearly demonstrate that the use of total alkaloids of RS 
extract is effective in reversing oxidative stress generated by chronic restraint. This 
indicates that the application of RS extract has greater beneficial effects rather than 
purified reserpine alone used by previous investigators (Burger et al., 2003; Abilio et 
al., 2004). The present findings are in conformity with a recent report that the whole 
extract of RS could abolish paracetamol-induced oxidative liver damage and 
hepatotoxicity, perhaps by itself acting as a free radical scavenger in vivo, thus 
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contributing to cell membrane stabilization as evidenced by lowered lipid 
peroxidation (Gupta et al, 2006). The observed replenishment of antioxidant 
defenses by RS following a stress-induced decline may further be related to the 
marked hepatoprotective and cardioprotective potential of RS, as evidenced by 
normalized serum levels of liver and heart function enzymes, attributable to reduced 
membrane lipid peroxidation and resultant improvement in the functional integrity 
of hepatic and cardiac cells. Oxidative stress and deficits in myocardial antioxidant 
status may precipitate cardiac dysfiinction through sub-cellular changes leading to 
cardiomyopathy, depressed contractile function and heart failure (Kaul et al., 1993; 
Singal et al., 1998). Clinical studies provide support for the concept that increased 
free radical production may play a role in the pathogenesis of heart failure 
(McMurray et al., 1993; Diaz-Velez et al., 1996). Thus the present results indicate 
that the cardioprotective property and clinical utility of RS for the treatment of 
cardiovascular disease and hypertension (Frishman et al., 2004) may possibly be 
related to increased antioxidant enzyme activities and resultant decline in lipid 
peroxidation. Furthermore, an enhancement of thiol status, by promoting the activity 
of GR to replenish intracellular GSH levels as evidenced presently, could also 
account for the mechanism of protection exerted by RS during exposure to 
prolonged stress. The traditional use of RS as an antidepressant (Reynolds, 1993; 
Mamedov, 2005) could also be related to its antioxidant action in the brain during 
prolonged exposure to psychological stressors. Oxidative damage resulting in 
neurodegeneration is a significant pathological finding in several psychiatric 
disorders as well as stress-induced depression (Michel et al., 2007). Morphological 
changes and brain atrophy in these conditions (Sheline et al., 1996; Koenen et al., 
2001) is evidenced by apoptotic cell death, which is preventable by upregulation of 
the neuroprotective enzyme SOD (Greenlund et al., 1995) and optimal GSH levels 
(Sato et al., 1995). The synergistic enhancement of several antioxidants related to 
both SOD and GSH by RS treatment as demonstrated in this study may thus 
possibly contribute to its neuroprotective action. 
In conclusion, an aqueous extract supplementation of WS may protect from a 
free radical onslaught generated by physical or emotional stress exerted due to 
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restraint/immobilization, implying that the antioxidant effect of WS may contribute 
towards its anti-stress properties. The active principles of WS, sitoindosides VII-X 
and withaferin A (glycowithanolides) are responsible for its observed antioxidant 
action. Thus, WS can be used as an effective treatment to provide protection in a 
diverse range of stress-related physical and mental disorders. Similarly, the 
protective effect of RS, comparable to that of WS, was observed in the present study 
in reversing stress-induced oxidative damage which may be related to the biological 
properties of its alkaloid constituents. The hepatoprotective and cardioprotective 
potential of RS, apart from its antioxidant effect in the brain, indicates a profile of 
activity that counters the long-term deleterious consequences of physical and 
psychological stress on important target organ systems. Both these herbal drugs can 
be used effectively either alone or with other medication to combat stress-induced 
oxidative damage and probably prevent several stress-induced degenerative diseases 
affecting various organs. 
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1. Introduction 
Free radical damage by ROS has been suggested to play a critical role in the 
pathophysiology of neurodegenerative diseases, neuropsychiatric disorders and 
stress-mduced depression (Jenner, 1991; Sapolsky, 2000; Bilici et al., 2001). 
Although clinical depression, depressive symptoms and psychological stress should 
be distinguished, they are closely related with one another (Tsuboi et al., 2006) and 
play an important role in the development of affective disorders (Post, 1992). 
Repeated stress has been associated with the development and manifestation of 
depression (Checkley, 1996). The syndrome of major depression is the prototypical 
example of detrimental alterations in the adaptive response to chronic 
hyperactivation of the stress system (Tsigos and Chrousos, 2002). With respect to 
potential mechanisms, a plausible pathway may proceed via imbalance in oxidative 
processes. Studies suggest that psychological stress influences oxidative stress 
(MoUer et al., 1996) and so it is possible that the HPA axis and this pathway 
stimulated by psychological stress increases the formation of ROS causing 
cytotoxicity (Busciglio et al., 1998). Experimental evidence regarding this has been 
recently presented, which clearly demonstrates stress hormones to cause extensive 
oxidative damage to the brain and peripheral organs (Perez-Nievas, 2007; Zafir and 
Banu, 2008). Since most of the mechanisms of stress-induced brain damage by 
glucocorticoids are associated with accumulation of oxidative/nitrosative mediators 
(Madrigal et al., 2006), therefore, antidepressant action leading to normalization of 
the HPA axis (Heuser et al., 1996), may possibly be associated with decline in 
stress-induced oxidative damage. 
Antidepressant drugs are widely used for the management/treatment of stress 
and stress-related depression and anxiety (Diamond and Rose, 1994). Although 
antidepressant drugs have been used for more than 40 years, their underlying 
mechanisms of action are still poorly understood (Lucassen et al., 2004). The 
clinical utility of antidepressant therapy may be related to the downstream effect of 
these drugs, which influence important signaling pathways that regulate 
neuroprotection and cell survival. Therefore, further characterization of the 
biological mechanisms contributing to their function is crucial for the development 
of novel and more effective treatments (Blendy, 2006), as well as for further 
understanding the pathophysiology of the depressive symptoms they treat. Recent in 
86 
SECTION 3 
vitro studies demonstrated that increasing SOD activity may be involved in the 
downstream neuroprotective actions of some antidepressants (KoUa et al., 2005). 
This suggests that the modulation of ROS generation may be relevant in 
antidepressant action; however, the effects of antidepressants on oxidative stress 
have not been studied in detail in vivo. Since SOD enzymes work in conjunction 
with H202-removing enzymes, such as catalases (Michiels et al., 1994), it is 
probable that CAT is also upregulated to participate in the cellular defense against 
H2O2 produced by activation of SOD. However, it was not determined in that study. 
Fluoxetine, a selective serotonin reuptake inhibitor (SSRI), effectively treats 
a wide spectrum of mood disorders (Wong et al., 1995) and also protects against the 
adverse effects of different types of stressors (Freire-Garabal et al., 1997; Ayelli 
Edgar et al., 2002). However, the underlying mechanisms of its therapeutic efficacy 
remain unclear, particularly with reference to preventing oxidative routes of damage 
in stress disorders. Restraint has been used extensively to study the impact of stress 
on disease process and the effects of drugs in stress-related pathology in animals 
(Glavin et al., 1994). Although restraint stress is widely employed to induce 
oxidative and neurotoxic damage, however, to the best of our knowledge, no study 
has as yet investigated the in vivo antioxidant modulating effects of antidepressants 
on restraint stress-induced oxidative damage. Thus, the main objective of the present 
work is to probe the antioxidant potential of fluoxetine and its comparison with 
turmeric (Curcuma longa L.) in rats submitted to restraint stress. For the purpose of 
comparison, turmeric has been selected as the reference standard, as it effectively 
incorporates both antioxidant and antidepressant properties (Yu et al., 2002). 
2. Experimental Protocol 
Animals (100-125 g) were randomly assigned to weight-matched groups of 
six animals each, receiving drug and/or restraint stress for 21 consecutive days. 
Unstressed, untreated animals constituted the control group and were accustomed to 
daily handling. Fluoxetine hydrochloride (20 mg/kg) dissolved in 0.9% 
physiological saline and aqueous turmeric extract (50 mg/kg) were administered via 
oral route to animals, either alone or 30 min following restraint, according to the 
treatment schedule presented below. Pilot studies revealed that 50 mg/kg of turmeric 
extract was effective in restoring antioxidant status and normalizing other markers of 
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oxidative stress after exposure to chronic restraint, and this dose was selected for the 
present investigation (data not given). Thus, the following six groups were 
constituted: 
Group I Control 
Group II Turmeric extract (50 mg/kg/day, p.o. for 21 days) 
Group III Fluoxetine (20 mg/kg/day, p.o. for 21 days) 
Group rV Restraint stress (4 h daily for 21 days) 
Group V Restrmnt stress (4 h dmly for 21 days) followed by turmeric 
extract (50 mg/kg, p.o. for 21 days) 
Group VI Restraint stress (4 h daily for 21 days) followed by fluoxetine 
(20 mg/kg, p.o. for 21 days) 
Animals were sacrificed 24 h after the last restraint or drug treatment. Blood 
samples were collected for separation of serum. Brain, liver and heart tissues were 
rapidly removed, washed in ice-cold sterile physiological saline (0.9%) and a 10% 
homogenate (0.1 M sodium phosphate buffer, pH 7.4) was prepared for analysis of 
enzymatic (SOD, CAT, GST, GR) and non-enzymatic antioxidants (GSH, uric acid, 
glucose). Oxidative damage was assessed by determining lipid peroxidation markers 
and protein carbonyl contents. Marker enzymes of liver and heart were also assayed. 
(Details given in Materials and Methods) 
3. Results 
i. Effect of fluoxetine on restraint stress-induced decline in antioxidant 
enzyme activities 
Figures 1-4 depict levels of SOD, CAT, GST and GR, respectively, in brain, 
liver and heart tissues of experimental animals, while table 1 summarizes the 
circulating levels of these enzymes, which reflect in vivo cellular antioxidant status. 
From the results depicted, stress was found to elicit a significant decrease in 
the levels of all antioxidant enzymes in comparison to controls (SOD: P<0.01 in 
brain, serum, P<0.05 in liver, P<0.001 in heart; CAT: P<0.02 in brain, P<0.01 in 
liver, heart, P<0.05 in serum; GST: P<0.01 in brain, liver, heart, serum; GR: P<0.02 
in brain, liver, P<0.01 in heart). However, compared to stressed animals, a 
significant repletion in enzymatic antioxidant status was observed by chronic 
88 
SECTION 3 
fluoxetine administration following the stress paradigm (SOD: P<0.01 in brain, 
liver, P<0.001 in heart, P<0.05 in serum; CAT: P<0.02 in brain, heart, P<0.01 in 
liver, P<0.05 in serum; GST: P<0.01 in brain, liver, P<0.02 in heart, P<0.05 in 
serum; GR: P<0.02 in brain, P<0.05 in liver, heart). The used reference antioxidant 
turmeric also produced comparable augmentation in enzyme activities (SOD: 
P<0.001 in bram, heart, P<0.01 in liver, P<0.02 in serum; CAT: P<0.01 in brain, 
heart, P<0.02 in liver, P<0.05 in serum; GST: P<0.01 in brain, heart, P<0.05 in Uver, 
P<0.001 in serum; GR: P<0.001 in brain, P<0.01 in liver, P <0.02 in heart). 
In non-stressed animals, neither fluoxetine nor turmeric caused any 
significant alteration of basal antioxidant enzyme activities. 
ii. Effect of fluoxetine on restraint stress-induced decline in non-
enzymatic antioxidant levels 
a. GSH 
Figure 5 shows the modulation of GSH by stress and drug intervention. In 
stressed animals, there was a significant reduction in the GSH content from controls 
(P<0.001 in brain, P<0.01 in liver, P<0.02 in heart). Following exposure to stress, 
treatment with fluoxetine significantly restored the basal levels of GSH (P<0.02 in 
brain, heart, P<0.01 in liver). Turmeric induced a similar increase in comparison to 
stressed animals (P<0.001 in brain, P<0.01 in liver, P<0.02 in heart). 
b. Uric acid 
Restraint stress also caused a significant decline in serum uric acid (table 1: 
P<0.01). In comparison to animals exposed to stress alone, treatment with fluoxetine 
was effective in significantly preventing stress-induced decrease of uric acid 
(P<0.001). Turmeric extract had the same protective effect (P<0.01). 
c. Glucose 
Circulating levels of glucose (table 1) were significantly decreased following 
restraint stress (P<0.01). Both fluoxetine and turmeric caused significant reversal of 
the stress-induced decline in serum glucose concentration (P<0.01) toward control 
values. 
Both fluoxetine and turmeric alone treatments to non-stressed animals did 
not significantly alter any of the assessed non-enzymatic antioxidants. 
89 
SECTION 3 
iii. Effect of fluoxetine on oxidative stress markers 
a. Lipid peroxidation 
Significant increase in the aldeiiydic product of lipid peroxidation, 
malondialdehyde (MDA) was observed in stressed animals (figure 6; P<0.05 in 
brain, serum, P<0.01 in liver, P<0.02 in heart). Pharmacological intervention by 
daily dosing of fluoxetine significantly prevented the accumulation of MDA after 
stress (P<0.01 in brain, liver, P<0.05 m heart, serum). Treatment with the positive 
control, turmeric extract, also caused a similar decrease in comparison to stress 
(P<0.01 in brain, P<0.001 in liver, P<0.02 in heart, P<0.05 in serum). 
In comparison to controls, fluoxetine alone and turmeric alone treatments did 
not cause any significant change in lipid peroxidation. 
b. Protein carbonyl production 
Restraint stress elicited a significant increase of carbonyl groups compared to 
controls (figure 7; P<0.01 in brain and heart, P<0.05 in liver). A significant effect on 
the inhibition of protein oxidation due to stress was exerted by fluoxetine (P<0.01 in 
brain, P<0.05 in liver, P<0.02 in heart). Turmeric extract yielded similar results 
(P<0.001 in brain, P<0.05 in liver, P<0.01 in heart). 
Administration of both drugs alone did not significantly change carbonyl 
content fi-om controls. 
iv. Effect of fluoxetine on marker enzymes of liver and heart 
As depicted in figure 8 and table 2, exposure to chronic stress resulted in a 
significant elevation in circulating, hepatic and cardiac levels of the marker enzymes 
GOT, GPT, ALP and LDH (P<0.001). A significant reversion of enzyme activities 
towards control values was caused by fluoxetine (P<0.001) as well as turmeric 
extract (P<0.001) following stress, in comparison to the effect of stress alone, while 
both these drugs when given alone did not alter the enzyme activities fi-om controls. 
V. Effect of fluoxetine on restraint stress-induced decline in body weight 
Figure 9 depicts influence of drug treatment on body weights of animals 
measured every seven days beginning fi-om the day of experimental manipulations. 
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Restraint stress induced a decrease in body weight evident from the first week 
onward and remained significantly decreased throughout exposure to the stress 
paradigm (days 7-21: P<0.05) as compared to controls. Treatment of restraint 
stressed-animals with fluoxetine as well as turmeric was effective in preventing 
stress-induced loss in body weight, which was significantly increased (P<0.05) 
relative to stress alone from day 14. 
Similar to controls, both the drugs when given alone markedly increased 
body weight of experimental animals over the treatment period of 21 days, with 
significant increases (P<0.05) observed by turmeric alone on days 7 and 14. 
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Figure 1. Effect of chronic fluoxetine administration on SOD activity in brain, liver 
and heart of experimental animals. Animals in treatment groups received turmeric 
extract (TURM; 50 mg/kg/day, p.o.) or fluoxetine (FLU; 20 mg/kg/day, po.) for 21 
consecutive days, either alone or following 4 h of daily restraint stress (Stress + TURM, 
Stress + FLU). Data represent group mean ± S.E.M (n = 6). A, B, C, D: P<0.05, P<0.02, 
P<0.01, P<0.001 as compared with the control group; a, b, c, d: P<0.05, P<0.02, P<0 01, 
P<0.001 as compared with stress alone. 
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Figure 2. Effect of chronic fluoxetine administration on CAT activity in brain, liver 
and heart of experimental animals. Animals in treatment groups received turmeric 
extract (TURM; 50 mg/kg/day, p.o.) or fluoxetine (FLU; 20 mg/kg/day, p.o.) for 21 
consecutive days, either alone or following 4 h of daily restraint stress (Stress + TURM, 
Stress + FLU). Data represent group mean ± S.E.M. (n = 6). A, B, C, D: P<0 05, P<0 02, 
P<0.01, P<0.001 as compared with the control group; a, b, c, d: P<0.05, P<0.02, P<0 01, 
P<0.001 as compared with stress alone. 
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Figure 3. Effect of chronic fluoxetine administration on GST activity in brain, liver 
and heart of experimental animals. Animals in treatment groups received turmeric 
ejctract (TURM; 50 mg/kg/day, p.o.) or fluoxetine (FLU; 20 mg/kg/day, p.o.) for 21 
consecutive days, either alone or following 4 h of daily restraint stress (Stress + TURM, 
Stress + FLU). Data represent group mean ± S.E.M. (n = 6). A, B, C, D: P<0 05, P<0.02, 
P<0.01, P<0.001 as compared with the control group; a, b, c, d: P<0.05, P<0.02, P<0 01, 
P<0.001 as compared with stress alone. 
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Figure 4. Effect of chronic fluoxetine administration on GR activity in brain, liver 
and heart of experimental animals. Animals in treatment groups received turmeric 
extract (TURM; 50 mg/kg/day, p.o.) or fluoxetine (FLU; 20 mg/kg/day, p.o.) for 21 
consecutive days, either alone or following 4 h of daily restraint stress (Stress + TURM, 
Stress + FLU). Data represent group mean ± S.E.M. (n = 6). A, B, C, D: P<0.05, P<0.02, 
P<0.01, P<0.001 as compared with the control group; a, b, c, d: P<0.05, P<0.02, P<0.01, 
P<0.001 as compared with stress alone. 
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Figure 5. EfTect of chronic fluoxetine administration on GSH levels in brain, liver 
and heart of experimental animals. Animals in treatment groups received turmeric 
extract (TURM; 50 mg/kg/day, p.o.) or fluoxetine (FLU; 20 mg/kg/day, p.o.) for 21 
consecutive days, either alone or following 4 h of daily restraint stress (Stress + TURM, 
Stress + FLU). Data represent group mean ± S.E.M. (n = 6). A, B, C, D: P<0.05, P<0 02, 
P<0.01, P<0.001 as compared with the control group; a, b, c, d: P<0.05, P<0.02, P<0 01, 
P<0.001 as compared with stress alone. 
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Figure 6. Inhibition of restraint stress-induced lipid peroxidation in brain, liver and 
heart of experimental animals by chronic fluoxetine administration. Animals in 
treatment groups received turmeric extract (TURM; 50 mg/kg/day, p.o.) or fluoxetine 
(FLU; 20 mg/kg/day, p.o.) for 21 consecutive days, either alone or following 4 h of daily 
restraint stress (Stress + TURM, Stress + FLU). Data represent group mean ± S.E.M. (n = 
6). A, B, C, D: P<0.05, P<0.02, P<0.01, P<0.001 as compared with the control group; a, b, 
c, d: P<0.05, P<0.02, P<0.01, P<0.001 as compared with stress alone. 
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Figure 7. Inhibition of restraint stress-induced protein carbonyl production in brain, 
liver and heart of experimental animals by chronic fluoxetine administration. 
Animals in treatment groups received turmeric extract (TURM; 50 mg/kg/day, p.o.) or 
fluoxetine (FLU; 20 mg/kg/day, p.o.) for 21 consecutive days, either alone or following 4 
h of daily restraint stress (Stress + TURM, Stress + FLU) Data represent group mean ± 
S.E.M. (n = 6). A, B, C, D: P<0.05, P<0.02, P<0.01, P<0.001 as compared with the control 
group; a, b, c, d: P<0.05, P<0.02, P<0 01, P<0.001 as compared with stress alone 
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Figure 8. Circulating (SGOT, SGPT) and hepatic (GOT, GPT) levels of liver function 
enzymes in response to chronic fluoxetine administration. Animals in treatment 
groups received turmeric extract (TURM; 50 mg/kg/day, p.o.) or fluoxetine (FLU; 20 
mg/kg/day, p.o.) for 21 consecutive days, either alone or following 4 h of daily restraint 
stress (Stress + TURM, Stress + FLU). Data represent group mean ± S.E.M. (n = 6). 
*P<O.OOI as compared with the control group; # P<0.001 as compared with stress alone. 
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Table 1. Modulatory effects of chronic fluoxetine treatment on restraint 
stress-induced alterations in circulating levels of antioxidant defenses and 
oxidative stress markers. 
Group 
Control 
TURM 
FLU 
Restraint 
stress 
Stress + 
TURM 
Stress + 
FLU 
SOD 
(U/mg 
protein) 
19.11 
±0.89 
23.34 
±2.48 
19.74 
±2.33 
13.83^ 
±1.87 
23.89'' 
±1.53 
20.79" 
±0.86 
CAT 
(U/mg 
protein) 
1.18 
±0.13 
1.74 
±0.33 
1.12 
±0.19 
0.59^ 
±0.26 
2.03" 
±0.40 
1.36" 
±0.01 
GST 
(U/mg 
protein) 
0.18 
±0.01 
0.41 
±0.06 
0.26 
±0.04 
0.12^ 
±0.02 
0.39" 
±0.01 
0.24" 
±0.03 
MDA 
(nmol/ 
mg 
protein) 
0.15 
±0.02 
0.05 
± 0.004 
0.07 
± 0.003 
0.17^ 
±0.02 
0.08" 
±0.02 
0.10" 
±0.02 
Glucose 
(mg/dl) 
112.44 
±1.60 
109.89 
±5.18 
115.00 
±6.47 
78.83^ 
±4.23 
118.50' 
±7.72 
108.50' 
±6.77 
Uric 
acid 
(mg/dl) 
3.29 
±0.37 
4.73 
±0.28 
3.17 
±0.27 
1.31^ 
±0.17 
4.13' 
±0.48 
3.46'' 
±0.20 
Animals in treatment groups received turmeric extract (TURM; 50 mg/kg/day, p.o.) or 
fluoxetine (FLU; 20 mg/kg/day, p.o.) for 21 consecutive days, either alone or following 4 
h of daily restraint stress (Stress + TURM, Stress + FLU). Data represent group mean ± 
S.E.M. (n = 6). A, B, C, D: P<0.05, P<0.02, P<0.01, P<0.001 as compared with the control 
group; a, b, c, d: P<0.05, P<0.02, P<0.01, P<0.001 as compared with stress alone. 
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Table 2. Circulating, hepatic and cardiac levels of marker enzymes in 
response to chronic fluoxetine administration. 
Group 
Control 
TURM 
FLU 
Restraint 
stress 
Stress + 
TURM 
Stress + FLU 
ALP (mg/ml) 
Serum 
0.328 
± 0.036 
0.288 
± 0.042 
0.338 
± 0.030 
0.695* 
± 0.050 
0.395* 
± 0.050 
0.423* 
± 0.034 
Liver 
2.490 
± 0.300 
2.158 
±0.316 
2.918 
± 0.356 
5.260* 
± 0.386 
2.665* 
± 0.385 
3.208* 
±0.444 
LDH (U/mg protein) 
Serum 
0.138 
± 0.023 
0.155 
±0.031 
0.127 
± 0.029 
0.325* 
± 0.028 
0.183* 
± 0.028 
0.195* 
±0.014 
Liver 
0.320 
± 0.038 
0.388 
± 0.032 
0.365 
± 0.037 
0.603* 
± 0.039 
0.423* 
± 0.036 
0.400* 
± 0.033 
Heart 
0.475 
±0.038 
0.515 
± 0.030 
0.432 
± 0.049 
0.790* 
± 0.026 
0.595* 
± 0.045 
0.555* 
± 0.028 
Animals in treatment groups received turmeric extract (TURM; 50 mg/kg/day, p.o.) or 
fluoxetine (FLU; 20 mg/kg/day, p.o.) for 21 consecutive days, either alone or following 4 
h of daily restraint stress (Stress + TURM, Stress + FLU). Data represent group mean ± 
S.E.M. (n = 6). * P <0.001 as compared with the control group; # P<0.001 as compared 
with stress alone. 
101 
SECTION 3 RESULTS 
Figure 9. Influence of chronic fluoxetine administration on body weight of 
experimental animals. Body weight was recorded every 7 days. Animals in treatment 
groups received turmeric extract (TURM; 50 mg/kg/day, p.o.) or fluoxetine (FLU; 20 
mg/kg/day, p.o.) for 21 consecutive days, either alone or following 4 h of daily restraint 
stress (Stress + TURM, Stress + FLU). Data represent group mean ± S.E.M. (n = 6). 
*P<0.05 as compared with the control group; # P<0.05 as compared with stress alone. 
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4. Discussion 
To the best of our knowledge, the data presented in this study demonstrates 
for the first time the in vivo antioxidant action of fluoxetine in restraint stress-treated 
rats (Zafir and Banu, 2007). Similar evidence corroborating this finding comes from 
a clinical study (Bilici et al., 2001) which showed that antioxidant enzymes may be 
state markers of depression and useful in monitoring the effects of selective 
serotonin reuptake inhibitors, as well as ftom certain in vitro studies (KoUa et al., 
2005). 
ROS generated by a severe stressor (restraint stress) significantly 
compromised the in vivo antioxidant defenses of animals submitted to restraint. 
Chronic fluoxetine administration to stressed animals for 21 days, which is the time 
course of therapeutic action of the antidepressant, produced a protective 
enhancement of the antioxidant status. This modulation of antioxidant parameters to 
basal levels (as in controls) was strikingly at par with the powerful antioxidant 
efficacy of turmeric, a natural antioxidant and indigenous food component 
implicated for the significantly lower prevalence of certain neurodegenerative 
diseases in the Asian Indian population (Ganguli et al., 2000). Thus the results 
obtained are also significant from the point of view of neuroprotection. 
Exposure to chronic restraint stress in rats, and psychosocial stress in 
humans, is implicated in the pathophysiology of mood and anxiety disorders 
(Walesiuk et al., 2006). Glucocorticoids promote brain damage after stress exposure 
by different ways such as potentiation of excitatory amino acid (EAA)-induced 
toxicity (Goodman et al., 1996), inhibition of EAA uptake, inhibition of glucose 
uptake in neurons (Virgin et al., 1991), etc. These processes are connected with free 
radical-mediated oxidative damage, like mitochondrial dysfunction, dysregulation of 
calcium homeostasis (Amoroso et al., 2000), disruption of energy pathways 
(Papadopoulos et al., 1997), damage to neuronal precursors, impairment of 
neiurogenesis (Kroemer, 1997), induction of signalling events in apoptotic cell death 
(Cregan et al., 2002), ultimately leading to atrophy and morphological changes in 
the brain characteristic in stress-induced depression (Bremner et al., 1999; Sapolsky, 
2000). Previously it was established that restraint stress increases the production of 
ROS, and consequent oxidative damage, with a concomitant decline in in vivo 
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antioxidant defenses (Zaidi and Banu, 2004; Zaidi et al., 2005). Moreover, 
immobilization stress in mice has been shown to cause neuronal death in the cerebral 
cortex by apoptosis, which was effectively prevented by antioxidant pretreatment 
with an associated decrease in ROS production (Lee et al., 2006). Recent in vitro 
studies on the underlying mechanisms of stress-induced neuronal damage have 
suggested that corticosterone released from the adrenal cortex during stress either 
induces the formation of ROS (Lin et al., 2004) or decreases antioxidant enzyme 
activity, resulting in increased neurotoxicity in cortical cultures (Brooke et al., 
2002). In addition, glucocorticoids have not only been implicated in the etiology of 
depression, but have also been shown to down-regulate SOD activity (Cvijic et al., 
1995). The present study has also demonstrated in vivo pro-oxidant effects of 
corticosterone, evident not only in the brain, but also in important peripheral organs 
such as the liver and the heart, as evidenced by coordinate decline in SOD activity 
and in a wide range of other enzymatic and non-enzymatic antioxidant defense 
components as well (Zafir and Banu, 2008). Thus, it will be interesting to investigate 
the upregulation of SOD as a protective measure against glucocorticoid toxicity and 
an important mechanism of antidepressant action protecting against cell death or 
atrophy caused by HPA axis dysregulation. In vitro studies have shown that 
upregulation of SOD and similar antioxidant enzymes may protect astrocytes from 
apoptosis or necrosis upon exposure to various neurotoxicants (KoUa et al., 2005). 
SOD is extensively distributed in the central nervous system, including regions 
which are atrophied in depression, such as the hippocampus (Jeste, 1988). In this 
context, the use of pharmacological agents targetting cellular antioxidants is a 
promising strategy for protecting against oxidative insults in depression. 
Accordingly, this study was undertaken to investigate the modulation of restraint 
stress-induced oxidative damage by fluoxetine in various vulnerable organs. 
A simultaneous decline in the activities of free radical-scavenging enzymes, 
SOD and CAT, by chronic restraint stress may be due to inactivation caused by 
excess ROS production, thus damaging the first line of enzymatic defense against 
superoxide anion and hydrogen peroxide. Consistent vdth these experimental 
findings, clinical studies on patients with affective disorders have also revealed 
lower levels of CAT (Ozcan et al., 2004). A coordinate decline in GSH and related 
enzymes, GST and GR, by restraint stress suggested a severely compromised in vivo 
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antioxidant statxis. This oxidative route of damage to the second line of antioxidant 
defense may act as a potential trigger to a plethora of detrimental events observed in 
stress and depression. A similar depletion of brain glutathione has been reported 
earlier in mice imder stress-induced depression (Pal and Dandiya, 1994). In the 
present findings, it is evident that fluoxetine could effectively limit/reverse the 
above-indicated stress-induced antioxidant deficits in all tissues as well as in 
circulation by the simultaneous elevation of SOD, CAT, GST, GR and GSH levels. 
Fluoxetine-mediated increase in GR activity, fluoxetine may have increased cellular 
levels of GSH, the predominant thiol antioxidant in the brain, which is controlled in 
part by GR. Glucose and uric acid, among the major circulating antioxidant 
molecules, were also severely depleted by chronic stress. Glucose is a scavenger of 
hydroxyl radicals, having a rate constant comparable with mannitol, while the 
antioxidant role of uric acid is important in directly scavenging oxidizing species 
and thus also inhibiting lipid peroxidation (Halliwell and Gutteridge, 1990). 
Therefore, fluoxetine-induced elevation in their levels demonstrates a direct ability 
to protect against highly damaging hydroxyl radicals that react with and damage 
most cellular targets including lipids, proteins and DNA (Warner et al., 2004). This 
may be another method by which fluoxetine prevents stress-induced oxidative 
damage. Since increased oxidative stress or impaired antioxidant activity are 
implicated in major depression (Tsuboi et al., 2006), the therapeutic efficacy 
demonstrated clinically by fluoxetine may be mediated, at least in part, via reversal 
of oxidative damage as evidenced by the present data. 
Lipid peroxidation is considered a critical mechanism of injury occurring in 
cells during oxidative stress (Halliwell and Gutteridge, 1989). An initial formation 
of large amounts of ROS during stress may also initiate lipid peroxidation as 
demonstrated to occur in brain (Liu et al., 1996) and liver (Hu et al., 2000), in 
agreement to the present findings. Psychological stress, which accompanies severe 
depression, may enhance lipid peroxidation (Hibbeln and Salem, 1995), and recent 
clinical studies have directly demonstrated higher levels of MDA in patients with 
affective disorders (Ozcan et al., 2004; Sarandol et al., 2007). This study showed 
that treatment with fluoxetine effectively prevented membrane lipid peroxidation. 
Since lipid peroxidation disrupts membrane integrity, high levels of LDH activity in 
stressed animals may be interpreted as a progression of cell injury because of the 
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intracellular localization of this enzyme (Campo et al., 2005). The decrease in LDH 
after treatment with fluoxetine may be a consequence of decreased oxidative stress 
and the concomitant prevention of cell membrane damage. Similar reductions in 
stress-induced elevated levels of other marker enzymes, GOT, GPT, ALP, etc., 
indicates membrane stabilization by fluoxetine therapy, preventing the leakage of 
these enzymes through the damaged membrane. Protein oxidation, measured as an 
increase in carbonyl groups has been shown to be an early event in oxidative stress 
(Pacific! and Davies, 1990). Treatment with fluoxetine inhibited protein carbonyl 
production in stressed animals, indicating that fluoxetine not only prevents the 
downstream cascade of oxidative damage comprising lipid peroxidation, but also 
targets early oxidative events as evidenced by a significant reduction in protein 
oxidation. Free radical scavenging enzyme activities may have been influenced by 
fluoxetine treatment possibly by preventing ROS-mediated damage to the structure 
and function of these proteins. 
The detailed molecular mechanisms underlying the fluoxetine-mediated 
elevation of antioxidant defenses, and concomitant reduction of oxidative stress 
markers, remain to be investigated. Since antidepressants act on many different 
neurotransmitter systems and receptors, a common mechanism of action has 
remained elusive. In vitro, various antidepressants were demonstrated to increase 
SODl gene expression, for eg., amitryptyline (a classic tricyclic antidepressant), 
bupropion (a second generation antidepressant), doxepin (a norepinephrine reuptake 
inhibitor), venlafaxine (a new 5HT/norepinephrine reuptake inhibitor) and L-
deprenyl (a selective MAO-B inhibitor). It has been suggested that upregulation of 
the antioxidant enzyme SOD could be a potential target of antidepressant action (Li 
et al., 1998; Li et al., 2000). The present study provides evidence for this effect in 
vivo for the first time in terms of enhanced activity, not only of SOD, but of other 
key antioxidant enzymes, too, by fluoxetine (a selective serotonin reuptake inhibitor) 
following stress exposure. Chronic antidepressant treatment has been demonstrated 
to upregulate cAMP-response element-mediated gene expression in rat cortex and 
hippocampus (Thome et al., 2000), and to upregulate the expression of cAMP-
response element-binding protein (CREB) in both rodents and humans. Upregulation 
of SODl may occur by an induction of cAMP and CREB (Nibuya et al., 1996; 
Dowlatshahi et al., 1998). Regarding other antioxidant enzymes, it may be suggested 
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that the enhanced activity demonstrated here may be through a mechanism similar to 
that for SOD. Thus, the increased activities of not only SOD, but also of CAT and 
GR, which act in concert with SOD, by fluoxetine could also probably be via a 
genomic action leading to enhanced gene expression of these critical antioxidant 
enzymes. Therefore, the present study not only confirms, but also extends previous 
findings, implicating the importance of antioxidant status in stress disorders and the 
consequent need to evaluate antidepressants in terms of their antioxidant/pro-oxidant 
ability. Although depression is currently considered a heterogeneous disease, stress 
has been implicated in the origin and exacerbation of this disorder. Thus, in patients 
whose depression is caused, or accompanied by stress, therapeutic strategies aimed 
at maintaining or increasing levels of neuroprotective enzymes such as SOD may 
prove extremely beneficial (KoUa et al., 2005). In addition, it is possible that 
upregulation of this enzyme by antidepressants may prevent fiirther progression of 
fi-ee radical-mediated neurotoxicity in depression caused by stress (Li et al., 2000). 
Therefore, the data presented here indicating the elevation of not only SOD, but a 
wide range of key components of the antioxidant defense system by fluoxetine may 
hold great potential in preventing further clinical deterioration in depression. 
Another major finding of this study is that in all antioxidant parameters 
evaluated, the protective efficacy of the antidepressant fluoxetine was strikingly 
comparable to that observed for the powerfiil natural antioxidant turmeric, used as a 
reference standard. Turmeric powder by itself, and its major bioactive component 
curcumin, is known to protect against oxidative stress (Cohly et al., 1998) by typical 
radical-trapping ability as a chain-breaking antioxidant (Sreejayan Rao, 1994). 
Turmeric also contains other antioxidant principles besides curcumin, such as 
demethoxycurcumin, bisdemothoxycurcumin and a number of polypeptides with 
antioxidant activity, such as turmerin (Ramirez-Tortosa et al., 1999). Dietary 
turmeric is known to lower lipid peroxidation by enhancing the activities of 
antioxidant enzymes (PuUa Reddy, 1994). The similar antioxidant efficacies of 
turmeric and fluoxetine demonstrated here may suggest a common mechanism of 
action. With the view that antioxidant defenses are also compromised in stress-
induced depression, it may be hypothesized that classical stress drugs such as 
fluoxetine which can reduce stress symptomatology, may probably also affect and 
act via modulation of endogenous antioxidant capacity. Since endogenous 
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antioxidants play a critical role in maintaining the integrity of the cell, their 
enhancement by fluoxetine with an efficacy similar to turmeric probably also 
accounts for the low side effects of fluoxetine observed clinically (Anderson, 1999). 
In conclusion, the present study indicates that the antioxidant potential of 
fluoxetine probably contributes to its therapeutic actions. As treatment with 
fluoxetine ameliorates stress-induced oxidative damage, this study thus demonstrates 
that enhancement of in vivo antioxidant defenses and improvement in cellular 
antioxidant status may be an important mechanism underlying the protective 
pharmacological effects of fluoxetine observed clinically in the treatment of various 
stress disorders. 
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1. Introduction 
Chronic exposure to stress can induce several psychiatric conditions, 
including depression (De Kloet et al., 2005). Conversely, a number of studies also 
suggest that people with a chronic somatic disease are more susceptible to 
psychological stress and depression than the average population (Katon and 
Sullivan, 1990; Kugaya et al., 2000). Primary/secondary consequences of the disease 
have been suggested to act as stressors in such cases (Heijmans et al., 2001). Thus, 
evidence of an interrelation between various diseases and depression is well-
documented and depression has been identified as a serious and debilitating disorder 
with a heavy social burden and a substantial lifetime risk (Greenberg et al., 2003). 
Alterations in oxidative biology are increasingly being recognized as a 
critical route of damage towards the pathophysiology of stress-induced psychiatric 
disorders (Berk, 2007). A growing number of clinical investigators have found 
increased oxidative stress to occur in major depression (Maes et al., 2000; Ozcan et 
al., 2004; Tsuboi et al., 2006). A plausible consequence of oxidative stress is the 
volumetric reduction observed in the brain structures of chronically depressed 
patients and other stress-related disorders (Sheline et al., 1996; Koenen et al., 2001). 
In this regard, attempts to modulate dysregulated oxidative biology may be 
successful as a therapeutic intervention in depression (Berk, 2007) and targeting the 
altered pro-oxidant:antioxidant balance may represent a rational approach towards 
stress management strategies in various stress-induced psychiatric or somatic 
diseases (Zafir and Banu, 2007; Zafir and Banu, 2008). In spite of the vital 
association of oxidative stress with depression pathophysiology, the role of 
endogenous antioxidant status in the therapeutic actions of chronic antidepressant 
treatments has been relatively understudied although they are widely prescribed for 
the treatment of stress and stress-related depression and anxiety. 
It was demonstrated in the previous section that treatment with fluoxetine 
(selective serotonin reuptake inhibitor) can reverse and prevent psychological stress-
induced oxidative damage, as evidenced by the elevation of not only SOD activity, 
but a wide range of key components of the endogenous antioxidant system (Zafir 
and Banu, 2007). However, the involvement of major cellular antioxidants, both 
enzymatic and non-enzymatic, as a possible target in the action of other 
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antidepressants, has not been investigated in detail in animal models of stress and 
depression that can be extrapolated to the human situation. Therefore, the present 
experiment was designed to study the pharmacological modulation of oxidative 
stress by imipramine (tricyclic antidepressant) and venlafaxine (new dual 
serotonin/norepinephrine reuptake inhibitor) (Redrobe et al., 1998; Nash and Nutt, 
2004), in comparison to fluoxetine, by determining the extent to which they prevent 
restraint stress-induced oxidative damage. 
Studies examining an association between the pro-oxidant effects of chronic 
stress and stress-induced behavioral aberrations are lacking. The forced swimming 
test (FST) is a validated model for experimental depression (Porsolt et al., 1977) to 
predict antidepressant efficacy and to determine depression-like behavior in rodents. 
Exposure to restraint stress also produces a hedonic deficit, a characteristic 
diagnostic feature of depression marked by decreased motivation and diminished 
interest in pleasurable experiences, evidenced by reduced preference for a palatable 
sucrose solution (American Psychiatric Association, 1994; Rademacher and Hillard, 
2007). Repeated antidepressant treatments antagonize stress-induced anhedonia 
(Zurita et al., 1996) as well as stress-induced behavioural passivity in the FST 
(Brotto et al., 2001). In the experiment described in this section, animals were 
subjected to restraint stress on a daily basis for 21 days in parallel with 
antidepressant treatment, and evaluated using these specific behavioural tests to 
reveal changes evoked by restraint-induced psychological stress and its reversal by 
therapeutic intervention. If oxidative stress plays any significant role in stress-
induced depressive illness, it may be expected to be reversed by chronic 
antidepressant administration, perhaps in parallel with normalization of behavioural 
parameters of depression. Therefore, to examine whether induction of experimental 
depression could be related to oxidative stress in the central nervous system, and to 
fiorther test the hypothesis that ascribes augmentation of cellular antioxidant status to 
antidepressant action, the reversal of restraint-induced oxidative stress by 
imipramine, venlafaxine and fluoxetine was investigated within the context of a 
simultaneous restoration of restraint-induced behavioural deficits. 
2. Experimental Protocol 
Subjects were experimentally naiVe Swiss Albino rats (100-125 g) habituated 
to maintenance conditions for a week, during which time they were randomly 
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assigned to weight-matched groups of six animals each receiving drug and/or 
restraint stress for 21 consecutive days. Unstressed, untreated animals constituted 
the control group and were accustomed to daily handling. Fluoxetine hydrochloride 
(20 mg/kg), miipramine hydrochloride (10 mg/kg) and verJafaxine hydrochloride 
(10 mg/kg) were dissolved in 0.9 % physiological saline and administered via oral 
route, either alone or 30 min following the daily stress regimen. Drug solutions were 
freshly prepared and all doses were selected based on preliminary pilot studies and 
reported findings (Kulkami and Dhir, 2007; Zafir and Banu, 2007). Thus, the 
following eight groups were constituted: 
Group I Control 
Group II Fluoxetine (20 mg/kg/day, p.o. for 21 days) 
Group III Imipramine (10 mg/kg/day, p.o. for 21 days) 
Group rV Venlafaxine (10 mg/kg/day, p.o. for 21 days) 
Group V Restraint stress (4 h daily for 21 days) 
Group VI Restraint stress (4 h daily for 21 days) followed by fluoxetine 
(20 mg/kg/day, p.o. for 21 days) 
Group VII Restraint stress (4 h daily for 21 days) followed by imipramine 
(10 mg/kg/day, p.o, for 21 days) 
Group VIII Restraint stress (4 h daily for 21 days) followed by venlafaxine 
(10 mg/kg/day, p.o. for 21 days) 
Baseline body weights and preference for a 1% sucrose solution was 
determined inmiediately prior to experimental manipulations. Subsequently, body 
weights and sucrose preference (as a hedonic measure) were monitored under 
similar conditions at weekly intervals throughout the duration of the experiment. 
Upon termination of the 21-day period, all animals were studied in the forced 
swimming test. The behavioural tests were performed during the light phase of the 
light/dark cycle. Animals were acclimated to the experimental room for at least 1 h 
prior to testing. At the end of the experimental period (24 h after the last test) all 
animals were sacrificed under ether anesthesia for determination of the antioxidant 
status. Enzymatic (SOD, CAT, GST, GR) and non-enzymatic antioxidants (GSH, 
uric acid, glucose) were assayed in serum and different tissues such as brain, liver 
and heart (10% homogenate in 0.1 M sodium phosphate buffer, pH 7.4). Oxidative 
damage was assessed by determining lipid peroxidation marker, MDA, and protein 
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carbonyl contents, as well as marker enzymes of liver and heart. {Details given in 
Materials and Methods) 
3. Results 
i. Effect of antidepressant treatments on restraint stress-induced 
decline in antioxidant enzyme activities 
Figures 1-8 illustrate the effects of imipramine, venlafaxine, and the 
reference standard, fluoxetine, on SOD, CAT, GST and GR activities, respectively, 
in brain, liver and heart of restraint stressed rats. Tables 1-2 show enzyme activities 
in serum. 
Results indicate that exposure to a 21-day restraint stress period significantly 
decreased all antioxidant enzyme activities, as compared to non-stressed, untreated 
controls (SOD: P<0.01 in brain, heart, serum, P<0.02 in liver; CAT: P<0.001 in 
brain, P<0.01 in liver, heart, serum; GST: P<0.01 in brain, liver, serum, P<0.05 in 
heart; GR: P<0.01 in brain, liver, P<0.02 in heart). 
Antidepressant drug administration to restraint stressed animals significantly 
recovered enzyme activities, as evidenced by significant increases following 
imipramine treatment (SOD: P<0.01 in brain, liver, heart, P<0.05 in serum; CAT: 
P<0.01 in brain, heart, serum, P<0.05 in liver; GST: P<0.01 in brain, liver, heart, 
P<0.02 in serum; GR: P<0.01 in brain, P<0.05 in liver, P<0.02 in heart) as well as 
treatment with venlafaxine (SOD: P<0.01 in brain, serum, P<0.001 in liver, heart; 
CAT: P<0.001 in brain, heart, P<0.01 in liver, serum; GST: P<0.01 in brain, serum, 
P<0.001 in liver, P<0.05 in heart, P<0.01 in serum; GR: P<0.02 in brain, P<0.01 in 
liver, heart). 
There were no significant differences between imipramine and venlafaxine 
fi-om the antioxidant potential of the reference standard, fluoxetine (SOD: P<0.01 in 
brain, heart, P<0.001 in liver, P<0.02 in serum; CAT: P<0.001 in brain, heart, 
P<0.02 in liver, P<0.01 m serum; GST: P<0.01 in all organs and serum; GR: P<0.01 
in brain, P<0.02 m liver, P<0.05 in heart). 
Similar to fluoxetine, no significant differences in antioxidant enzyme levels 
were observed fi"om controls when either imipramine or venlafaxine were 
administered to naive (non-stresssed) animals. 
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ii. Effect of antidepressants on restraint stress-induced decline in non-
enzymatic antioxidant levels 
a. GSH 
The effects of treatment of restraint stressed animals with antidepressants on 
GSH levels are shown in figures 9-10. Restraint stress produced a significant 
decrease in GSH in brain (P<0.05), liver and heart (for both P<0.01), whereas no 
statistically significant differences were foimd relative to controls upon 
administering antidepressants to unstressed animals. In each case, chronic 
administration of antidepressants resulted in a significant increase of GSH in all 
tissues, in comparison to stress-induced decline in their levels (imipramine: P<0.05 
in brain, P<0.01 in liver, heart; venlafaxine: P<0.01 in brain, liver, heart; fluoxetine: 
P<0.05 in brain, P<0.01 in liver, P<0.02 in heart). All three drugs were comparable 
in efficacy. 
b. Uric acid 
Tables 1-2 also show restraint stress-induced significant reduction (P<0.001) 
in uric acid levels as compared to controls. A significant increase in serum uric acid 
fi-om stressed rats was produced by chronic treatments with imipramine (P<0.01) 
and venlafaxine (P<0.01), similar to that induced by fluoxetine administration 
(P<0.01). 
Uric acid levels did not differ statistically fi-om untreated controls in any of 
the drug alone-treated groups. 
c Glucose 
As shown in tables 1-2, both imipramine and venlafaxine induced significant 
reversal of stress-induced decline (P<0.001) in circulating glucose concentrations 
towards baseline control values (for both P<0.01). Their potency in this regard 
compared well with that of fluoxetine which also caused a significant increase 
(P<0.01). 
In unstressed animals, these antidepressants did not significantly alter serum 
glucose fi"om control values. 
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iii. Effect of antidepressants on other oxidative stress markers 
a. Lipid peroxidation 
The significantly increased production of malondialdehyde (MDA) by 
restraint stress and its recovery in stressed animals receiving antidepressants is 
presented in figures 11-12 and tables 1-2. As depicted, restraint stress caused an 
excessive accumulation of the aldehydic product of lipid peroxidation, MDA, in all 
tissues and serum (P<0.01) relative to control animals. Both imipramine and 
venlafaxine significantly decreased MDA levels in stressed animals (imipramine: 
P<0.05 in brain, heart, P<0.02 in liver, serum; venlafaxine: P<0.05 in brain, P<0.01 
in liver, heart, serum), similar to the effect of fluoxetine (P<0.05 in brain, liver, 
P<0.02 in heart, serum). 
In comparison to control animals, antidepressant treatment of unstressed 
animals caused no significant variations in lipid peroxidation. 
b. Protein carbonyl production 
Restraint stress exerted significant increase in carbonyl content from controls 
(figures 13-14; P<0.01 in brain, P<0.05 in liver, heart). This was significantly 
decreased in all tissues by imipramine (P<0.01 in brain, P<0.05 in liver, heart) and 
venlafaxme treatments (P<0.01 in brain, P<0.05 in liver, P<0.02 in heart). 
Fluoxetine also significantly reduced stress-elevated production of protein carbonyls 
(P<0.01 in brain, P<0.05 in liver, heart). 
No statistically significant differences were foimd from control values in 
unstressed animals receiving any of these drugs. 
iv. Effect of antidepressants on marker enzymes of liver and heart 
Liver and heart function enzymes are presented in figure 15 and tables 3-4. 
Circulating, hepatic and cardiac levels of the marker enzymes GOT, GPT, ALP and 
LDH were significantly increased (P<0.001) in response to chronic restraint stress, 
as compared to controls. In contrast, a significant reversion (P<0.001) of these 
enzyme activities toward control values was found upon administering 
antidepressants during the stress regime, as compared to stress alone. 
Activities of marker enzymes were not significantly altered relative to 
controls by drug alone treatments. 
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V. Effect of antidepressants on restraint stress-induced decline in body 
weight 
In comparison to untreated, non-stressed controls, restraint stress 
significantly decreased (P<0.05) body weight of animals during the 21 day 
experimental period (figure 16). However, chronic administration of imipramine, 
venlafaxine and fluoxetine to these animals significantly increased (P<0.05; days 14 
and 21) their body weights similar to controls. 
Animals receiving drug treatments alone were not found to differ 
significantly in weight fi-om controls. 
vi. Effect of antidepressants on behavioural parameters 
a. Forced swimming test 
Restraint stressed animals exhibited a pronounced decrease in the latency to 
begin floating relative to controls (P<0.01) as shown in figure 17. The total time 
spent immobile was significantly elevated in these animals (P<0.01), whereas the 
time spent swimming during the test was substantially decreased (P<0.01). All three 
antidepressants, imipramine, venlafaxine and fluoxetine, effected a significant 
reversal of these behavioural parameters induced by restraint stress; thus, treatment 
of stressed animals with these drugs significantly increased swimming time and the 
latency to become immobile (both P<0.01), while decreasing the immobility time 
significantly (P<0.01) from stressed animals receiving no treatment. 
b. Sucrose preference test 
Animals subjected to chronic restraint stress exhibited significantly 
decreased sucrose preference relative to non-stressed controls (P<0.01; figure 18). 
By contrast, this effect induced by restraint stress was significantly normalized 
(P<0.01) by chronic administration of any of the three antidepressants, imipramine, 
venlafaxine or fluoxetine, as compared to stressed animals. 
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Figure 1. Effect of chronic administration of imipramine and venlafaxine on brain 
SOD activity of experimental animals. Animals in treatment groups received 
imipramine (IMI; 10 mg/kg/day, p.o.), venlafaxine (VEN; 10 mg/kg/day, p.o.) or 
fluoxetine (FLU; 20 mg/kg/day, p.o.) for 21 consecutive days, either alone or following 4 
h of daily restraint stress (Stress + MI, Stress + VEN, Stress + FLU). Data represent group 
mean ± S.E.M. (n = 6). A, B, C, D: P<0.05, P<0.02, P<0.01, P<0.001 as compared widi 
the control group; a, b, c, d: P<0.05, P<0.02, P<0.01, P<0.001 as compared with stress 
alone. 
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Figure 2. Effect of chronic administration of imipramine and venlafaxine on SOD 
activity in liver and heart of experimental animals. Animals in treatment poups 
received imipramine (IMI; 10 mg/kg/day, p.o.), venlafaxine (VEN; 10 mg/kg/day, p.o.) or 
fluoxetine (FLU; 20 mg/kg/day, p.o.) for 21 consecutive days, eidier alone or foUowmg 4 
h of daily restraint stress (Stress + IMI, Stress + VEN, Stress + FLU). Data represent group 
mean ± S.E.M. (n = 6). A, B, C, D: P<0.05, P<0.02, P<0.01, P<0.001 as compared with 
the control group; a, b, c, d: P<0 05, P<0.02, P<0.01, P<0.001 as compared with stress 
alone. 
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Figure 3. Effect of chronic administration of imipramine and venlafaxine on brain 
CAT activity of experimental animals. Animals in treatment groups received 
imipramine (IMI; 10 mg/kg/day, p.o.), venlafaxine (VEN; 10 mg/kg/day, p.o.) or 
fluoxetine (FLU; 20 mg/kg/day, p.o.) for 21 consecutive days, either alone or following 4 
h of daily restraint stress (Stress + IMI, Stress + VEN, Stress + FLU). Data represent group 
mean ± S.E.M. (n = 6). A, B, C, D: P<0.05, P<0.02, P<0.01, P<0.001 as compared with 
the control group; a, b, c, d: P<0.05, P<0.02, P<0.01, P<0.001 as compared widi stress 
alone. 
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Figure 4. Effect of chronic administration of imipramine and venlafaxine on CAT 
activity in liver and heart of experimental animals. Animals in treatment groups 
received imipramine (IMI; 10 mg/kg/day, p.o.), venlafaxine (VEN; 10 mg/kg/day, p.o.) or 
fluoxetine (FLU; 20 mg/kg/day, p.o.) for 21 consecutive days, eiflier alone or following 4 
h of daily restraint stress (Stress + IMI, Stress + VEN, Stress + FLU). Data represent group 
mean ± S.E.M. (n = 6). A, B, C, D: P<0.05, P<0.02, P<0.01, P<0.001 as compared with 
the control group; a, b, c, d: P<0.05, P<0.02, P<0.01, P<0.001 as compared with stress 
alone 
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Figure 5. Effect of chronic administration of imipramine and venlafaxine on brain 
GST activity of experimental animals. Animals in treatment groups received 
imipramine (IMI; 10 mg/kg/day, p.o.), venlafaxine (VEN; 10 mg/kg/day, p.o.) or 
fluoxetine (FLU; 20 mg/kg/day, p.o.) for 21 consecutive days, either alone or following 4 
h of daily restraint stress (Stress + IMI, Stress + VEN, Stress + FLU). Data represent group 
mean ± S.E.M. (n = 6). A, B, C, D: P<0.05, P<0.02, P<0.01, P<0.001 as compared with 
the control group; a, b, c, d: P<0.05, P<0.02, P<0.01, P<0.001 as compared with stress 
alone. 
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Figure 6. Effect of chronic administration of imipramine and venlafaxine on GST 
activity in liver and heart of experimental animals. Animals in treatment groups 
received imipramine (IMI; 10 mg/kg/day, p.o.), venlafaxine (VEN; 10 mg/kg/day, p.o.) or 
fluoxetine (FLU; 20 mg/kg/day, p.o.) for 21 consecutive days, either alone or following 4 
h of daily restraint stress (Stress + IMI, Stress + VEN, Stress + FLU). Data represent group 
mean ± S.E.M. (n = 6). A, B, C, D- P<0.05, P<0.02, P<0 01, P<0.001 as compared with 
the control group, a, b, c, d- P<0 05, P<0.02, P<0.01, P<0 001 as compared with stress 
alone. 
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Figure 7. Effect of chronic administration of imipramine and venlafaxine on brain 
GR activity of experimental animals. Animals in treatment groups received 
imipramine (IMI; 10 mg/kg/day, p.c), venlafaxine (VEN; 10 mg/kg/day, p.o.) or 
fluoxetine (FLU; 20 mg/kg/day, p.o.) for 21 consecutive days, either alone or following 4 
h of daily restraint stress (Stress + IMI, Stress + VEN, Stress + FLU). Data represent group 
mean ± S.E.M. (n = 6). A, B, C, D: P<0.05, P<0.02, P<0.01, P<0.001 as compared with 
the control group; a, b, c, d: P<0.05, P<0.02, P<0.01, P<0.001 as compared with stress 
alone. 
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Figure 8. Effect of chronic administration of imipramine and venlafaxine on GR 
activity in liver and heart of experimental animals. Animals in treatment groups 
received imipramine (IMI; 10 mg/kg/day, p.o.), venlafaxine (VEN; 10 mg/kg/day, p.o.) or 
fluoxetine (FLU; 20 mg/kg/day, p.o.) for 21 consecutive days, either alone or following 4 
h of daily restraint stress (Stress + IMI, Stress + VEN, Stress + FLU). Data represent group 
mean ± S.E.M. (n = 6) A, B, C, D P<0 05, P<0.02, P<0.01, P<0.001 as compared with 
the control group; a, b, c, d: P<0 05, P<0 02, P<0 01, P<0.001 as compared with stress 
alone 
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Figure 9. Effect of chronic administration of imipramioe and venlafaxine on brain 
GSH levels of experimental animals. Animals in treatment groups received 
imipramine (IMI; 10 mg/kg/day, p.o.), venlafaxine (VEN; 10 mg/kg/day, p.o.) or 
fluoxetine (FLU; 20 mg/kg/day, p.o.) for 21 consecutive days, either alone or following 4 
h of daily restraint stress (Stress + IMI, Stress + VEN, Stress + FLU). Data represent group 
mean ± S.E.M. (n = 6). A, B, C, D: P<0.05, P<0.02, P<0.01, P<0.001 as compared with 
the control group; a, b, c, d: P<0.05, P<0.02, P<0.01, P<0.00] as compared with stress 
alone. 
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Figure 10. Effect of chronic administration of imipramine and venlafaxine on GSH 
levels in liver and heart of experimental animals. Animals in treatment groups 
received imipramine (IMI; 10 mg/kg/day, p.c), venlafaxine (VEN; 10 mg/kg/day, p.o.) or 
fluoxetine (FLU; 20 mg/kg/day, p.o.) for 21 consecutive days, either alone or following 4 
h of daily restraint stress (Stress + IMI, Stress + VEN, Stress + FLU). Data represent group 
mean ± S.E.M. (n = 6). A, B, C, D: P<0.05, P<0.02, P<0.01, P<0.001 as compared with 
the control group; a, b, c, d. P<0.05, P<0.02, P<0.01, P<0.001 as compared with stress 
alone. 
125 
SECTION 4 RESULTS 
t 
— Control 
ta^j^ FLU 
^ ^ IMI 
^m VEN 
B W Stress 
WMW stress + 
WW stress + 
emmm Stress + 
FLU 
IMI 
VEN 
No Stress Stress 
Figure 11. Inhibition of restraint stress-induced brain lipid peroxidation of 
experimental animals by chronic administration of imipramine and 
venlafaxine. Animals in treatment groups received imipramine (IMI; 10 mg/kg/day, 
p.c), venlafaxine (VEN; 10 mg/kg/day, p.o.) or fluoxetine (FLU; 20 mg/kg/day, p.o.) for 
21 consecutive days, either alone or following 4 h of daily restraint stress (Stress + IMI, 
Stress + VEN, Stress + FLU). Data represent group mean ± S.E.M. (n = 6). A, B, C, D: 
P<0.05, P<0.02, P<0.01, P<0.001 as compared with the control group; a, b, c, d: P<0.05, 
P<0.02, P<0.01, P<0.001 as compared with stress alone. 
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Figure 12. Inhibition of restraint stress-induced lipid peroxidation in liver and heart 
of experimental animals by chronic administration of imipramine and 
venlafaxine. Animals in treatment groups received imipramine (IMI; 10 mg/kg/day, 
P.O.), venlafaxine (VEN; 10 mg/kg/day, p.o.) or fluoxetine (FLU; 20 mg/kg/day, p.o.) for 
21 consecutive days, either alone or following 4 h of daily restraint stress (Stress + IMI, 
Stress + VEN, Stress + FLU). Data represent group mean ± S.E.M (n = 6). A, B, C, D-
P<0.05, P<0.02, P<0 01, P<0 001 as compared with the control group; a, b, c, d P<0 05, 
P<0 02, P<0.01, P<0.001 as compared with stress alone 
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Figure 13. Inhibition of restraint stress-induced brain protein carbonyl production of 
experimental animals by chronic administration of imipramine and 
venlafaxine. Animals in treatment groups received imipramine (IMI; 10 mg/kg/day, 
P.O.), venlafexine (VEN; 10 mg/kg/day, p.o.) or fluoxetine (FLU; 20 mg/kg/day, p.o.) for 
21 consecutive days, either alone or following 4 h of daily restraint stress (Stress + IMI, 
Stress + VEN, Stress + FLU). Data represent group mean ± S.E.M. (n = 6). A, B, C, D: 
P<0.05, P<0.02, P<0.01, P<0.001 as compared with the control group; a, b, c, d: P<0.05, 
P<0.02, P<0.01, P<0.001 as compared with stress alone. 
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Figure 14. Inhibitioa of restraint stress-induced protein carbonyl production in liver 
and heart of experimental animals by chronic administration of imipramine 
and venlafaxine. Animals in treatment groups received imipramine (IMI; 10 mg/kg/day, 
P.O.), venlafaxine (VEN; 10 mg/kg/day, p.o.) or fluoxetine (FLU; 20 mg/kg/day, p.o.) for 
21 consecutive days, either alone or following 4 h of daily restraint stress (Stress + IMI, 
Stress + VEN, Stress + FLU). Data represent group mean ± S.E.M. (n = 6). A, B, C, D: 
P<0.05, P<0.02, P<0.01, P<0.001 as compared with the control group; a, b, c, d: P<0.05, 
P<0.02, P<0.01, P<0.001 as compared with stress alone. 
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Figure 15. Circulating (SCOT, SGPT) and hepatic (GOT, GPT) levels of liver 
function enzymes in response to chronic administration of imipramine and 
venlafaxine. Animals in treatment groups received imipramine (IMI; 10 mg/kg/day, 
P.O.), venlafaxine (VEN; 10 mg/kg/day, p.o.) or fluoxetine (FLU; 20 mg/kg/day, p.o.) for 
21 consecutive days, either alone or following 4 h of daily restraint stress (Stress + IMI, 
Stress + VEN, Stress + FLU). Data represent group mean ± S.E.M. (n = 6). • P<0.001 as 
compared with the control group; # P<0.001 as compared with stress alone. 
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Table 1. Effect of antidepressants on basal circulating levels of antioxidant 
defenses and oxidative stress markers. 
Group 
Control 
FLU 
IMI 
VEN 
SOD 
(U/mg 
protein) 
20.57 
±1.14 
18.07 
±0.58 
17.40 
±0.56 
19.05 
±0.36 
CAT 
(U/mg 
protein) 
1.35 
±0.14 
1.24 
±0.09 
1.10 
±0.06 
1.32 
±0.10 
GST 
(U/mg 
protein) 
0.24 
±0.02 
0.21 
±0.02 
0.19 
±0.01 
0.23 
±0.01 
MDA 
(nmol/ 
mg 
protein) 
0.133 
± 0.003 
0.140 
± 0.006 
0.148 
± 0.003 
0.129 
± 0.005 
Glucose 
(mg/dl) 
123.30 
±3.49 
126.00 
±3.56 
118.83 
±5.04 
128.88 
±4.40 
Uric 
acid 
(mg/dl) 
4.51 
±0.29 
4.11 
±0.40 
3.72 
±0.24 
4.34 
±0.38 
Drug alone treatments were administered for 21 consecutive days and are indicated as: 
IMI: imipramine (10 mg/kg/day, p.c), VEN: venlafaxine (10 mg/kg/day, p.c), FLU: 
fluoxetine (20 mg/kg/day, p.c). Data represent group mean ± S.E.M. (n = 6). 
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Table 2. Modulatory effects of antidepressants on restraint stress-induced 
alterations in circulating levels of antioxidant defenses and oxidative stress 
markers. 
Group 
Control 
1 Restraint 
stress 
Stress + 
FLU 
Stress + 
IMI 
Stress + 
VEN-
SOD 
(U/mg 
protein) 
20.57 
±1.14 
9.76^ 
±1.15 
16.52" 
±0.95 
15.93" 
±1.25 
17.30' 
±0.77 
CAT 
(U/mg 
protein) 
1.35 
±0.14 
0.43*^  
±0.07 
1.16' 
±0.12 
0.98' 
±0.06 
1.24' 
±0.13 
GST 
(U/mg 
protein) 
0.24 
±0.02 
0.11^ 
±0.01 
0.18' 
±0.01 
0.17" 
±0.01 
0.21' 
±0.01 
MDA 
(nmol/ 
mg 
protein) 
0.13 
± 0.003 
0.21^ 
±0.014 
0.15" 
± 0.008 
0.16" 
± 0.007 
0.14' 
± 0.002 
Glucose 
(mg/dl) 
123.30 
±3.49 
81.04° 
±4.77 
111.67' 
±4.40 
109.00' 
±4.96 
115.00' 
±3.18 
Uric 
acid 
(mg/dl) 
4.51 
±0.29 
2.06'^  
±0.29 
3.96' 
±0.34 
3.78' 
±0.15 
4.09' 
±0.22 
Animals in treatment groups received imipramine (Stress + IMI; 10 mg/kg/day, p.o.), 
venlafaxine (Stress + VEN; 10 mg/kg/day, p.o.) or fluoxetine (Stress + FLU; 20 
mg/kg/day, p.o.) following 4 h of daily restraint stress for 21 consecutive days. Data 
represent group mean ± S.E.M. (n = 6). A, B, C, D: P<0.05, P<0.02, P<0.01, P<0.001 as 
compared with the control group; a, b, c, d: P<0.05, P<0.02, P<0.01, P<0.001 as compared 
with stress alone. 
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Table 3. Effect of antidepressants on circulating, hepatic and cardiac levels of 
marker enzymes. 
Group 
Control 
FLU 
IMI 
VEN 
ALP (mg/ml) 
Serum 
0.407 
± 0.024 
0.457 
± 0.026 
0.490 
± 0.027 
0.387 
±0.012 
Liver 
3.083 
±0.217 
3.613 
± 0.280 
4.053 
± 0.253 
3.400 
± 0.362 
LDH (U/mg protein) 
Serum 
0.200 
±0.012 
0.223 
± 0.038 
0.307 
±0.012 
0.183 
± 0.020 
Liver 
0.390 
± 0.052 
0.413 
± 0.041 
0.457 
± 0.029 
0.323 
± 0.023 
Heart 
0.513 
± 0.020 
0.567 
± 0.023 
0.597 
± 0.026 
0.533 
± 0.026 
Drug alone treatments were administered for 21 consecutive days and are indicated as: 
IMI: imipramine (10 mg/kg/day, p.c), VEN: venlafaxine (10 mg/kg/day, p.c), FLU: 
fluoxetine (20 mg/kg/day, p.c.). Data represent group mean ± S.E.M. (n = 6). 
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Table 4. Modulatory effects of antidepressants on restraint stress-induced 
alterations in circulating, hepatic and cardiac levels of marker enzymes. 
Group 
Control 
Restraint stress 
Stress + FLU 
Stress + IMI 
Stress + VEN 
ALP (mg/ml) 
Serum 
0.407 
± 0.024 
0.847* 
± 0.033 
0.527* 
± 0.049 
0.597* 
± 0.089 
0.487* 
± 0.035 
Liver 
3.083 
±0.217 
6.000* 
± 0.361 
3.817* 
± 0.280 
4.260* 
±0.333 
3.670* 
± 0.340 
LDH (U/mg protein) 
Serum 
0.200 
±0.012 
0.487* 
± 0.024 
0.253* 
± 0.029 
0.303* 
± 0.048 
0.217* 
± 0.020 
Liver 
0.390 
± 0.052 
0.870* 
± 0.085 
0.443* 
± 0.038 
0.513* 
± 0.029 
0.353* 
± 0.033 
Heart 
0.513 
± 0.020 
0.912* 
± 0.032 
0.593* 
± 0.029 
0.643* 
±0.015 
0.573* 
± 0.020 
Animals in treatment groups received imipramine (Stress + IMI; 10 mg/kg/day, p.c), 
venlafaxine (Stress + VEN; 10 mg/kg/day, p.o.) or fluoxetine (Stress + FLU; 20 
mg/kg/day, p.o.) following 4 h of daily restraint stress for 21 consecutive days. Data 
represent group mean ± S.E.M. (n = 6). *P<0.001 as compared with the control group; 
#P<0.001 as compared with stress alone. 
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Figure 16. Influence of chronic administration of antidepressants on body weight of 
experimental animals. Body weight was recorded every 7 days. Animals in treatment 
groups received imipramine (IMI; 10 mg/kg/day, p.c), venlafaxine (VEN; 10 mg/kg/day, 
p.o.) or fluoxetine (FLU; 20 mg/kg/day, p.o.) for 21 consecutive days, either alone or 
following 4 h of daily restraint stress (Stress + IMI, Stress + VEN, Stress + FLU). Data 
represent group mean ± S.E.M. (n = 6). * P<0.05 as compared with the control group; # 
P<0.05 as compared with stress alone. 
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Figure 17. Modulatory effects of antidepressants on restraint stress-induced 
alterations in behavioural parameters of the forced swimming test. Animals in 
treatment groups received imipramine (Stress + IMI; 10 mg/kg/day, p.c), venlafaxine 
(Stress + VEN; 10 mg/kg/day, p.o.) or fluoxetine (Stress + FLU; 20 mg/kg/day, p.o.) 
following 4 h of daily restraint stress for 21 consecutive days. Data represent group mean 
± S.E.M. (n = 6). * P<0.01 as compared with the control group; #P<0.01 compared with 
stress alone. 
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Figure 18. Reversal of restraint stress-induced anhedonia by chronic administration 
of imipramine, venlafaxine and fluoxetine. Animals in treatment groups received 
imipramine (Stress + IMI; 10 mg/kg/day, p.o.), venlafaxine (Stress + VEN; 10 mg/kg/day, 
p.o.) or fluoxetine (Stress + FLU; 20 mg/kg/day, p.o.) following 4 h of daily restraint stress 
for 21 consecutive days. Data represent group mean ± S.E.M. (n = 6). * P<0.01 as 
compared with the control group; # P<0.01 compared with stress alone. 
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4. Discussion 
The present study examined the effect of chronic antidepressant treatment on 
oxidative damage in the context of restraint stress-evoked behavioural aberrations to 
deduce a possible association between the two. This investigation revealed that the 
therapeutic benefits of three antidepressants, as evidenced by the normalization of 
stress-induced behavioural changes, also extend to protective augmentation of 
endogenous antioxidant defenses. Treatment with imipramine (tricyclic 
antidepressant) and venlafaxine (dual serotonin/norepinephrine reuptake inhibitor) 
were effectual in enhancing activities, of not only SOD, but also other key 
antioxidant enzymes such as CAT, GST and GR, following stress exposure. 
Disruptions in non-enzymatic components of the antioxidant cascade (GSH, uric 
acid, glucose) were also restored. This was concomitant to marked reductions in 
lipid peroxidation and protein oxidation events. The present findings complement 
the prior studies on fluoxetine (selective serotonin reuptake inhibitor; Section 3), and 
show that chronically appUed antidepressants are capable of alleviating oxidative 
damage induced by chronic psychological stress. 
Oxidative stress is primarily or secondarily mvolved in the pathogenesis of 
major depression (Maes et al., 2000). The co-existence of increased oxidative stress 
with symptoms of depression in patients has been established, as evidenced by 
defective plasma antioxidant defenses in association with enhanced susceptibility to 
lipid peroxidation (Khanzode et al., 2003; Herken et al., 2007; Sarandol et al., 2007). 
Therefore, antidepressant therapeutic intervention may be associated with the 
normalization of critical oxidative processes along with alleviating the depressive 
symptoms. The present work provides evidence for the cumulative antioxidant-
promoting effects of different classes of antidepressants, which may represent a 
more universal mechanism of action that not only involves SOD - a potential target 
of antidepressant regulation (Li et al., 2000; Kolla et al., 2005) - but also extends to 
other enzymatic and non-enzymatic antioxidants. 
The restraint stress-induced behavioural modifications in rodents were found 
similar to the core symptoms of depression in humans (Willner, 1995). In fact, 
uncontrollable long-term restraint stress is a validated method for experimental 
depression studies (Kennett et al, 1985) because of the behavioral aberrations 
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produced by this model. Specifically, it was observed that when restraint stressed 
animals were forced to swim with no possibility to escape, they eventually ceased to 
struggle, and surrendered themselves to the experimental conditions. This typical 
despair reaction signifying helplessness is considered to be the state of depression 
(Porsolt et al., 1977, 1978) and is used as a stressant situation (Pedreanez et al., 
2006) to induce depression or to determine depressive behavior in animals after 
exposiire to other stressors (Naitoh et al., 1992; Detke et al., 1997, Lucki, 1997; 
Takeda et al., 2006). In response to this test, the behavioural passivity displayed by 
the 21-day restraint stressed animals is an analogue of decreased motivation, which 
is a behavioural correlate of depressive symptoms in humans (Porsolt, 1979). 
The weekly sucrose preference tests, where rats were offered sucrose 
solution in a fi"ee choice trial with water, revealed that control animals typically 
exhibited a high preference for palatable sucrose solutions over plain drinking water 
(Plaznik et al., 1989; Zurita et al., 1996), while this tendency was markedly reduced 
following exposure to imcontroUable restraint stress, in agreement with earlier 
reports (Zurita and Molina, 1999; Rademacher and Hillard, 2007). This progressive 
decline in the sensitivity to the rewarding stimulus (sucrose solution) due to chronic 
stress exposure represents a disturbance in the capacity to experience pleasure in 
rodents (Willner et al., 1992; Moreau, 1997), an effect modelling human anhedonia 
(Katz, 1982; Willner, 1991; Zacharko and Anisman, 1991). These behavioural 
changes were also coupled to reduced body weight, which is an organic correlate of 
stress effects (Sapolsky et al., 2000). 
Predictably, both these depression-like phenotypes were completely reversed 
when animals were chronically administered any of the three antidepressants, 
fluoxetine, imipramine or venlafaxine, during the stressor period. This is a consistent 
fmding by other researchers (Borsini and Meli, 1988; Murua et al., 1991; Reul et al., 
1993; Mizoguchi et al., 2002), and indicates the effectiveness and therapeutic 
efficacy of the drug treatments employed. Since depressive symptoms are critically 
associated with oxidative processes, it was further investigated whether the effective 
behavioural reversal by antidepressant treatment is associated with the modulation 
of antioxidant defenses. 
In this study, it was found that chronic antidepressant administration per se 
did not alter the optimal antioxidant status of naive, imstressed animals, relative to 
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controls. This may reveal that antidepressants do not possess antioxidant effects in 
the absence of oxidative stress conditions; rather they possibly interfere with stress-
induced pathways of oxidative damage. As these drugs are reported effective within 
the context of a clinical situation, such as a stress history, and after chronic 
administration (Lucassen et al., 2004), therefore, the specific effects of chronic 
antidepressant treatment were investigated in the restraint stress model which 
induces decline in in vivo antioxidant defenses and concomitant oxidative damage 
(Zaidi and Banu, 2004; Zaidi et al., 2005). Oral application was selected because it 
is the most common route of administration for antidepressants in psychiatric 
patients (Lucassen et al., 2004). 
The present results evidenced a parallel increase in both SOD and CAT, the 
most important antioxidant enzymes, in response to antidepressant treatments to 
stressed animals. Enhancement of their activities may provide an effective defense 
from the damaging effects of not only superoxide anion and hydrogen peroxide 
(neutralized by these enzymes), but also from the highly reactive and damaging 
hydroxyl radical, generated by Haber-Weiss or Fenton reactions of the former 
radicals (Winterboum, 1995). Therefore, antidepressant administration may possibly 
act to avert extensive damage to different types of molecules, including proteins, 
nucleic acids, and lipids, thus playing a critical role in maintaining integrity at the 
cellular level. An increase in the serum concentrations of the major circulating non-
enzymatic antioxidant molecules, glucose and uric acid, was also induced by 
treatment with imipramine and venlafaxine, similar to fluoxetine administration in 
stressed animals. Moreover, all three antidepressants could effectively limit/reverse 
restraint stress-induced coordinate decline in GSH and related enzymes. By restoring 
disrupted glutathione pathways, it is plausible that chronic antidepressant 
administration may exert the observed antioxidant effects via restoration of critical 
GSH-related processes such as free radical scavenging, regulation of intracellular 
redox homeostasis and thiol-disulphide status of proteins, or by enhancement of the 
activities of several enzymes involved in cell defense which utilize GSH as a 
coenzyme (Pompella et al., 2003). Increase in cellular GSH by antidepressants may 
also have had inhibitory effects on signalling pathways in apoptotic cell death, 
which are triggered by the loss of glutathione and oxidative damage (Kane et al., 
1993; Sato et al., 1995). Enhanced SOD activity, as observed here by antidepressant 
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treatment, is also an important neuronal defense mechanism against apoptosis, 
thereby preventing atrophy of brain regions in stress-induced depression (Greenlund 
et al., 1995). Such cellular changes as a consequence of lowered antioxidant defense 
during prolonged stress contribute to the neuroanatomical abnormalities observed in 
mood disorders, including volume loss of certain brain regions in chronically 
depressed patients and other stress-related disorders (Drevets et al., 1997). Apart 
from glucocorticoid hormone-mediated toxicity observed in response to stress and in 
depression (Baghai et al., 2002), it has been demonstrated that these brain structural 
changes are also closely associated with increased oxidative stress (Michel et al., 
2007). Enzymes working in conjunction with SOD and GSH are thus crucial in 
negating free radical-mediated neurotoxicity. In essence, the concurrent and 
synchronized elevation of key endogenous antioxidants, SOD, CAT, GST, GR and 
GSH levels by treatment with imipramine and venlafaxine, similar to fluoxetine, 
may thus largely contribute to neuroprotection and increased resistance of 
chronically stressed rats to in vivo oxidative and neurodegenerative damage, in 
comparison to animals that were exposed to restraint stress, but did not receive any 
treatment. Thus, oxidative biology may represent a unifying mechanism for multiple 
classes of mitidepressant drugs. 
Furthermore, a significant reversal of stress-induced lipid peroxidation and 
protein carbonyl production by all three antidepressants also reduces the secondary 
effects of oxidative stress which adversely affect several key processes in the brain. 
Prevention of lipid peroxidation by these drugs probably serves to maintain 
membrane integrity by protecting membrane phospholipids from damage, which is 
the result of a complex cascade involving impairment of membrane-transport protein 
functions and ion channels that, in tum, mediates membrane lipid peroxidation-
induced disruption of neuronal ion homeostasis (Mattson, 1998). The destruction of 
phospholipids affects membrane viscosity and thereby the action of monoamine 
neurotransmitters through changes in their receptor density or function (Van-der-
Vliet and Bast, 1992). By reducing lipid peroxidation, antidepressants may possibly 
prevent the inhibitory effects which MDA directly exerts on serotonin-binding areas 
of the receptor (Britt et al., 1992). Furthermore, membrane lipid peroxidation also 
modifies neurotransmitter release and uptake, ion-channel activity, the function of 
ATPases and glucose transporters, and the coupling of cell-surface receptors to 
141 
SECTION 4 
GTP-binding proteins, to impair mitochondrial function and promote a cascade of 
events that culminates in apoptotic cell death (Mattson, 1998). Prevention of these 
potentially damaging factors during restraint stress-induced lipid peroxidation may 
possibly be a target of antidepressant action, relevant to their therapeutic benefits. 
Protein oxidation is an earlier consequence of oxidative stress than lipid 
peroxidation. The current findings of a significant decrease in protein carbonyl 
content in stressed animals treated with antidepressants may indicate overall 
preservation of protein functions during the period of chronic stress, since protein 
oxidation rapidly contributes to oxidative stress by directly affecting cell structure 
and signaling, and enzymatic processes such as metabolism, all vital processes for 
cellular homeostasis (Cecarini et al., 2007). In fact, detection of elevated levels of 
protein carbonyls is generally a sign not only of oxidative stress but also of a protein 
dysfunction (Dalle-Doime et al., 2003). This may also be related in a general way 
toward maintenance of antioxidant enzyme activities by antidepressants to 
effectively counter restraint-induced oxidative stress. All these effects were not 
restricted to the brain, but additionally evident in the liver and heart, vital target 
organs as regards adverse susceptibility to stress. 
The mechanism responsible for the therapeutic action of antidepressants has 
not yet been fully explained (Garcia, 2002; Xu et al., 2003; Holsboer, 2004). The 
initial supposition for the action of antidepressants, the monoamine hypothesis 
(Bunny and Davis, 1965; Schildkraut, 1965), is based on the increased availability of 
monoamines (primarily serotonin and norepinephrine) and neurotransmission by 
these drugs. However, antidepressants exert their effects after prolonged 
administration. This discrepancy in time lag between pharmacological action and 
clinical effect reveals that enhancement of monaminergic transmission per se does 
not have a direct causative role in the therapeutic benefits of antidepressants (Nestler 
et al., 2002) and indicates that there must be other targets beyond the level of 
monoamines that may be the downstream effects of these drugs (Garcia, 2002). To 
explain this protracted action, it is increasingly being demonstrated that 
antidepressants activate several signalling cascades leading to activation of 
transcription factors such as CREB (Nibuya et al., 1996; Dowlatshahi et al., 1998). 
Upregulation of CREB by chronic antidepressant treatment has been suggested to 
activate downstream targets such as brain-derived neurotrophic factor (BDNF) 
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(Malberg et al., 2000), as well as SOD (Nibuya et al., 1996; Li et al., 2000), both of 
which are key mediators in the therapeutic response of antidepressant medications 
(Smith et al., 1995; Li et al., 2000; KoUa et al., 2005; Zafir and Banu, 2007). BDNF 
promotes neurogenesis in the brain, therefore, in the context of a link between 
neurogenesis and neuropsychiatric disorders, oxidative stress has been proposed as a 
major regulatory factor in neurogenesis since excess levels of ROS and decreased 
antioxidants can damage neuronal precursors, DNA, cell membranes and induce cell 
death by disrupting mitochondrial function (Kim et al., 2003). Therefore, strategies 
to counteract oxidative damage may be useful in the treatment of stress and 
depression (Kim et al., 2003), which potentially also affect neurogenesis. 
The present data may gather importance in view of several facts. Firstly, the 
results solidify the suggested Imk between stress, depression and oxidative stress, 
thereby further strengthening an "oxidative stress hypothesis of depression" (Michel 
et al., 2007). In this regard, modulation of endogenous antioxidants not only seems 
to provide further evidence for a role of oxidative biology in depression, being 
effectively alleviated by antidepressants, but also may indicate that intervention with 
antioxidant compounds could have a successful outcome. Secondly, epidemiological 
data show strong evidence of an interrelation between various diseases and 
depression. Chronic medical disease can have consequences for mental health, and 
vice versa (Verhaak et al., 2005). In such a scenario, intervention with 
antidepressants may be found efficacious. This is currently attributed solely to 
alleviating depressive symptoms, but it is possible that this occurs in concurrence to 
reduction of oxidative stress by these drugs. Such a possibility is supported by this 
study. This notion may be strengthened in view of the fact that oxidative stress is a 
common element in many cases of cancers, neurological disorders and 
cardiovascular events associated with psychological stress and depression (Mazza et 
al., 2007). The core findings of the present study also indicate the prospective 
clinical utility of exploiting biochemical variables, such as antioxidant parameters 
and oxidative stress markers, as supportive or predictive prognostic markers of 
therapeutic response towards not only SSRIs, but also the classic tricyclic 
antidepressants and newer dual reuptake inhibitors. 
In conclusion, the present study may add to an understanding of the 
mechanisms of antidepressants. Augmentation of in vivo antioxidant defenses could 
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serve as a convergence point for multiple classes of antidepressants as an important 
shared mechanism underlying the protective pharmacological effects of these drugs 
observed clinically in the treatment of various stress disorders. Consequently, 
emphasis must be placed on pharmacological modulation of stress-induced oxidative 
damage as a possible stress-management approach. A dual-edged strategy utilizing 
antioxidants to control dysregulated oxidative biology may represent a valid 
therapeutic option in future avenues of research. 
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1. Introduction 
Changes at the cellular and molecular level, such as regulation of gene 
transcription factors, contribute to the pathology of stress (McEwen, 1999; McEwen, 
2000, Joels et al., 2007). Restraint stress-induced downregulation of glutathione S-
transferase, pi2 gene (Gstp2) and expression of nitric oxide synthase (NOS-2) 
(Olivenza et al., 2000; Cohen et al., 2006) directly result in elevation of ROS in the 
rodent brain and consequent free radical-mediated damage (Liu et al., 1996; 
Madrigal et al., 2001; Fontella et al., 2005), leading directly or indirectly to 
neurodegeneration and behavioral changes (Abidin et al., 2004, Manikandan et al., 
2006; Chakraborti et al., 2007). ROS-mediated processes constitute a fundamental 
pathological mechanism of brain dysfunction in neurodegenerative and major 
psychiatric disorders such as depressive illness (Mattson, 1998; Bilici et al., 2001; 
Berk, 2007; Sarandol et al., 2007). 
Nutrition and dietary patterns are found to have a direct influence on the 
health of the general population, in aging, and in critically ill patients. Adjunctive 
therapy using antioxidant vitamins, micronutrients and trace element intakes has 
been shown to be a promising approach in the prevention of diseases related with 
oxidative stress, particularly cancer, cardiovascular diseases, age-related ocular 
diseases and other geriatric as well as psychogeriatric conditions (Willcox et al., 
2004; Berger, 2005). Various constituents of a normal healthy diet play an important 
role in normal brain functioning and mental health (Bodnar and Wisner, 2005), but a 
thorough exploration of the nutrition-related risk factors of stress-induced depression 
is lacking. 
Folate deficiency can contribute to depressed mood; this effect may be 
mediated partly by alterations in brain S-adenosylmethionine (SAM) and serotonin 
levels (Young, 1993) or probably by influencing homocysteine levels (Coppen and 
Bolander-Gouaille, 2005). Another water-soluble vitamin, pyridoxine, has also been 
suggested to be an effective anti-stress measure, protecting from detrimental health 
associated with chronic psychological stress (McCarty, 2000) and is known to boost 
the central production of the neurotransmitters serotonin and GABA, which have an 
impact on depression and anxiety (Hartvig et al., 1995). These micronutrient 
vitamins are critical to optimal central nervous system function. Though free radical 
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scavenging properties have also been reported for both vitamins, however, the 
involvement of antioxidant status in their possible therapeutic actions in stress 
disorders has not been studied in detail. Thus, investigations on a possible role of 
nutritional factors in depressive symptoms and the associated dysregulations in 
oxidant status are necessary towards the control and understanding of the 
mechanisms underlying stress-related psychiatric disorders. 
Recognizing the importance of nutritional status and antioxidants in stress 
and depression, the objective of the present work was to investigate the role of 
dietary components in reducing or reversing stress-induced oxidative damage and 
depression in the restraint stress model. For this purpose, oral administration of folic 
acid and pyridoxine was studied in animals exposed to restraint stress and the 
modulation of endogenous antioxidant parameters was compared with the known 
antioxidant effects of ascorbic acid. Studies dealing with the antidepressant-like 
activity of these vitamins are also lacking. Since free radicals are involved in the 
biochemical mechanisms miderlying neuropsychiatric disorders, a therapeutic 
benefit from antioxidant supplementation may be expected in stress-induced 
depression. To study this possible association, the effects of folic acid, pyridoxine 
and ascorbic acid were evaluated on stress-induced behavioural aberrations 
produced in the forced swimming test and preference for sucrose, as a hedonic 
measure. Comparisons for antidepressant-like action were made with the standard 
fluoxetine. 
2. Experimental Protocol 
Swiss Albino rats (100-125 g) were acclimatized to standard laboratory 
conditions for a week, during which time they were randomly assigned to weight-
matched groups of 6-9 animals, each receiving drug and/or restraint stress for 21 
consecutive days. Unstressed, untreated animals constituted the control group and 
were accustomed to daily handling. Pyridoxine hydrochloride (10 mg/kg), folic acid 
(10 mg/kg), ascorbic acid (50 mg/kg) and fluoxetine hydrochloride (20 mg/kg) were 
dissolved in physiological saline and administered via oral route, either alone or 30 
min following the stress regimen. Drug solutions were freshly prepared and all doses 
were selected based on preliminary pilot studies and the reported literature 
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(Calderon-Guzman et al., 2004; Kulkami and Dhir, 2007; Zafir and Banu, 2007). 
The following ten groups were constituted: 
Group I Control 
Group II Pyridoxine (10 mg/kg/day, p.o. for 21 days) 
Group III Folic acid (10 mg/kg/day, p.o. for 21 days) 
Group IV Ascorbic acid (50 mg/kg/day, p.o. for 21 days) 
Group V Fluoxetine (20 mg/kg/day, p.o. for 21 days) 
Group VI Restraint stress (4 h daily for 21 days) 
Group VII Restraint stress (4 h daily for 21 days) followed by pyridoxine 
(10 mg/kg, p.o. for 21 days) 
Group VIII Restraint stress (4 h daily for 21 days) followed by folic acid (10 
mg/kg, p.o. for 21 days) 
Group IX Restraint stress (4 h daily for 21 days) followed by ascorbic acid 
(50 mg/kg, p.o. for 21 days) 
Group X Restraint stress (4 h daily for 21 days) followed by fluoxetine 
(20 mg/kg, p.o. for 21 days) 
At the end of the acclimatization period, baseline body weights of rats and 
sucrose preference (as a hedonic measure) were recorded, one day prior to 
commencing the experiments. These two parameters were then noted at the end of 
every week during the 21-day experiment. At the end of this period, all animals were 
subjected to the forced swimming test. Behavioural testing was performed during 
the light phase of the light/dark cycle after animals had adapted to the experimental 
room for at least 1 h. Twenty-four hours later animals were sacrificed imder ether 
anesthesia for biochemical analyses. Brain and liver tissues obtained from three 
animals in each group were immediately fixed in 10% buffered neutral formalin 
solution, embedded in paraffin and serial sections were stained with hematoxylin 
and eosin for histological examination. {Details given in Materials and Methods) 
3. Results 
i. Effect of vitamin-treatments on restraint stress-induced decline in 
antioxidant enzyme activities 
Rats subjected to restraint stress had significantly lower SOD, CAT, GST 
and GR activities in all tissues compared with non-stressed controls (P<0.01; figures 
147 
SECTION 5 
1-8, tables 1-2). There was a significant increase in antioxidant enzyme activities 
after treatment of non-stressed animals with pyridoxine (P<0.05, except for cardiac 
GST activity) and folic acid (P<0.05), which was remarkably similar to the 
antioxidant effect of ascorbic acid (P<0.05). Fluoxetine treatment in naive animals 
did not alter SOD activity from control levels. 
As compared to stress-alone treatment, administration of pyridoxine or folic 
acid to stressed animals was observed to significantly revert the stress-induced 
decline in enzyme activities back towards the control range (P<0.05). The potency 
of this effect was similar to the antioxidant action of ascorbic acid (P<0.05) m 
stressed animals. Fluoxetine exerted a similar protective effect (P<0.05) against 
restraint-induced oxidative stress. 
ii. Effect of vitamin-treatments on restraint stress-induced decline in 
non-enzymatic antioxidant levels 
a. GSH 
Chronic restraint stress markedly depleted GSH content in brain, liver and 
heart (P<0.01) as compared with controls (figures 9-10). In non-stressed animals, 
pyridoxine per se did not significantly alter levels of GSH from controls, but folic 
acid was found to increase brain and heart GSH significantly (P<0.05) compared 
with controls. Ascorbic acid significantly increased GSH in all organs (P<0.05), 
while fluoxetine did not cause any change. 
However, in stressed animals receiving drug treatments, both pyridoxine 
(P<0.05) and folic acid (P<0.01) were found to have a protective effect against 
stress-induced alterations, evidenced by a significant increase in GSH content in all 
organs. Similarly, ascorbic acid administration to the stressed animals significantly 
increased (P<0.01) GSH in brain, liver and heart, relative to stressed animals that did 
not receive any treatment. Fluoxetine plus stress also caused a significant increase 
(P<0.05) of GSH content in all organs, as opposed to the effects of stress alone. 
b. Uric acid 
Restraint stress significantly lowered serum uric acid concentrations 
(P<0.01) in comparison to control animals (tables 1-2). Restraint followed by 
treatment with either pyridoxine (P<0.01) or folic acid (P<0.001) was observed to 
significantly increase uric acid levels relative to stressed rats receiving no treatment. 
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Their protective effect was similar to that exerted by ascorbic acid (P<0.001). 
Fluoxetine also significantly augmented circulating uric acid (P<0.001) in stressed 
animals. 
In non-stressed subjects, folic acid and ascorbic acid significantly increased 
serum uric acid levels, whereas pyridoxine and fluoxetine treatments had no marked 
effect. 
c. Glucose 
A significant reduction in circulating glucose was observed in animals of the 
restraint stress group (P<0.001) as compared to controls (tables 1-2), but this was 
significantly restored by pyridoxine as well as folic acid (P<0.001) administration to 
stressed rats. Ascorbic acid treatment also normalized serum glucose concentrations 
(P<0.001) relative to stressed animals. An increase in serum glucose back towards 
the control range was observed after stressed animals were treated with fluoxetine 
(P<0.001). 
The administration of the above drugs to non-stressed animals did not affect 
glucose levels in a significant manner. 
ill. EfTect of vitamin-treatments on oxidative stress markers 
0. Lipid peroxidation 
As depicted in figures 11 and 12, restraint stress significantly increased lipid 
peroxidation in brain (P<0.05), liver and heart (P<0.01) as compared to controls, and 
a parallel rise was observed in circulation (P<0.01). In non-stressed animals, lipid 
peroxidation was maintained near basal levels by all drugs. 
Pyridoxine exerted a normalizing effect by significantly reducing stress-
elevated MDA levels in brain, liver, heart and serum (P<0.05). Similarly, folic acid 
administration to stressed animals also caused a significant decrease (P<0.05) in 
lipid peroxidation relative to stress alone treatment. The same effect was produced 
by the antioxidant ascorbic acid (P<0.05). Fluoxetine was also observed to 
significantly prevent lipid peroxidation (P<0.05) induced by stress, 
b. Protein carbonyl production 
Figures 13 and 14 show the effects of stress and drug treatments on the 
extent of protein oxidation in brain, liver and heart. The results indicate a significant 
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rise in protein carbonyl production in all these tissues due to prolonged restraint 
stress (P<0.01) as compared with the control group. Drug treatments/7er se did not 
produce significant variations from the control group. 
However, oral administration of pyridoxine during restraint stress was found 
to significantly reduce carbonyl contents (P<0.01) in comparison to stress alone-
treated animals. Folic acid had a similar protective effect as evidenced by a 
significant decrease in protein oxidation (P<0.01) in all organs. Both the vitamins 
were equally effective as ascorbic acid treatment to stressed animals, which induced 
a significant decrease in protein carbonyl production (P<0.01). A reversal of stress-
induced protein oxidation was also observed in the fluoxetine plus stress group 
(P<0.01). 
iv. Effect of vitamin-treatments on markers enzymes of liver and heart 
While chronically applied restraint stress was characterized by a significant 
rise (P<0.001) in all marker enzymes of the liver and the heart, such as GOT, GPT, 
ALP and LDH (figxare 15, tables 3-4), the effects of all drugs indicated a 
considerable hepatoprotective and cardioprotective potential as evidenced by a 
significant decline (P<0.001) in the levels of these enzymes, in tissues (GOT, GPT, 
ALP and LDH) as well as in circulation (SGOT, SGPT), compared to stressed 
animals. 
Drug alone treatments with pyridoxine, folic acid, ascorbic acid or fluoxetine 
maintained the levels of marker enzymes near normal. 
v. Effect of vitamin-treatments on restraint stress-induced decline in 
body weight of animals 
Figure 16 shows a decline in body weight during the first week of restraint 
stress, which became significantly reduced (P<0.05) from Day 7 onwards in 
comparison to confrol animals. Stress-induced weight loss was effectively 
antagonized by all drugs in a comparable maimer and body weights of these rats 
were significantly higher (P<0.05) than those of stressed animals on Days 14 and 21. 
Drug treatment to non-sfressed animals maintained body weight close to that 
observed in controls throughout the duration of the experiment, with no significant 
changes being produced. 
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vi. Effect of antidepressants on behavioural parameters 
a. Forced swimming test 
As indicated in figure 17, animals subjected to chronic restraint developed a 
marked decrease in the latency to begin floating during the forced swimming test 
relative to controls (P<0.01). The total time spent immobile was significantly 
elevated in these animals (P<0.01), but the time spent swimming was substantially 
decreased (P<0.01). Pyridoxine, folic acid and ascorbic acid produced a significant 
increase in the latency to assume an irrmiobile posture in the FST (P<0.01), while 
significantly reducing the duration of immobility (P<0.01), associated with an 
increase in the duration of swimming time (P<0.01). The magnitude of restoration of 
the behavioral indices by these vitamins was comparable to the antidepressant effect 
of fluoxetine. 
b. Sucrose preference test 
At baseline (one day prior to experimentation), all animals were observed to 
have a similar preference for a 1% sucrose solution. Chronic restraint stress 
significantly reduced the preference for sucrose as compared to controls (P<0.01; 
figure 18), as early as at the end of Day 1 of exposure to restraint. Weekly tests 
revealed that these animals exhibited significantly lower sucrose preference 
(P<0.01) than controls throughout the experimental period. Restraint stress-induced 
anhedonia was abolished by chronic administration of any of the three vitamins, 
pyridoxine, folic acid and ascorbic acid, as compared to stressed animals (P<0.01). 
Fluoxetine also increased sucrose preference significantly (P<0.01). 
vii. Histopathological observations 
a. Brain 
As displayed in Figure 19, normal trilaminar structure with molecular, 
granular and polymorphic layers were observed in brain tissues of the control group 
(panel A). No anatomical pathological signals were found in any of the control 
specimens. 
Marked decrease in the thickness of the pyramidal and molecular layers, as 
well as reduced number of axons, was observed in animals exposed to chronic 
restraint stress (panel B). Supplementation of stressed animals with folic acid (panel 
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C) was found to be neuroprotective as indicated by the normal thickness of granular 
layer. Oral administration of ascorbic acid (panel F) and fluoxetine (panel E) to 
restraint-stressed animals showed a good neuroprotective effect and the thickness of 
the neuronal layer was maintained to normal. Pyridoxine treatment (panel D) 
demonstrated partially normal and partially decreased number of neurons in 
pyramidal layer; however, the recovery from stress was clearly evident in this group 
also. 
b. Liver 
Routine histological staining showed normal histological architecture in the 
control liver (Figure 20; panel A). 
Severe pathological alterations were produced following chronic exposure to 
restraint stress (panel B). Marked dilatation of the central vein and portal tract 
vessels was observed and these were congested with blood. Mononuclear infiltrate 
was also evident in the portal tract. The sinusoids were also dilated and congested. A 
large increase in Kupfifer cells was observed as compared to the control specimen. 
Focal necrosis of hepatocytes had occurred along with hydropic degeneration and 
apoptotic cells were present. 
Reversal of stress-induced changes by pyridoxine administration (panel D) 
was observed in the form of absence of hydropic degeneration and reduction of 
apoptotic figures. Kupffer cells were also reduced. There was a decrease in vascular 
dilatation and engorgement and reduction in mononuclear infiltrate around portal 
vessels; only a slight increase in neutrophils and eosinophils was seen. 
The best recovery from stress-induced histological damage was observed 
following oral treatment with folic acid (panel C) and ascorbic acid (panel F); most 
of the pathological changes were reversed completely, especially degeneration and 
necrosis, and the inflammatory infiltrate was also markedly reduced. 
Reversal of stress-induced changes was also noted with fluoxetine treatment 
(panel E). There was a marked recovery from stress in most of the altered 
parameters. However, slight focal hydropic degeneration and mononuclear cell 
infiltrate was still present, and these changes were not reduced to the extent as 
observed with folic acid and pyridoxine. 
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Figure 1. Effect of chronic administration of pyridoxine, folic acid and ascorbic acid 
on brain SOD activity of experimental animals. Animals in treatment groups 
received pyridoxine (PYR; 10 mg/kg/day, p.o.), folic acid (FA; 10 mg/kg/day, p.c), 
ascorbic acid (AA; 50 mg/kg/day, p.o.) or fluoxetine (FLU; 20 rag/kg/day, p.o.) for 21 
consecutive days, either alone or following 4 h of daily restraint stress (Stress + PYR, 
Stress + FA, Stress + AA, Stress + FLU). Data represent group mean ± S.E.M. (n = 6). A, 
B, C, D: P<0.05, P<0.02, P<0.01, P<0.001 as compared with the control group; a, b, c, d: 
P<0.05, P<0.02, P<0.01, P<0.001 as compared with stress alone. 
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Figure 2. Effect of chronic administration of pyridoxine, folic acid and ascorbic acid 
on SOD activity in liver and heart of experimental animals. Animals in treatment 
groups received pyridoxine (PYR; 10 mg/kg/day, p.c), folic acid (FA; 10 mg/kg/day, 
P.O.), ascorbic acid (AA; 50 mg/kg/day, p.c.) or fluoxetine (FLU; 20 mg/kg/day, p.o.) for 
21 consecutive days, either alone or following 4 h of daily restraint stress (Stress + PYR, 
Stress + FA, Stress + AA, Stress + FLU). Data represent group mean ± S.E.M. (n = 6). A, 
B, C, D: P<0.05, P<0.02, P<0.01, P<0.001 as compared with the control group; a, b, c, d: 
P<0.05, P<0.02, P<0.01, P<0.001 as compared with stress alone. 
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Figure 3. Effect of chronic administration of pyridoxine, folic acid and ascorbic acid 
on brain CAT activity of experimental animals. Animals in treatment groups 
received pyridoxine (PYR; 10 mg/kg/day, p.c), folic acid (FA; 10 mg/kg/day, p.c), 
ascorbic acid (AA; 50 mg/kg/day, p.c.) or fluoxetine (FLU; 20 mg/kg/day, p.o.) for 21 
consecutive days, either alone or following 4 h of daily restraint stress (Stress + PYR, 
Stress + FA, Stress + AA, Stress + FLU). Data represent group mean ± S.E.M. (n = 6). A, 
B, C, D: P<0.05, P<0.02, P<0.01, P<0.001 as compared with the control group; a, b, c, d: 
P<0.05, P<0.02, P<0.01, P<0.001 as compared with stress alone. 
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Figure 4. Effect of chronic administration of pyridoxine, folic acid and ascorbic acid 
on CAT activity in liver and heart of experimental animals. Animals in 
treatment groups received pyridoxine (PYR; 10 mg/kg/day, p.o.), folic acid (FA; 10 
mg/kg/day, p.o.), ascorbic acid (AA; 50 mg/kg/day, p.o.) or fluoxetine (FLU; 20 
mg/kg/day, p.o.) for 21 consecutive days, either alone or following 4 h of daily restraint 
stress (Stress + PYR, Stress + FA, Stress + AA, Stress + FLU). Data represent group mean 
± S.E.M. (n = 6). A, B, C, D: P<0.05, P<0.02, P<0.01, P<0.001 as compared with the 
control group; a, b, c, d: P<0.05, P<0.02, P<0.01, P<0.001 as compared with stress alone. 
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Figure 5. Effect of chronic administration of pyridoxine, folic acid and ascorbic acid 
on brain GST activity of experimental animals. Animals in treatment groups 
received pyridoxine (PYR; 10 mg/kg/day, p.c), folic acid (FA; 10 mg/kg/day, p.o.), 
ascorbic acid (AA; 50 mg/kg/day, p.o.) or fluoxetine (FLU; 20 mg/kg/day, p.o.) for 21 
consecutive days, either alone or following 4 h of daily restraint stress (Stress + PYR, 
Stress + FA, Stress + AA, Stress + FLU). Data represent group mean ± S.E.M. (n = 6). A, 
B, C, D: P<0.05, P<0.02, P<0.01, P<0.001 as compared with the control group; a, b, c, d: 
P<0.05, P<0.02, P<0.01, P<0.001 as compared with stress alone. 
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Figure 6. Effect of chronic administration of pyridoxine, folic acid and ascorbic acid 
on GST activity in liver and heart of experimental animals. Animals in treatment 
groups received pyridoxine (PYR; 10 mg/kg/day, p.c), folic acid (FA; 10 mg/kg/day, 
P.O.), ascorbic acid (AA; 50 mg/kg/day, p.o.) or fluoxetine (FLU; 20 mg/kg/day, p.o.) for 
21 consecutive days, either alone or following 4 h of daily restraint stress (Stress + PYR, 
Stress + FA, Stress + AA, Stress + FLU). Data represent group mean ± S.E.M. (n = 6). A, 
B, C, D: P<0.05, P<0.02, P<0.01, P<0.001 as compared with the control group; a, b, c, d: 
P<0.05, P<0.02, P<0.01, P<0.001 as compared with stress alone. 
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Figure 7. Effect of chronic administration of pyridoxine, folic acid and ascorbic acid 
on brain GR activity of experimental animals. Animals in treatment groups 
received pyridoxine (PYR; 10 mg/kg/day, p.o.), folic acid (FA; 10 mg/kg/day, p.o.), 
ascorbic acid (AA; 50 mg/kg/day, p.o.) or fluoxetine (FLU; 20 mg/kg/day, p.o.) for 21 
consecutive days, either alone or following 4 h of daily restraint stress (Stress + PYR, 
Stress + FA, Stress + AA, Stress + FLU). Data represent group mean ± S.E.M. (n = 6). A, 
B, C, D: P<0.05, P<0.02, P<0.01, P<0.001 as compared with the control group; a, b, c, d: 
P<0.05, P<0.02, P<0.01, P<0.001 as compared with stress alone. 
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Figure 8. Effect of chronic administration of pyridoxine, folic acid and ascorbic acid 
on GR activity in liver and heart of experimental animals. Animals in treatment 
groups received pyridoxine (PYR; 10 mg/kg/day, p.o.), folic acid (FA; 10 mg/kg/day, 
P.O.), ascorbic acid (AA; 50 mg/kg/day, p.o.) or fluoxetine (FLU; 20 mg/kg/day, p.o.) for 
21 consecutive days, either alone or following 4 h of daily restraint stress (Stress + PYR, 
Stress + FA, Stress + AA, Stress + FLU). Data represent group mean ± S.E.M. (n = 6). A, 
B, C, D: P<0.05, P<0.02, P<0.01, P<0.001 as compared with the control group; a, b, c, d: 
P<0.05, P<0.02, P<0.01, P<0.001 as compared with stress alone. 
160 
SECTION 5 RESULTS 
35 
30 
c 25 
E 
20 
E 15 
I 10 
B 
a n Control 
^ ^ a PYR 
t^ SSS FA 
^ ^ AA 
LMUjScQ CI 1 1 
B B Stress 
lUUM Stress + 
• H Stress + 
^ ^ Stress + 
E S ^ Stress + 
PYR 
FA 
AA 
FLU 
No Stress Stress 
Figure 9. Effect of chronic administration of pyridoxine, folic acid and ascorbic acid 
on brain GSH levels of experimental animals. Animals in treatment groups 
received pyridoxine (PYR; 10 mg/kg/day, p.o.), folic acid (FA; 10 mg/kg/day, p.c), 
ascorbic acid (AA; 50 mg/kg/day, p.o.) or fluoxetine (FLU; 20 mg/kg/day, p.o.) for 21 
consecutive days, either alone or following 4 h of daily restraint stress (Stress + PYR, 
Stress + FA, Stress + AA, Stress + FLU). Data represent group mean ± S.E.M. (n = 6). A, 
B, C, D: P<0.05, P<0.02, P<0.01, P<0.001 as compared with the control group; a, b, c, d: 
P<0.05, P<0.02, P<0.01, P<0.001 as compared with stress alone. 
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Figure 10. Effect of chronic administration of pyridoxine, folic acid and ascorbic acid 
on GSH levels in liver and heart of experimental animals. Animals in treatment 
groups received pyridoxine (PYR; 10 mg/kg/day, p.c), folic acid (FA; 10 mg/kg/day, 
P.O.), ascorbic acid (AA; 50 mg/kg/day, p.o.) or fluoxetine (FLU; 20 mg/kg/day, p.o.) for 
21 consecutive days, either alone or following 4 h of daily restraint stress (Stress + PYR, 
Stress + FA, Stress + AA, Stress + FLU). Data represent group mean ± S.E.M. (n = 6). A, 
B, C, D: P<0.05, P<0.02, P<0.01, P<0.001 as compared with the control group; a, b, c, d: 
P<0.05, P<0.02, P<0.01, P<0.001 as compared with stress alone. 
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Figure 11. Inhibition of restraint stress-induced brain lipid peroxidation by chronic 
administration of pyridoxine, folic acid and ascorbic acid. Animals in treatment 
groups received pyridoxine (PYR; 10 mg/kg/day, p.o.), folic acid (FA; 10 mg/kg/day, 
P.O.), ascorbic acid (AA; 50 mg/kg/day, p.o.) or fluoxetine (FLU; 20 mg/kg/day, p.o.) for 
21 consecutive days, either alone or following 4 h of daily restraint stress (Stress + PYR, 
Stress + FA, Stress + AA, Stress + FLU). Data represent group mean ± S.E.M. (n = 6). A, 
B, C, D: P<0.05, P<0.02, P<0.01, P<0.001 as compared with the control group; a, b, c, d: 
P<0.05, P<0.02, P<0.01, P<0.001 as compared with stress alone. 
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Figure 12. lahibition of restraint stress-induced lipid peroxidation in liver and heart 
by chronic administration of pyridoxine, folic acid and ascorbic acid. Animals 
in treatment groups received pyridoxine (PYR; 10 mg/kg/day, p.c), folic acid (FA; 10 
mg/kg/day, p.o.), ascorbic acid (AA; 50 mg/kg/day, p.o.) or fluoxetine (FLU; 20 
mg/kg/day, p.o.) for 21 consecutive days, either alone or following 4 h of daily restraint 
stress (Stress + PYR, Stress + FA, Stress + AA, Stress + FLU). Data represent group mean 
± S.E.M. (n = 6). A, B, C, D: P<0.05, P<0.02, P<0.01, P<0.001 as compared with the 
control group; a, b, c, d: P<0.05, P<0.02, P<0.01, P<0.001 as compared with stress alone. 
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Figure 13. Inhibition of restraint stress-induced protein carbonyl production in brain 
by chronic administration of pyridoxine, folic acid and ascorbic acid. Animals 
in treatment groups received pyridoxine (PYR; 10 mg/kg/day, p.o.), folic acid (FA; 10 
mg/kg/day, p.o.), ascorbic acid (AA; 50 mg/kg/day, p.o.) or fluoxetine (FLU; 20 
mg/kg/day, p.o.) for 21 consecutive days, either alone or following 4 h of daily restraint 
stress (Stress + PYR, Stress + FA, Stress + AA, Stress + FLU). Data represent group mean 
± S.E.M. (n = 6). A, B, C, D; P<0.05, P<0.02, P<0.01, P<0.001 as compared with the 
control group; a, b, c, d: P<0.05, P<0.02, P<0.01, P<0.001 as compared with stress alone. 
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Figure 14. Inhibition of restraint stress-induced protein carbonyl production in liver 
and heart by chronic administration of pyridoxine, folic acid and ascorbic 
acid. Animals in treatment groups received pyridoxine (PYR; 10 mg/kg/day, p.c), folic 
acid (FA; 10 mg/kg/day, p.o.), ascorbic acid (AA; 50 mg/kg/day, p.o.) or fluoxetine (FLU; 
20 mg/kg/day, p.o.) for 21 consecutive days, either alone or following 4 h of daily restraint 
stress (Stress + PYR, Stress + FA, Stress + AA, Stress + FLU). Data represent group mean 
± S.E.M. (n = 6). A, B, C, D: P<0.05, P<0.02, P<0.01, P<0.001 as compared with the 
control group; a, b, c, d: P<0.05, P<0.02, P<0.01, P<0.001 as compared with stress alone. 
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Figure 15. Circulating (SGOT, SGPT) and hepatic (GOT, GPT) levels of liver 
function enzymes in response to chronic administration of pyridoxine, folic 
acid and ascorbic acid. Animals in treatment groups received pyridoxine (PYR; 10 
mg/kg/day, p.o.), folic acid (FA; 10 mg/kg/day, p.o.), ascorbic acid (AA; 50 mg/kg/day, 
p.o.) or fluoxetine (FLU; 20 mg/kg/day, p.o.) for 21 consecutive days, either alone or 
following 4 h of daily restraint stress (Stress + PYR, Stress + FA, Stress + AA, Stress + 
FLU). Data represent group mean ± S.E.M. (n = 6). * P<0.001 as compared with the 
control group; # P<0.001 as compared with stress alone. 
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Table 1. Effect of pyridoxine, folic acid and ascorbic acid on basal circulating 
levels of antioxidant defenses and oxidative stress markers. 
Group 
Control 
PYR 
FA 
AA 
FLU 
SOD 
(U/mg 
protein) 
16.50 
±0.60 
17.78' 
±0.21 
18.90' 
±0.80 
18.01' 
±0.54 
15.51 
±0.60 
CAT 
(U/mg 
protein) 
1.85 
±0.09 
2.06' 
±0.08 
2.71' 
±0.13 
2.24' 
±0.21 
1.60 
±0.10 
GST 
(U/mg 
protein) 
0.19 
±0.04 
0.20 
±0.01 
0.23' 
±0.01 
0.22' 
±0.02 
0.17 
±0.03 
MDA 
(nmol/ 
mg 
protein) 
0.170 
± 0.034 
0.165 
± 0.027 
0.149 
± 0.020 
0.160 
±0.01 
0.177 
± 0.020 
Glucose 
(mg/dl) 
118.13 
±2.77 
120.00 
±2.65 
116.00 
±4.67 
113.75 
±2.95 
126.75 
±2.90 
Uric 
acid 
(mg/dl) 
4.93 
±0.40 
5.13 
±0.40 
5,48' 
±0.38 
5.76' 
±0.39 
4.40 
±0.26 
Drug alone treatments were administered for 21 consecutive days and are indicated as: 
PYR: pyridoxine (10 mg/kg/day, p.c), FA: folic acid (10 mg/kg/day, p.o.), AA: ascorbic 
acid (50 mg/kg/day, p.c), FLU: fluoxetine (20 mg/kg, p.o.). Data represent group mean ± 
S.E.M. (n = 6). A, B, C, D: P<0.05, P<0.02, P<0.01, P<0.001 as compared with the control 
group; a, b, c, d: P<0.05, P<0.02, P<0.01, P<0.001 as compared with stress alone. 
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Table 2. Modulatory effects of pyridoxine, folic acid and ascorbic acid on 
restraint stress-induced alterations in circulating levels of antioxidant 
defenses and oxidative stress markers. 
1 Group 
Control 
Restraint 
1 stress 
Stress + 
PYR 
Stress + FA 
1 Stress + AA 
Stress + 
1 FLU 
SOD 
(U/mg 
protein) 
16.50 
±0.60 
7.65^ 
±0.41 
15.25' 
±0.33 
15.88' 
±0.38 
16.09^ 
±0.25 
13.72" 
±0.32 
CAT 
(U/mg 
protein) 
1.85 
±0.09 
0.72*= 
±0.17 
1.40' 
±0.13 
2.10*^  
±0.20 
1.90' 
±0.09 
1.15' 
±0.10 
GST 
(U/mg 
protein) 
0.19 
±0.04 
0.08^ 
±0.02 
0.17' 
±0.02 
0.20*^  
±0.02 
0.19" 
±0.01 
0.16' 
±0.03 
MDA 
(nmol/ 
mg 
protein) 
0.170 
± 0.034 
0.281^ 
±0.031 
0.195' 
±0.031 
0.179' 
± 0.030 
0.184' 
±0.016 
0.204' 
± 0.022 
Glucose 
(mg/dl) 
118.13 
±2.77 
85.50^ 
±3.62 
122.75'' 
±2.63 
121.00" 
±4.04 
114.25" 
±2.32 
127.25" 
±2.69 
Uric 
acid 
(mg/dl) 
4.93 
±0.40 
2.20^ 
±0.28 
4.45' 
±0.31 
4.75" 
±0.26 
5.24" 
±0.29 
4.35" 
±0.16 
Animals in treatment groups received pyridoxine (Stress + PYR; 10 mg/kg/day, p.o.), folic 
acid (Stress + FA; 10 mg/kg/day, p.o.), ascorbic acid (Stress + AA; 50 mg/kg/day, p.o.) or 
fluoxetine (Stress + FLU; 20 mg/kg, p.o.) following 4 h of daily restraint stress for 21 
consecutive days. Data represent group mean ± S.E.M. (n = 6). A, B, C, D: P<0.05, 
P<0.02, P<0.01, P<0.001 as compared with the control group; a, b, c, d: P<0.05, P<0.02, 
P<0.01, P<0.001 as compared with stress alone. 
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Table 3. Effect of pyridoxine, folic acid and ascorbic acid on circulating, 
hepatic and cardiac levels of marker enzymes. 
1 Group 
Control 
PYR 
FA 
AA 
FLU 
ALP (mg/ml) 
Serum 
0.350 
± 0.038 
0.371 
±0.015 
0.335 
±0.135 
0.329 
±0.010 
0.399 
±0.015 
Liver 
3.427 
± 0.340 
3.807 
±0.126 
3.140 
±0.187 
2.750 
±0.128 
3.653 
±0.189 
LDH (U/mg protein) 
Serum 
0.107 
± 0.027 
0.133 
±0.018 
0.114 
±0.019 
0.093 
±0.017 
0.140 
± 0.014 
Liver 
0.427 
± 0.059 
0.447 
± 0.025 
0.403 
± 0.023 
0.383 
±0.015 
0.504 
±0.173 
Heart 
0.407 
± 0.032 
0.410 
±0.015 
0.387 1 
±0.016 
0.370 
±0.012 
0.430 
±0.017 
Drug alone treatments were administered for 21 consecutive days and are indicated as: 
PYR: pyridoxine (10 mg/kg/day, p.c), FA: folic acid (10 mg/kg/day, p.c), AA: ascorbic 
acid (50 mg/kg/day, p.c.), FLU: fluoxetine (20 mg/kg, p.o.). Data represent group mean ± 
S.E.M. (n = 6). 
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Table 4. Modulatory effects of pyridoxine, folic acid and ascorbic acid on 
restraint stress-induced alterations in circulating, hepatic and cardiac levels of 
marker enzymes 
Group 
Control 
Restraint 
stress 
Stress + 
PYR 
Stress + FA 
Stress + AA 
Stress + 
FLU 
ALP( 
Serum 
0.350 
± 0.038 
0.737* 
± 0.203 
0.454* 
± 0.026 
0.435* 
±0.018 
0.387* 
± 0.034 
0.493** 
±0.018 
mg/ml) 
Liver 
3.427 
± 0.340 
4.940* 
±0.137 
4.237* 
± 0.086 
3.550* 
±0.161 
3.063* 
±0.168 
3.910** 
±0.127 
LDH (U/mg protein) 
Serum 
0.107 
± 0.027 
0.302* 
±0.017 
0.180* 
±0.015 
0.163* 
±0.018 
0.140* 
±0.012 
0.190** 
±0.019 
Liver 
0.427 
± 0.059 
0.740* 
± 0.046 
0.530* 
± 0.025 
0.523* 
± 0.030 
0.490* 
±0.017 
0.570** 
± 0.037 
Heart 
0.407 
± 0.032 
0.690* 
± 0.023 
0.520* 
± 0.027 
0.467* 
± 0.020 
0.450* 
± 0.021 
0.537** 
± 0.026 
Animals in treatment groups received pyridoxine (Stress + PYR; 10 mg/kg/day, p.c), folic 
acid (Stress + FA; 10 mg/kg/day, p.c), ascorbic acid (Stress + AA; 50 mg^g/day, p.c.) or 
fluoxetine (Stress + FLU; 20 mg/kg, p.c.) following 4 h of daily restraint stress for 21 
consecutive days. Data represent group mean ± S.E.M. (n = 6). *P<0.001 as compared 
with the control group; # P<0.001 as compared with stress alone. 
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Figure 16. Influence of chronic administration of pyridoxine, folic acid and ascorbic 
acid on body weight of experimental animals. Body weight was recorded every 7 
days. Animals in treatment groups received pyridoxine (PYR; 10 mg/kg/day, p.o.), folic 
acid (FA; 10 mg/kg/day, p.o.), ascorbic acid (AA; 50 mg/kg/day, p.o.) or fluoxetine (FLU; 
20 mg/kg/day, p.o.) for 21 consecutive days, either alone or following 4 h of daily restraint 
stress (Stress + PYR, Stress + FA, Stress + AA, Stress + FLU). Data represent group mean 
± S.E.M. (n = 6). * P<0.05 as compared with the control group; # P<0.05 as compared 
with stress alone. 
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Figure 17. Modulatory effects of pyridoxine, folic acid and ascorbic acid on restraint 
stress-induced alterations in behavioural parameters of the forced swimming 
test. Animals in treatment groups received pyridoxine (Stress + PYR; 10 mg/kg/day, p.o.), 
folic acid (Stress + FA; 10 mg/kg/day, p.o.), ascorbic acid (Stress + AA; 50 mg/kg/day, 
p.o.) or fluoxetine (Stress + FLU; 20 mg/kg/day, p.o.) following 4 h of daily restraint stress 
for 21 consecutive days. Data represent group mean ± S.E.M. (n = 6). * P<0.01 as 
compared with the control group; # P<0.01 as compared with stress alone. 
173 
SECTION 5 RESULTS 
90 
80 
g 
S 70 
2 
o 3 (0 
S 6 0 
>*• 
o 
u 
c 
o fe 50 
Q. 
40 
30 
J < 1 
r # _ 
• * 
1 1 1 
-1 1 7 
Day 
1 
—•— Control 
—o— Stress 
- T - Stress+ PYR 
—£^ Stress + FA 
—•— Stress+ AA 
- D - Stress + FLU 
^ ^ # 
r! V 
[ ± 
< 
14 21 
f 
Figure 18. Reversal of restraint stress-induced anhedonia by chronic administration 
of pyridoxine, folic acid and ascorbic acid. Animals in treatment groups received 
pyridoxine (Stress + PYR; 10 mg/kg/day, p.o.), folic acid (Stress + FA; 10 mg/kg/day, 
P.O.), ascorbic acid (Stress + AA; 50 mg/kg/day, p.o.) or fluoxetine (Stress + FLU; 20 
mg/kg/day, p.o.) following 4 h of daily restraint stress for 21 consecutive days. Data 
represent group mean ± S.E.M. (n = 6). * P<0.01 as compared with the control group; # 
P<0.01 as compared with stress alone. 
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Figure 19. Sections (lOX) showing histology in brain of (A) Control rat, (B) 
Restraint stressed rat (4h/day, 21 days), (C) Stress + Folic acid (10 
mg/kg/day, p.o., 21 days), (D) Stress + Pyridoxine (10 mg/kg/day, 
P.O., 21 days), (E) Stress + Fluoxetine (20 mg/kg/day, p.o., 21 days), 
and (F) Stress + Ascorbic Acid (50 mg/kg/day, p.o., 21 days). In (A) 
normal trilaminar structure (molecular, polymorphic, granular layer) is 
visible. (B) Chronic stress reduced the thickness of neuronal layer. (C) 
Normal thickness of granular layer was evident with folic acid 
supplementation. (E, F) A good neuroprotective effect was seen by Stress + 
Fluoxetine and Stress + Ascorbic acid, respectively. (D) Improvement was 
seen with Stress + Pyridoxine treatment as compared to stress alone. 
SECTION 5 RESULTS 
(A) (B) 
(C) (D) 
175 
Figure 20. H&E stained sections (500 hp) showing morphology in liver of (A) 
Control rat, (B) Restraint stressed rat (4h/day, 21 days), (C) Stress + 
Folic acid (10 mg/kg/day, p.o., 21 days), (D) Stress + Fyridoxine (10 
mg/l^day, p.o., 21 days), (E) Stress + Fluoxetine (20 mg/kg/day, p.o., 
21 days), and (F) Stress + Ascorbic Acid (50 mg/kg/day, p.o., 21 
days). (A) Normal histological structure was seen in control liver. (B) Chronic 
restraint stress: dilatation of central vein and marked features of injury were 
present like focal hepatonecrosis and apoptosis. (C, F) Marked recovery of all 
these pathological changes was seen in Stress + Folic acid and Stress + 
Ascorbic acid, respectively. (D, E) Stress + Pyridoxine and Stress + Fluoxetine, 
respectively, evidenced a good hepatoprotective effect. Mononuclear cell 
infiltrate and presence of Kupffer cells was reduced in comparison to stress 
alone. 
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4. Discussion 
The results of this study provide evidence for the antidepressant-like activity 
and coexisting antioxidant action of the water-soluble vitamins, folic acid, 
pyridoxine and ascorbic acid. Of significance, folic acid and pyridoxine were found 
to be as effective as ascorbic acid in enhancing a wide spectrum of critical in vivo 
antioxidants, thus effectively limiting ROS-mediated damage to biological 
macromolecules. A novel finding demonstrated here is the potential of ascorbic acid 
to reverse stress-induced hedonic deficits and attenuate behavioral despair in the 
forced swimming test (FST). Furthermore, the finding of the effects of specific 
inhibition of oxidative stress by antioxidants coinciding with a parallel 
disappearance of depressive phenotypes in restraint stressed animals strongly 
suggests that imbalance in oxidant homeostasis directly or indirectly influences 
behavioural aberrations found in this particular experimental model. 
The experimental application of long-term stress allows investigators to 
model risk factors for human brain (neuropsychiatric) disorders, particularly the 
features of depression, for which stress is clinically both a predisposing and 
contributing factor (Madrigal et al., 2003; De Kloet et al., 2005; Lu et al., 2006). 
Animals subjected to inescapable restraint stress develop several characteristic 
physiological and behavioural patterns that reflect the diagnostic symptoms of 
human depression. The present study shows increased behavioural "despair" 
(increase in the time spent immobile) and reduction in escape-oriented active 
behaviour (swimming) in restraint stressed-animals exposed to the FST, which is in 
agreement with previous reports (Cancela et al., 1991; Zurita and Molina, 1999). 
Restraint stressed animals also exhibited a consistent decrease in sucrose preference, 
indicative of diminished sensitivity to natural reward in rodents, resembling a 
defining phenotype of depression according to DSM-IV criteria (American 
Psychiatric Association, 1994; Willner, 2005). These behavioural abnormalities 
occurred along v^th a coincident loss of body weight in the experimental animals 
during the entire stressor period, which is also a core aspect of stress and depression 
(Sapolsky et al., 2000). 
Free radical-mediated processes play an aberrant role in the mechanism of 
stress and are involved in different pathways leading directly or indirectly to 
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neurodegenerative and behavioral changes (Abidin et al., 2004, Manikandan et al., 
2006; Chakraborti et al., 2007). These events are critical towards the understanding 
of the mechanisms underlying stress-related psychiatric disorders. Chronic restraint 
stress induced a significant suppression of in vivo antioxidant status in rodents. The 
resultant oxidative environment favours ROS attack on membrane lipids leading to 
their peroxidation, which contributes to cellular cytoxicity by the production of 
aldehydic products of this chain reaction process, such as malondialdehyde (MDA) 
(Esterbauer, 1991). Lipid peroxidation is a fundamental pathological mechanism in 
neurodegenerative diseases and major psychiatric disorders such as depressive 
ilbiess (Mattson, 1998; Bilici et al., 2001; Berk, 2007; Sarandol et al., 2007). 
Clinical studies, too, have demonstrated oxidative stress to be a primary or 
secondary pathological factor in depression (Khanzode et al., 2003; Sarandol et al., 
2007) and implicated oxidative damage for brain morphological changes observed in 
these stress-induced disorders (Sheline et al., 1996; Koenen et al., 2001; Cotter et al., 
2002; Michel et al., 2007). Therefore, there is a concordance of clinical evidence 
strongly supporting the investigation of antioxidant and dietary micronutrients in 
attenuating oxidative stress found in stress-induced depression. Thus, the present 
investigation focused on the effects of the water-soluble vitamins, folic acid and 
pyridoxine, on restraint-induced oxidative stress. 
Besides their classical in vivo roles as cofactors and coenzymes in several 
important physiological reactions (Crellin et al., 1993; Stanger, 2002; Stocker et al., 
2003), novel antioxidant properties were recently identified for both vitamins 
(Chumnantana et al., 2005; Stiefel et al., 2005). The results presented here 
demonstrate a significant increase in antioxidant defenses and decline in markers of 
lipid and protein oxidation by treatment of restrained animals with both the vitamins. 
Major enzymatic and non-enzymatic antioxidant defenses found to be augmented by 
these vitamins foUov^ng a stress-induced declme were SOD, CAT, GST, GR, GSH, 
glucose and uric acid, thereby markedly diminishing the secondary effects of 
oxidative damage, i.e., lipid peroxidation and protein carbonyl production. This 
antioxidant action may be attributable to a direct quenching action of ROS (Swiglo 
et al., 2006), since folic acid can efficiently scavenge several free radicals such as 
CCl30'2, N'3, SOV, BrV, OH' and 0' (Joshi et al., 2001), while pyridoxine acts as a 
quencher of singlet oxygen (Bilski, 2000; Ohta and Foote, 2002). The physiological 
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reduced forms of folic acid are also peroxynitrite scavengers as well as inhibitors of 
lipid peroxidation (Nakano et al., 2001; Rezk et al., 2003). The present investigation 
also provides evidence that the antioxidant potency of folic acid and pyridoxine is 
comparable to the well-known antioxidant ascorbic acid, although the former 
vitamins are not classified as antioxidant compounds. This antioxidant action was 
exerted not only in the brain of animals subjected to restraint, but also in vital target 
organs of stress, liver and heart, where elevated levels of marker enzymes were 
subsequently found to be normalized. Thus, folic acid and pyridoxine are 
significantly effective in reversing oxidative damage by physical, emotional and 
psychological stress imposed by inescapable restraint in rodents. 
The histological examination of brain and liver further confirmed tissue 
damage by restraint stress, as evidenced by decreased thickness in neuronal layers of 
the brain and reduced number of axons, along with degenerative changes in the liver, 
like necrosis, apoptosis and pathological structural changes. Vitamin treatments and 
fluoxetine reversed these histological lesions in both the tissues. According to their 
neuroprotective action, efficacy of these drugs can be simimarized as: ascorbic 
acid=fluoxetine>folic acid>pyridoxine, while the order of hepatoprotective effect 
was: folic acid=ascorbic acid>pyridoxine>fluoxetine. Thus, both biochemical and 
histological findings were in close corroboration. 
With respect to possible mechanisms, restoration of cellular GSH may be of 
particular significance in the antioxidant action of these water-soluble vitamins. 
Vitamin C (ascorbic acid) spares or increases intracellular reduced glutathione levels 
(Winkler et al., 1994), which occupies a central role in endogenous antioxidant 
defenses involved in all the lines of protection against ROS (Sies, 1999). Similarly, 
stimulation of GSH synthesis by pyridoxine has been suggested to be directly 
responsible for increased in vivo concentrations of GSH (Stocker et al., 2003; 
Chumnantana et al., 2005), as observed here following a stress-induced decline, 
since pyridoxal phosphate is involved in the anabolic pathway of cysteine, the rate-
limiting substrate in glutathione synthesis (Watanabe and Bannai, 1987). GR 
activity has also been shown to be regulated in response to stress and its mRNA 
expression is enhanced upon exposure to oxidative stress; furthermore it plays a 
crucial role in regenerating GSH (Rogers et al., 2004). Thus, it is also possible that 
increased GR activity, evidenced here by folic acid and pyridoxine treatments to 
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Stressed animals, may also stimulate the recycling pathway for the replenishment of 
GSH, thus preventing ROS cytotoxicity via numerous GSH-dependent antioxidant 
defense reactions (Cnubben et al., 2001). These alterations in the multifunctional 
GSH system may cumulatively contribute towards protection from the detrimental 
onset of lipid peroxidation chain reactions in stressed animals treated with folic acid 
and pyridoxine. Such a possibility is supported by an earlier study demonstrating an 
inhibitory action of folic acid on lipid peroxidation, despite being a water-soluble 
vitamin (Joshi et al., 2001). Ascorbic acid also effectively prevents lipid 
peroxidation as it is a potent antioxidant scavenger of ROS including superoxide 
radicals, hydrogen peroxide (Frei et al., 1992) and peroxy radical (Frei et al., 1989). 
Thus, in view of the direct radical-scavenging action of folic acid and pyridoxine, it 
may be suggested that this quenching property is responsible for maintaining the 
balance between antioxidant defenses and pro-oxidant factors, as substantiated by 
the present results, thereby preventing the downstream cascade of early protein 
oxidation events and lipid peroxidation induced by stress. 
Clinical data have implicated folic acid in the pathophysiology of depression 
(Reynolds, 2002; Paul et al., 2004; Ramos et al., 2004; Abou-Saleh and Coppen, 
2006). Folic acid is critical to optimal functioning of the nervous system since its in 
vivo reduced forms are chief determinants of one-carbon metabolism, leading to the 
formation of S-adenosylmethionine (SAM), the methyl group donor for methylation 
reactions in the brain involving monoamines, neurotransmitters, proteins, 
nucleoproteins and membrane phospholipids (Bottiglieri et al., 1994; Bottiglieri et 
al., 2000; Reynolds, 2007). Therefore, its supplementation during depression 
enhances mood and cognitive functions, which may be linked to methylation 
processes in the brain (Reynolds et al., 1984; Reynolds, 2002). Despite the strong 
association of folic acid in the pathophysiology of depression, there is a considerable 
lack of experimental investigations regardmg the plausible antidepressant action of 
folic acid and its influence on stress-induced behavioural or depressive changes. 
Similar to folic acid, pyridoxine therapy has been suggested to be an effective anti-
stress measure, protecting from detrimental health associated with chronic 
psychological stress (McCarty, 2000). Pyridoxine is involved in the biosynthesis of 
serotonin which has an impact on depression, mood and anxiety (Hartvig et al., 
1995). As it has already been demonstrated in the previous sections (3 and 4) that 
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antidepressant therapy is effective in reversing oxidative stress, it was of further 
interest to examine whether compounds with antioxidant action could conversely 
induce an antidepressant-like effect in behavioural tests sensitive to antidepressant 
drugs (Porsolt et al., 1978; Willner, 2005). 
The possible anti-stress/antidepressant properties of folic acid and 
pyridoxine were investigated in terms of modulation of restraint stress-induced 
behavioural abnormalities. Both these vitamins, similar to antidepressant fluoxetine 
used as standard here, reversed hedonic deficits in animals exposed to chronic stress, 
as evidenced by an increase in sucrose preference in vitamin-treated animals during 
the experimental period, which was similar to cliiucally active antidepressants (Papp 
et al., 2003). Thus, indicating a potential antidepressant-like activity of these 
vitamins. Effects on behaviour were further assessed in the forced swimming test 
(FST), an animal model of depression, used to screen the antidepressant effect of 
drugs (Porsolt et al., 1977). A depressive phenotype was inferred in restraint stressed 
animals from prolonged immobility and reduced active behaviour in this test 
(Porsoh et al., 1978; Lucki, 1997; Johnson et al., 2006), while folic acid and 
pyridoxine interventions were demonstrated to attenuate these stress effects. Oral 
administration of both the vitamins produced a substantial reduction in the time 
spent immobile during the FST, while exerting a reciprocal enhancing effect on the 
duration spent in swimming. This behavioural profile appears very similar to that 
produced by the action of standard antidepressants in the FST (Kulkami and Dhir, 
2007). Increase in swimming time during the FST is selectively produced by 
antidepressants targeting serotonin neurotransmission, such as fluoxetine (Detke et 
al., 1995; Lucki, 1997). In this study, a functional resemblance was observed with 
fluoxetine (selective serotonin reuptake inhibitor) in the behavioural strategy 
adopted by rats in the FST after treatment with folic acid and pyridoxine, implying 
that these vitamins may probably target serotonergic systems to produce an 
antidepressant-like action. This observation is consistent with a recent study 
reporting the antidepressant-like effect of folic acid in mice probably mediated by 
interactions with serotonergic and noradrenergic neurotransnussion (Brocardo et al., 
2008). Mechanistically, folic acid may be directly involved in the regulation of the 
serotonergic function in depression (Bottiglieri, 2005) and is similar to fluoxetine in 
increasing levels of 5HT in the synaptic cleft (Brocardo et al., 2008). Alterations in 
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the serotonergic ftinction by folate deficiency have been reported to be associated 
with impaired 5HT metabolism (Botez et al., 1982; Gospe et al., 1995; Alpert et al., 
2002; Bottiglieri, 2005). Thus, in those patients where folate and related methylation 
processes contribute to depressive ilhiess, supplementation with this vitamin has 
been found to be highly effective (Godfrey et al., 1990; Coppen and Bailey, 2000). 
Although such adjunctive therapy with folic acid has been shown to enhance the 
therapeutic effect of antidepressant medication (Coppen and Bailey, 2000; Abou-
Saleh and Coppen, 2006), however, it is more important to note that vitamin therapy 
alone has been demonstrated to be as effective as standard antidepressant treatment, 
irrespective of the folate status (Passeri et al., 1993). The present experimental 
results on folic acid are similar to clinical findings of Passeri et al. (1993) as the 
present study has also focused on the effects of folic acid administration alone. The 
present findings also provide evidence for the anti-stress effects of pyridoxine in 
combating psychological or emotional stress-induced behavioural changes exerted 
due to restraint and may contribute towards the understanding of the role of 
pyridoxine as an anti-stress therapeutic intervention. 
This investigation also revealed that ascorbic acid, a powerful antioxidant 
vitamin, has remarkable potential to overcome the behavioural deficits produced by 
chronic restraint stress, functioning as a novel antidepressant. It is acknowledged 
that ascorbic acid levels in the brain are much more elevated than in plasma 
(Schriber and Trojan, 1991; Rose and Bote, 1993). This vitan^n is supposed to be a 
vital cofactor of dopamine p-hydroxylase, and is involved in catecholamme 
biosynthesis (Path, 1990). However, it is the serotonergic system that plays a 
significant role in the pathophysiology of depression and is implicated as a target of 
antidepressant action in animal models of depression and behavioural despair 
(Kreiss and Lucki, 1995; Elhwuegi, 2004), it will be interesting to evaluate a 
possible role of vitamin C in the synthesis of serotonin (apart from 
tetrahydrobiopterin), as it takes part in hydroxylation reactions. The observation that 
treatment with ascorbic acid increased swimming behaviour in rats may be 
mdicative of an involvement of the serotonin system (Detke et al., 1995; Page et al., 
1999). It may be possible that vitamin C indirectly influences monoamine function 
via its strong anti-lipoperoxidation action; since it is well-established that this 
vitamin protects membranes against oxidation (Retsky et al., 1999), which can 
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modify neurotransmitter release and uptake because peroxidative damage to 
phospholipids alters the membrane viscosity, thereby possibly impacting receptor 
density or function of serotonergic/catecholaminergic receptors (Van-der-Vliet and 
Bast, 1992; Mattson, 1998). Moreover, it has been reported that MDA directly exerts 
inhibitory effects on serotonin-binding areas of the receptor (Britt et al., 1992). 
Vitamin C not only exerts protection from membrane damage, but also recycles 
vitamin E, the predominant membrane antioxidant, as well as many other oxidised 
biomolecules, and scavenges free radicals (Chan, 1993), apart from maintaining the 
redox status of cells (Englard and Seifter, 1986). Given that depression is associated 
with poor antioxidant status and elevated lipid peroxidation, and that behaviour as 
well as cognition are also influenced by these factors, it may be suggested that 
prevention of oxidative stress and concomitant lipid peroxidation by ascorbic acid 
treatments may indirectly contribute to its observed antidepressant-like activity in 
this study. It has been established that membrane lipid peroxidation promotes a 
cascade of events that culminates in apoptotic cell death (Mattson, 1998). Its ability 
to regulate factors influencing gene expression, apoptosis and other cellular 
functions (You et al., 2000) has been established and several studies demonstrated 
that the anti-apoptotic effect of vitamin C against cell death triggered by various 
stimuli is crucially associated with its antioxidant ability. Thus, it may be 
hypothesized that a certain degree of antioxidant action is involved in modifying the 
behavioural anomalies observed after prolonged exposure to restraint stress. 
Thus, the present investigation provides evidence for the antioxidant efficacy 
of folic acid and pyridoxine, in striking similarity to ascorbic acid, and indicates that 
oral administration of these water-soluble vitamins is able to counter behavioural 
deficits produced by chronic psychological stress during restraint. The present 
evidence seems to indicate a strong possibility for the association of antioxidant and 
antidepressant activities of these vitamins and endorses the view that modulation of 
endogenous antioxidant systems to balance oxidant status may have potential 
therapeutic benefit in attenuating stress and related psychiatric conditions. Given the 
high emotional, social and financial costs of depression and the low cost of vitamin 
supplements, the use of these dietary constituents in therapeutic intervention of 
stress and depression seem to be a sensible course of action because nutrition is 
modifiable. 
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CONCLUSION 
Chronic subjection of rats to uncontrollable physical, emotional and 
psychological stress exerted by restraint was found to decrease the protective 
antioxidant defenses, leading to oxidative stress and damage. The activities of 
primary and secondary antioxidant enzymes, superoxide dismutase (SOD), catalase 
(CAT), glutathione S-transferase (GST) and glutathione reductase (GR) were 
significantly reduced in the brain, liver, heart and serum of restraint stressed animals 
in comparison to unstressed control animals. Non-enzymatic antioxidant defenses 
such as glutathione (GSH) in tissues, and uric acid as well as glucose in circulation, 
were also markedly decreased. In consequence, oxidative stress markers were found 
elevated, as evidenced by a significant rise in malondialdehyde (MDA), the product 
of lipid peroxidation, and increase in protein carbonyl contents. Loss of structural 
integrity at the cellular level due to stress-induced oxidative damage was 
demonstrated by significant increases in the tissue and serum levels of intracellular 
marker enzymes of the liver and heart, such as glutamate oxaloacetate transaminase 
(GOT), glutamate pyruvate transaminase (GPT), alkaline phosphatase (ALP) and 
lactate dehydrogenase (LDH). 
The impact of repetitive prolonged stress on the development of behavioural 
abnormalities characterizing depression-like symptoms was also demonstrated. 
Restraint stressed animals subjected to the forced swimming test manifested 
behavioural passivity and despair as evidenced by reduced time spent swimming and 
consequent increase in the time spent immobile, as compared to imstressed controls 
which displayed more active escape-oriented swimming behaviour. Restraint stress 
also produced a hedonic deficit in rodents as evidenced by a diminished preference 
for sucrose solution m contrast to controls which responded adequately when 
presented with this rewarding stimulus. Behavioural anomalies were associated with 
loss in total body weight in stressed animals over the experimental period of 21 
days. The induction of experimental depression and reduction in weight was found 
associated with reduced antioxidant defenses leading to a prominent increase in 
oxidative stress and damage. 
Prolonged exposure to glucocorticoid stress hormones, the central effectors 
of the stress response, also induces depression and contributes towards chronic 
disease processes. Chronic exogenous administration of corticosterone was found to 
cause oxidative damage by significantly decreasing endogenous antioxidant 
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defenses, both enzymatic and non-enzymatic, in the brain and other organs like liver 
and heart, similar to a pro-oxidant status produced by chronic restraint stress. Thus, 
a corticosterone-induced deficit in overall antioxidant status strongly implicates 
oxidative damage as a putative mechanism for stress-induced psychopathological 
disorders like depression as well as general somatic diseases. Given this, the 
following studies investigated the modulation of oxidative biology in restraint stress 
as a possible target of different therapeutic agents including herbal drugs, broad 
spectrum standard antidepressants and dietary micronutrients. 
Withania somnifera and Raicwolfia serpentina herbs were found to be almost 
equally effective against restraint stress-induced oxidative damage and loss in body 
weight. Therefore, in general, protection from oxidative stress during chronic stress 
may possibly avert the precipitation of stress-induced degenerative diseases 
affecting various organs and their physiological fimctions. 
The selective serotonin reuptake inhibitor, fluoxetine, also inhibited the 
effects of stress by enhancing the activities of SOD, CAT, GST and GR, thereby 
replenishing GSH levels as well. Uric acid and glucose concentrations were also 
increased, while the downstream effects of oxidative stress, lipid peroxidation and 
protein oxidation, were markedly reduced. Fluoxetine treatment could exert 
sufficient antioxidant activity in vivo to reverse stress-induced oxidative damage 
with an efficacy at par with Curcuma longa. This finding further demonstrates the 
importance of antioxidant status in stress disorders and provided a strong basis to 
evaluate other classes of antidepressant drugs in terms of their antioxidant/pro-
oxidant ability. 
Apart from normalizing restraint stress-evoked behavioural aberrations, the 
tricyclic antidepressant, imipramine, and the newer dual reuptake inhibitor, 
venlafaxine, inhibited stress-induced alterations in the antioxidant defenses and 
oxidative stress markers. Since treatment with these drugs was found to ameliorate 
stress-induced oxidative damage in association with abolishing depressive 
symptoms, the present data thus demonstrate that improvement in cellular 
antioxidant status may be an important mechanism underlying the protective 
pharmacological effects for multiple classes of antidepressants observed clinically in 
the treatment of various stress disorders. 
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Treatment with pyridoxine and folic acid exerted significant antioxidant 
action which had a beneficial impact during stress by preventing oxidative damage, 
with an efficacy similar to ascorbic acid. The finding that treatment with pyridoxine, 
folic acid and ascorbic acid, attenuated both stress-induced behavioral suppression 
as well as oxidative stress in a consistent manner suggested that alteration of pro-
oxidant:antioxidant balance might be associated to the stress-induced 
neurobehavioral changes. 
Besides preventing stress-induced oxidative damage to the brain, all the 
drugs investigated also had a significant hepatoprotective and cardioprotective 
action, evidenced by normalization of tissue and serum levels of marker enzymes. 
They also inhibited loss of body weight in restraint stressed animals. 
To conclude, the close integration of antioxidant and antidepressant 
activities of these vitamins and the antidepressant agents investigated endorses the 
view that modulation of endogenous antioxidant systems to balance oxidant status 
has potential therapeutic benefit as a possible stress-management approach in all 
kinds of stress-induced psychiatric and non-psychiatric conditions. 
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Abstract 
Stress plays a potential role in the onset and exacerbation of depression. Chronic restraint stress in rats, and psychosocial stress in humans, is 
implicated in the pathophysiology of mood and anxiety disorders. Oxidative damage is an established outcome of restraint stress, which has been 
suggested to induce many damaging processes contributing to the pathology of stress-induced depression. However, the modulatory role of 
clinically effective antidepressants, such as fluoxetine, in attenuating oxidative stress has not been well characterized. Therefore, the current study 
was designed to investigate the antioxidant effects of chronic treatment with fluoxetine in animals submitted to restraint stress. The antioxidant 
potential of the antidepressant fluoxetine was compared with that of turmeric, used as a standard since it integrates both antioxidant and 
antidepressant properties. Chronic fluoxetine administration to stressed animals for 21 days prevented restraint stress-induced oxidative damage 
with an efficacy similar to that of turmeric, as evidenced by significant enhancement of key endogenous antioxidant defense components, 
comprising the free-radical scavenging enzymes, superoxide:supeFoxide oxidoreductase (EC 1.15.1.1), hydrogen-peroxide:hydrogcn-peroxide 
oxidoreductase (EC 1.11.1.6), glutathione S-transferase (EC 2.5.1.18) and glutathione:NADP*oxidoreductase (EC 1.8.1.7), as well as non-
enzymatic antioxidants, GSH, glucose and uric acid, which were severely depleted by restraint stress in animals receiving no treatment. Oxidative 
stress markers, (5)-lactate:NAD'^  oxidoreductase activity (EC 1.1.1.27), malondialdehyde levels (lipid peroxidation product) and protein caibonyl 
content were also significantly decreased following fluoxetine treatment Bodi these drugs when given alone to non-stressed animals did not alter 
basal levels of antioxidant defense components and oxidative stress markets significantly. Our findings suggest that the therapeutic efficacy of 
fluoxetine may be mediated, at least partially, via reversal of oxidative damage as demonstrated by protective enhancement of antioxidant status 
following a stress-induced decline. In addition, this study demonstrates important implications for phaimacological interventions targeting cellular 
antioxidants as a promising strategy for protecting against oxidative insults in stress-induced depression. 
© 2007 Elsevier B.V. All rights reserved. 
Keywords: Fluoxetine; Antidepressant: Antioxidant: Restraint stress; Oxidative damage 
1. Introduction 
Stress exerts detrimental effects on several cell functions, 
through impairment of antioxidant defenses, leading to oxidative 
damage, which is central to many diseases (Torres et al., 2004). 
Free-radical damage by reactive oxygen species has been sug-
gested to play a critical role in the pathophysiology of neuro-
degenerative diseases, ncuropsychiatric disorders and stress-
induced depression (Jenner. 1991: Sapolsky, 2000; Bilici et al., 
2001). Although clinical depression, depressive symptoms and 
• Corresponding author. Tel.; +91 571 2705438. 
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psychological stress should be distinguished, they are closely 
related with one another (Tsuboi et al., 2006) and play an 
important role in the development of affective disorders (Post, 
1992). Repeated chronic stress has been associated with the 
development and manifestation of depression (Checkley, 1996). 
Restraint as a stress model combines both emotional and physi-
cal components of stress in addition to producing robust in-
creases in basal oxidative stress (Zaidi and Banu, 2004; Zaidi 
et al., 2005; Walesiuk et al., 2006). Restraint has been used 
extensively to study the impact of stress on disease process and 
the effects of drugs in stress-related pathology in animals 
(Glavin et al., 1994). 
Antidepressant drugs are widely used for the management/ 
treatment of stress and stress-related depression and anxiety 
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(Diamond and Rose, 1994). Fluoxetine, a selective serotonin 
reuptake inhibitor (SSRI), effectively treats a wide spectrum of 
mood disorders (Wong et al., 1995) and also protects against the 
adverse effects of different types of stressors (Freire-Garabal 
et al., 1997; Ayelli Edgar et al., 2002). Fluoxetine has emerged 
as the treatment of choice for depression due to a better safety 
profile, fewer side effects and improved tolerability compared to 
the older tricyclic antidepressants (Wilde and Benfield, 1998; 
Anderson, 1999). However, the underlying mechanisms of its 
therapeutic efficacy remain unclear, particularly with reference 
to preventing oxidative routes of damage in stress disorders. 
Although restraint stress is widely employed to induce oxidative 
and neurotoxic damage, however, to the best of our knowledge, 
no study has as yet investigated the in vivo antioxidant modu-
lating effects of antidepressants on restraint stress-induced 
oxidative damage. 
Thus, the main objective of the present work is to probe 
the antioxidant potential of fluoxetine and its comparison 
with turmeric {Curcuma longa L.) in rats submitted to re-
straint stress. For the purpose of comparison, turmeric has 
been selected as the reference standard, as it effectively incor-
porates both antioxidant and antidepressant properties (Yu 
et al., 2002). 
2. Materials and methods 
2.1. Chemicals and test drugs 
Fluoxetine hydrochloride was purchased from Cadilla, India. 
All other chemicals used were of analytical grade and purchased 
from commercial sources. Glucose estimation kit was pur-
chased from Techno Pharmchem, Bahadurgarh, India and uric 
acid diagnostic reagent kit from Span Diagnostics Ltd., SiuBt, 
India. TUnneric (C. hnga L.) rhizomes were purchased from the 
local market, washed extensively with sterilized water, air-dried 
and pulverized to obtain turmeric powder. It was stored at room 
temperature throughout the experiments. 
2.2. Experimental animals 
Swiss Albino rats weighing 100-150 g were housed under 
standard laboratory conditions of temperature (25±5 °C) and 
natural 12-h light/dark cycle with free access to standard pellet 
chow (Ashirwad Industries, Chandigarh, India) and drinking 
water ad libitum. The experimental protocol strictly adhered to 
the prescribed animal ethical procedures according to the 
guidelines of the Institutional Research Committee. 
2.3. Experimental protocol 
Fluoxetine hydrochloride (20 mg/kg) dissolved in physio-
logical saline and aqueous turmeric extract (50 mg/kg) was 
administered via oral route to animals according to the 
treatment schedule presented below. Pilot studies revealed 
that 50 mg/kg of turmeric extract was effective in restoring 
antioxidant status and normalizing other markers of oxidative 
stress, and this dose was selected for the present investigation 
(data not given). After 1 week of acclimatization, animals were 
randomized into six groups of six animals each. Group I 
animals served as non-stressed controls. Animals in groups II, 
III, IV, V and VI received drug and/or stress for 21 consecutive 
days as follows: 
Group II; Oral administration of aqueous turmeric extract 
(50 mg/kg) (indicated as T in figures and table) 
Group ni: Oral administration of fluoxetine (20 mg/kg) (FL) 
Group IV: Stress (4 h restraint stress daily) (S) 
Group V: Stress, followed by oral administration of aqueous 
turmeric extract (50 mg/kg) (S+T) 
Group VI: Stress, followed by oral administration of fluoxe-
tine (20 mg/kg) (S+FL) 
2.4. Restraint stress 
All animals were exposed to stress for 4 h during the light 
phase of the cycle. Restraint stress was accomplished by 
immobilizing animals in snug body-size cages of wire mesh. 
This restrained all physical movement without subjection to 
pain. The animals were deprived of food and water during the 
entire period of exposure to stress. Subsequently the animals 
were released from their enclosure and provided access to 
water. 30 min post-release the animals received either food 
or the treatment under study, according to the experimental 
protocol. The stress regimen was followed daily during the 
experimental period of 21 days, at the end of which animals 
were sacrificed under light ether anesthesia for biochemical 
studies. 
2.5. Collection of serum and preparation of tissue 
homogenates 
Blood samples were collected under anesthesia for separa-
tion of serum. Brain and liver tissues were quickly removed and 
washed with ice-cold sterile physiological saline (0.9%). A 
10% homogenate was prepared in 0.1 M sodium phosphate 
buffer, pH 7.4, centrifuged at 10,000 g (4 °C) for 15 rain to 
remove cellular debris and the supernatant was used for fiirther 
studies. 
2.6. Antioxidant investigations 
Brain and liver homogenates were used for the estimation of 
the following antioxidant enzymes: superoxide:superoxide oxi-
doreductase [superoxide dismutase: SOD; EC 1.15.1.1] (Mark-
lund and Marklund, 1974), hydrogen-peroxide:hydrogen-
peroxide oxidoreductase [catalase: CAT; EC 1.11.1.6] (Aebi, 
1984), glutathione ^'-transferase [GST; EC 2.5.1.18] (Habig 
et al., 1974) and glutathione:NADP"^ oxidoreductase [glutathi-
one reductase: GR; EC 1.8.1.7] (Carlberg and Mannervik, 
1975). Lipid peroxidation [aldehydic product, raalondialde-
hyde: MDA] (Beuge and Aust, 1978), glutathione content: GSH 
(Jollow et al., 1974) and protein carbonyl content (Levine et al., 
1990) were determined by standard protocols. Serum was as-
sayed for antioxidant enzyme activities and lipid peroxidation; 
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fluoxetine (FL) p o for 21 consecutive days, either alone or following 4 h of daily 
restraint stress (S+T, S+FL) Values shown for each group are the mean±S E M 
obtained from six observations *, '*, *" , * • " P<0 05, P<0 02 P<0 01 
P<000\ con j^arcd with stress alone by ANOVA # P<0 01 in brain and 
P<0 05 in liver, compared with the control group by ANOVA 
Fig 3 Effect of chrome fluoxetine administration on glutathione 5-transferase 
activity in brain and liver Animals m treatment groups received turmeric 
extract (T) or fluoxetine (FL) p o for 21 consecutive days, either alone or 
following 4 h of daily restraint stress (S+T, S+FL) Values shown for each 
group are the mean±S E M obtained from six observations *, '*, ***, * * " 
P<0 0^ P<0 02, P<0 01, P<0 001 compared with stress alone by ANOVA # 
P<001 mbrainandP<005 in liver compared with the control group by ANOVA 
non-enzymatic circulatory antioxidants glucose and unc acid 
were also detemuned using commercial kits (S)-lactate NAD^ 
oxidoreductase activity [lactate dehydrogenase LDH, EC 
1 1 1 27] was evaluated as an oxidative stress marker and 
index of membrane mtegnty (Wroblewski and La Due, 1955) 
Protcm concentration was estimated usmg BSA as standard 
(Lowryetal, 1951) 
trols Stress+T/FL (groups Vand VI) were also compared with 
stress alone treatment (group IV) 
3. Results 
3 1 Effect of fluoxetine on restraint stress-induced decline in 
antioxidant enzyme activities 
2 7 Statistical evaluation 
Data was expressed as mean±SEM of sue values and 
analyzed by one-way ANOVA Differences among controls and 
treatment groups were determmed using Student's / test P 
values less than 0 05 were considered statistically significant 
All comparisons were made with non-stressed, untreated con-
Figs 1-4 depict levels of superoxide dismutase, catalase, 
glutaduone 5-transferase and glutathione reductase, respective-
ly, m bram and Uver tissues of experimental animals, while 
Table 1 summarizes the circulatmg levels of these enzymes, 
which reflect m vivo cellular antioxidant status 
From the results depicted, stress was found to ehcit a signif-
icant decrease in the levels of all antioxidant enzymes in 
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Fig 2 Effect of chrome fluoxctmc admimstration on catalase activity in biain 
and liver Animals m treatment groups received hirmenc extract (T) or fluoxetine 
(FL) p o for 21 consecutive days, either alone or following 4 h of daily restraint 
stress (S+T, S+FL) Values shown for each group are the mean±SEM 
obtained from six obscrvaUons ' , *', •**, •*•* P<0 05, P<0 02 P<0 01, 
P<0 001 compared widi stress alone by ANOVA, # P<0 01 in braui and 
bver, compared with the control group by ANOVA 
Fig 4 EfTcctofchronicfhioxetine administration on glutathione reductase activity 
in bram and kver Animals ui treatment groups received tunnenc extract (T) or 
fluoxetine (FL) p o for 21 consecutrve days, either alone or following 4 h of daily 
restramt stress (S+T, S+FL) Values shown for each group are the mean±S E M. 
obtamcd from six observations •, " , * " , • •*• P<005, / '<002, P<001, 
P<0OO\ compared with stress alone by ANOVA, #• P<0 02 in brain and hver, 
compared with the control group by ANOVA 
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Table I 
Modulatory effects of chronic fluoxetme treatment on restraint 'itress-induced alterations in circulating levels of antioxidant defenses and oxidative stress maiicers 
Parameter Groups 
Control Turmeric (T) Fluoxetme (FL) Stress (S) S+T S+FL 
Superoxide dismutase (U/mg protein) 22 80±0 23 23 34±4 29 19 74±4 03 13 83"=±187 23 89»''±I53 20 79'a±0 85 
Calalase (U/mg protcm) 1 52±014 174±057 1 12±033 059"*±026 203*a±040 1 27*a±015 
Glutathione 5-transferasc (U/mg protein) 0 30±0 06 0 41J-0 10 0 26*0 06 0 12™±0 02 0 39*<'-t0 02 0 24*ai-0 03 
MDA (nmoUmg protein) 0090*001*; 0052±0008 0070±0006 0 17**1:0016 0084*c±00n 00%»ai0017 
Glucose (mg/dl) 110 83*4 99 109 89±10 36 115 00±12 93 78 83*^*4 23 118 50*^*7 72 108 5*<:±6 77 
Unc acid (mg/dl) 3 76*0 39 4 73*0 55 3 17*0 53 131*^*0 17 4 13*c*0 48 3 46*d±0 20 
Animals m treatment groups received turmenc extract (T) or fluoxetme (FL) p o for 21 consecuti\e days, either alone or following 4 h of daily restramt stress (S-t-T, 
S+FL) Results arc expressed as meantS E M obtamed from six observations 
a, b, c, d. P<0 05, P<0 02, P<0 01, P<0 001 # compared with the control group, * compared with stress alone by ANOVA 
companson to controls (superoxide dismutase f <0 01 m brain, 
<0 05 in liver, <0 01 in serum, cdtaldse P<OQ[ m brain, <0 01 
in liver, <0 05 in serum, glutathione ^-transferase P<0 01 in 
brain, <0 05 in liver, <0 05 m serum, glutathione reductase 
P<0 02 m brain, <0 02 in liver) However, compared to stressed 
amniais, a significant repletion m enzymatic antioxidant status 
was observed by chronic fluoxetme administration following the 
stress paradigm (superoxide dismutase / '<0 01 in bram, <0 01 
in liver, < 0 05 m serum, catalase / '<0 02inbtain,<001inliver, 
<0 05 m serum, glutathione S-transferase P<0 01 in brain, 
<0 01 in liver, <0 05 in serum, glutathione reductase P<0 02 m 
brain, <0 05 m liver) The used reference antioxidant turmenc 
also produced comparable augmentation m enzyme activities 
(superoxide dismutase P<0 001 m brain, <0 01 in liver. <0 02 
in serum, catalase P<OQl in biam, <0 02 m liver, <0 05 in 
serum, glutathione 5-transferase. / '<0 02 m bram, <0 05 m liver, 
<0 001 m serum; ghitathione reductase P<0 001 in brain, <0 01 
m hver) In non-stressed animals, neither fluoxetme nor turmenc 
caused any sigmficant alteration of basal antioxidant enzyme 
activities 
3 2 Effect of fluoxetine on restraint stress-induced decline m 
non-enzymatic antioxidant levels 
Fig 5 shows the modulation of GSH by stress and drug 
mtervention In stressed animals, there was a significant reduc-
tion m the GSH content from controls (P<0 001 in bram, <0 01 
m liver) Following exposure to stress, treatment with fluoxetine 
significantly restored the basal levels of GSH (P<0 02 m brain, 
<0 01 in liver) Turmenc induced a similar increase in com-
panson to stressed animals {P<0 001 m bram, <0 01 in liver) 
Circulating levels of glucose (Table 1) were significantly 
decreased foUowmg restramt stress (P<0 01) Both fluoxetme 
and turmenc caused significant reversal of the stress-mduced 
decline m serum glucose concentration (P<0 01) toward control 
values 
Restramt stress also caused a sigmficant declme m serum unc 
acid (Table 1 P<0 01) In companson to animals exposed to 
stress alone, treatment with fluoxetme was efifecuve in sigmfi-
cantly preventing stress-mduced decrease of unc acid (/*< 0 001) 
Turmenc extract had the same protective effect (P<0 01) 
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9 Control . 
ITlirmwicfr) * 
I Fluoxetine (FL) 
I Stress (S) 
3 S+T 
i s+a 
Brain Uvef Brain Liver 
Fig 5 Effect of chrome fluoxetine administration on GSH levels m bram and 
liver Animals in trcalment groups received turmenc extract (T) or fluoxetine 
(FL) p o for 21 consecutive days, either alone or following 4 h of daily restraint 
stress (S+T, S+FL) Values shown for each group are the meaniSEM 
obtamed from six observations *, **, *•», •*•* P<0 05, P<0 02, P<0 01, 
P<0 001 compared with stress alone by ANOVA, # P<0 001 in bram and 
P<0 01 in Uvet, compared with the control group by ANOVA 
Fig 6 Inhibition of lipid peroxidation in bram and liver by chrome fluoxetme 
admmistration Ammals in treatment groups received turmenc extract (T) or 
fluoxetine (FL) p o for 21 consecutive days, either alone or following 4 h of daily 
restraint stress (S+T S+FL) Values shown for each group are the mean * S E M 
obtamed from six observations •_ *»^  ••*^ *»•• /'<0 05,/'<0 02 P<0 01, 
P<0 001 compared with stress alone by ANOVA, # P<0 05 in brain and 
P<0 01 m hvei, compared with the control group by ANOVA 
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Both fluoxetine and turmenc alone treatments to non-
stressed animals did not alter significantly any of the assessed 
ncn-enzymatic antioxidants. 
3 3 Effect of fluoxetine on other oxidative stress markers 
3 3.1 Lipid peroxidation 
The previously described depletion of antioxidant defenses in 
brain, liver and circulation induced by restraint stress was paral-
leled by an increase in lipid peroxidation, as demonstrated (Fig. 6) 
by the accumulation of the aldehydic product of lipid peroxida-
tion, malondialdehyde (MDA) in stressed animals (/'<0.05 in 
brain, <0.01 in liver, <0.05 in serum) Pharmacological inter-
vention by daily dosing of fluoxetine significandy prevented the 
accumulation of MDA after stress (P<0.02 in brain, <0.01 in 
liver, <0.05 in serum) Treatment with the positive control, tur-
meric extract, also caused a similar decrease in companson to 
stress {P<0 01 in brain, <0.001 in liver, <0 01 m serum) In 
companson to controls, fluoxetine alone and turmeric alone treat-
ments did not cause any significant change in lipid peroxidation 
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Fig 8 Inhibition ofrcstiaintsticss-induced protein carbonyl production in brain 
and liver by chronic fluoxetine administration Animals in treatment groups 
received turmenc extract (T) or fluoxetine (FL) p o for 21 consecutive days, 
either alone or following 4 h of daily restramt stress (S+T, S+FL) Values 
shown for each group are the mean±S E M obtamcd from six observation !^ 
. .,_ .«._ * .* . p<0 05. P<0 02, P<OOI, / '<0 001 compared with stress 
alone by A N O V A , # P<0 01 in brain and P<0 05 m liver, compared with the 
control group by ANOVA 
3 3 2. Lactate dehydrogenase activity 
Due to Its intracellular location, lactate dehydrogenase ac-
tivity was evahiated as an index of membrane damage exerted 
by free radical production in response to stress. As depicted in 
Fig. 7, restraint stress resulted in a significant elevation in 
lactate dehydrogenase (P<0.02) A significant reversion of 
lactate dehydrogenase levels to control values was caused by 
fluoxetme {P<Q.01) as well as tunnenc extract (P<0 02) 
following stress, in companson to the effect of stress alone, 
while both these drugs when given alone did not alter the 
enzyme activity from controls. 
Restramt stress elicited a significant increase of carbonyl groups 
compared to controls (Fig. 8; P<O.Q\ in brain, <0.05 in liver) 
A sigmficant effect on the inhibition of protein oxidation due to 
stress was exerted by fluoxetine (P<0 01 in brain, <0.05 in 
liver). Turmenc extract yielded similar results {/*< 0.001 m 
brain, <0.05 m liver). Administration of both drugs alone did 
not change carbonyl content from controls 
3 4 Effect of fluoxetine on restraint stress-induced decline in 
body weight 
3.3.3. Protein carbonyl production 
Oxidative stress is known to mtroduce carbonyl groups into 
the ammo acid side chains of proteins (Levme et al, 1990) 
Fig. 9 depicts influence of drug treatment on body weights of 
animals measured eveiy 7 days beginning from the day of 
expenmental manipulations Restramt stress induced a decrease 
¥ 0 . 5 
Fig 7 Effect of chrome fluoxetine admimstration on lactate dehydrogenase 
activity Ammals m treatment groups received turmenc extract (T) or fluoxetine 
(FL) p o for 21 consecutive days, either alone or following 4 h of daily restramt 
stress (S+T, S+FL) Vahies shown for each group are the mean±SEM 
obtained from six observations ', **, '* ' , **** P<OOS, P<0 02. P<001, 
P<0 001 compared wiA stress alone by ANOVA, # P<0 02, compared with 
the control group by ANOVA 
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Fig 9 Influence of chronic fluoxetine administration on weight gam of 
rats Animals in treatment groups received turmenc extract (T) or fluoxetine 
(FL)po for21 consecutive days, either alone or following 4 h of daily restraint 
stress (S+T, S+FL) Body weight was measured every 7 days Values shown for 
each group are the mcan<0 05) in body weight compared with the control group 
by ANOVA 
28 A. Zafir. ,V. Banu I Eumpeun Journal of Pharmacology 572 (2007) 23-31 
in body weight evident from the first week onward and re-
mained significantly decreased throughout exposure to the 
stress paradigm (day 7: P<0.02; day 14: <0.001; day 21: 
<0.001). Following exposure to stress, treatment with both 
fluoxetine and turmeric was effective in preventing restraint 
stress-induced losses in body weight, which was particularly 
significant (/'<0.05) on day 14 for fluoxetine. Similar to con-
trols, both drug alone treatments maikedly increased weight 
gain over the treatment period of 21 days, with significant 
increases observed by turmeric alone on day 7 (P<0.01) and 14 
(/'<0.02). 
4. Discussion 
To the best of our knowledge, the data presented in this study 
demonstrates for the first time the in vivo antioxidant action of 
fluoxetine in restraint stress-treated rats. Similar evidence 
corroborating this finding comes from a clinical study (Bilici 
et al., 2001) which showed that antioxidant enzymes may be 
state markers of depression and useful in monitoring SSRI 
effects, as well as from certain in vitro studies (KoUa et al„ 
2005). 
Reactive oxygen species generated by a severe stressor 
(restraint stress) significantly compromises the in vivo antiox-
idant defenses of animals submitted to restraint Chronic fluo-
xetine administration to stressed animals for 21 days, which is 
the time course of therapeutic action of the antidepressant, 
produced a protective enhancement of the antioxidant status. 
This modulation of antioxidant parameter to basal levels (as in 
controls) was strikingly at par with the powerful antioxidant 
efficacy of turmeric, a natural antioxidant and indigenous food 
component implicated for the significantly lower prevalence of 
certain neurodegenerative diseases in India (Ganguli et a]., 
2000). Thus our results are also significant fix>m the point of 
view of neuroprotection. 
Expostire to chronic restraint stress in rats, and psychosocial 
stress in humans, is implicated in the pathophysiology of mood 
and anxiety disorders (Walesiuk et al., 2006). Previous work in 
our laboratory has established that restraint stress causes robust 
increases in the production of reactive oxygen species, and 
consequent oxidative damage, with a concomitant decline in in 
vivo antioxidant defenses (Zaidi and Banu, 2004; Zaidi et al., 
2005). Oxidative stress induces many damaging processes in 
stress disorders such as mitochondrial dysfunction, dysregula-
tion of calcium homeostasis (Amoroso et al., 2000), disruption 
of energy pathways (Papadopoulos et al., 1997), damage to 
neuronal precursors, impairment of neurogenesis (Kroemer, 
1997), induction of signalling events in apoptotic cell death 
(Cregan et al., 2002), ultimately leading to atrophy and mor-
phological changes in the brain characteristic in stress-induced 
depression (Bremner, 1999; Sapolsky, 2000). Moreover, immo-
bilization stress in mice has been shown to cause neuronal death 
in the cerebral cortex by apoptosis, which was effectively pre-
vented by antioxidant pretreatment with an associated decrease 
in reactive oxygen species production (Lee et al., 2006). Recent 
in vitro studies on the underlying mechanisms of stress-induced 
neuronal damage have demonstrated that corticosterone re-
leased from the adrenal cortex during stress either induces the 
formation of reactive oxygen species (Lin et al., 2004) or 
decreases antioxidant enzyme activity, resulting in increased 
neurotoxicity in cortical cultures (Brooke ct al., 2002). Other in 
vitro studies have also shown that upregulation of superoxide 
dismutase and similar antioxidant enzymes may protect astro-
cytes from apoptosis or necrosis upon exposure to a range of 
neurotoxicants (KoUa et al., 2005). Superoxide dismutase is 
extensively distributed in the central nervous system, including 
regions puiported to be atrophied in depression, such as the 
hippocampus (Jeste et al., 1988). Thus, if episodes of clinical 
depression are accompanied by progressive hippocampal 
atrophy throughout the duration of the disease, antidepressant 
therapy or other forms of treatment that upregulate superoxide 
dismutase 1 gene expression may prevent worsening of affective 
symptoms that are either directly or indirectly related to hippo-
campal degeneration (Li et al., 2000). In this context, the use of 
pharmacological agents targetting cellular antioxidants is a 
promising strategy for protecting against oxidative insults in 
depression. Accordingly, our study was imdertaken to clarify 
and characterize the modulation of restraint stress-induced 
oxidative damage by fluoxetine. The brain is a target of stress 
along with the metabolic systems of the body, of which the liver 
is the central organ (McEwen, 2000). Hence, our antioxidant 
investigations were made on these two tissues. 
A simultaneous decline in the activities of free-radical 
scavenging enzymes, superoxide dismutase and catalase, as 
evidenced by the data obtained in this smdy following chronic 
restraint stress, may be due to inactivation caused by excess 
reactive oxygen species production. This damages the first line 
of enzymatic defense against superoxide anion and hydrogen-
peroxide. Consistent with our experimental findings, clinical 
smdies on patients with affective disorders have also revealed 
lower levels of superoxide dismutase (Bilici et al., 2001) and 
catalase (Ozcan et al., 2004). Moreover, we also observed a 
significant depletion of GSH, glutathione 5-transferase and 
glutathione reductase in brain and liver of restraint-stressed rats, 
indicating damage to the second line of antioxidant defense. This 
probably fiirther exacerbates oxidative damage by adversely 
affecting critical GSH-related processes such as fi-ee-radical 
scavenging, detoxification of electrophilic compounds, modu-
lation of cellular redox status and thiol-disulphide status of 
proteins, and regulation of cell signalling and repair pathways. A 
similar depletion of brain glutathione has been reported earlier in 
mice under stress-induced depression (Pal and Dandiya, 1994). 
Therefore, a coordinate decline in GSH and related enzymes by 
restraint stress suggests a severely compromised in vivo anti-
oxidant stsias. This oxidative route of damage may act as a 
potential trigger to a plethora of damaging events observed in 
stress and depression. In our findings, we show that fluoxetine 
could effectively limit/reverse the above-indicated stress-
induced antioxidant deficits in brain and liver tissues as well 
as in circulation in all considered parameters. The simultaneous 
elevation of key endogenous antioxidants, superoxide dismu-
tase, catalase, glutathione 5-transferase, glutathione reductase 
and GSH levels by fluoxetine treatment may thus largely con-
tribute to the increased resistance of chronically stressed rats to 
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in vivo oxidative damage, in comparison to stressed animals 
receiving no treatment. By restoring the activity of glutathione 
reductase, fluoxetine may act to increase cellular levels of GSH, 
the predominant thiol antioxidant in the brain, which is con-
trolled in part by glutathione reductase. Glucose and uric acid, 
among the major circulating antioxidant molecules, were also 
severely depleted by chronic stress. Glucose is a scavenger of 
hydroxy! radicals, having a rate constant comparable with 
mannitol, while the antioxidant role of uric acid is important in 
directly scavenging oxidizing species and thus also inhibiting 
lipid peroxidation (Halliwell and Gutteridge, 1990). Therefore, 
fluoxetine-induced elevation in their levels demonstrates a direct 
ability to protect against highly damaging hydroxy! radicals that 
react with and damage most cellular targets including lipids, 
proteins and DNA (Warner et a!., 2004). This may be another 
method by which fluoxetine prevents stress-induced oxidative 
damage. Since increased oxidative stress or impaired antioxidant 
activity are implicated in major depression (Tsuboi et a!., 2006), 
the therapeutic efficacy demonstrated clinically by fluoxetine 
may be mediated, at least in part, via reversal of oxidative 
damage as evidenced by our data. 
Lipid peroxidation is considered a critical mechanism of 
injury occuning in cells during oxidative stress (Halliwell and 
Gutteridge, 1989). An initial formation of large amounts of 
reactive oxygen species during stress may also initiate Upid 
peroxidation as demonstrated to occur in brain (Liu et al., 1996) 
and liver (Hu et a!., 2000), in agreement to our present findings. 
Psychological stress, which accompanies severe depression, 
may enhance lipid peroxidation (Hibbeln and Salem, 1995) and 
recent clinical studies have directly demonstrated higher levels 
of MDA in patients with affective disorders (Gzcan et al., 2004). 
Our study showed that treatment with fluoxetine effectively 
prevented membrane lipid peroxidation. Since lipid peroxida-
tion disrapts membrane integrity, high levels of lactate dehydro-
genase activity in stressed animals may be interpreted as a 
progression of cell injury because of its intracellular localization 
(Campo et al., 200S). The decrease in lactate dehydrogenase 
after treatment with fluoxetine may be a consequence of de-
creased oxidative stress and the concomitant prevention of cell 
membrane damage. Protein oxidation, measured as an increase 
in carfoonyl groups has been shown to tie an early event in 
oxidative stress (Pacifici and Davies, 1990). Treatment with 
fluoxetine inhibited protein caibonyl production in stressed 
animals, indicating that fluoxetine not only prevents the down-
stream cascade of oxidative damage comprising lipid peroxida-
tion, but also targets early oxidative events as evidenced by a 
significant reduction in protein oxidation. 
The molecular mechanisms underlying the fluoxetine-me-
diated elevation of antioxidant defenses, and concomitant re-
duction of oxidative stress markers, remain to be investigated. It 
has been suggested that the in vitro neiux)protective actions of 
some antidepressants include the upregulation of superoxide 
dismutase activity, with superoxide dismutase! gene expression 
as a potential target of antidepressant regulation (Li et a!., 2000; 
KoUa et al., 2005). Several antidepressants with different mech-
anisms of action were demonstrated to increase superoxide 
dismutase! gene expression, for e.g., amitryptyline (a classic 
tricyclic antidepressant), bupropion (a second generation anti-
depressant), doxepin (a norepinephrine reuptake inhibitor), 
venlafaxine (a new 5HT/norepinephrine reuptake inhibitor) and 
L-deprenyl (a selective MAO-B inhibitor). Thus, although a 
common mechanism of action of antidepressants has eluded 
researchers for years, and since antidepressants act on many 
different neurotransmitter systems and receptors, it is proposed 
that one of the shared mechanisms of action of antidepressants 
is the upregulation of antioxidant enzymes such as superoxide 
dismutase! (Li et al., 1998; Li et al., 2000). Our smdy provides 
evidence for this effect in vivo for the first time in terms of 
enhanced activity, not only of superoxide dismutase, but also of 
other key antioxidant enzymes, by fluoxetine (a selective 
serotonin reuptake inhibitor) following stress exposure. Chronic 
antidepressant treatment has been demonstrated to upregulate 
cAMP-response element-mediated gene expression in rat cortex 
and hippocampus (Thome et a!., 2000), and to upregulate the 
expression of cAMP-response element-binding protein (CREB) 
in both rodents and humans. Upregulation of superoxide 
dismutase! may occur by an induction of cAMP and CREB 
(Nibuya et al., 1996; Dowlatshahi et al., 1998). Regarding other 
antioxidant enzymes, it may be suggested that the enhanced 
activity demonstrated by us, may be through a mechanism 
similar to that for superoxide dismutase described above. Thus, 
the increased activities of not only superoxide dismutase, but 
also catalase and glutathione reductase, which act in concert 
with superoxide dismutase, by fluoxetine treatment in our study, 
may be via a genomic action leading to enhanced gene expres-
sion of these critical antioxidant enzymes. Thus, our study not 
only confirms, but also extends previous findings, implicating 
the importance of antioxidant status in stress disorders and the 
consequent need to evaluate antidepressants in terms of their 
antioxidant/prooxidant ability. Although depression is currently 
considered a heterogeneous disease (KoUa et al., 2005), stress 
has been implicated in the origin and exacerbation of this 
disease. Thus, in patients whose depression is caused, or ac-
companied by stress, therapeutic strategies aimed at maintaining 
or increasing levels of neuroprotective enzymes such as 
superoxide dismutase may prove extremely beneficial (KoUa 
et al., 2005). In addition, it is possible that upregulation of this 
enzyme by antidepressants may prevent further free radical-
mediated neurotoxicity in depression caused by stress (Li et al., 
2000). Therefore, the data presented here indicating the ele-
vation of not only superoxide dismutase, but a wide range of 
key components of the antioxidant defense system by fluoxetine 
may hold great potential in preventing further clinical deterio-
ration in depression. 
Another major finding of our study is that in all antioxidant 
parameters evaluated, the protective efficacy of the antidepressant 
fluoxetine was strikingly comparable to that observed for the 
powerfiil natural antioxidant turmeric (Sreejayan Rao, 1994), 
used as a reference standard. Turmeric powder by itself, and its 
major bioactive component rarcumin, is known to protect against 
oxidative stress (Cohly et al., 1998) by typical radical-trapping 
ability as a chain-breaking antioxidant (Sreejayan Rao, 1994). 
Turmeric also contains other antioxidant principles besides 
curcumin, such as demethoxycurcumin, bisdemothoxycurcumin 
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and a number of polypeptides with antioxidant activity, such as 
turmenn (Ramirez-Tortosa et al, 1999) Dietary turmeric is 
known to lower lipid peroxidation by enhancing the activities of 
antioxidant enzymes (PuUa Rcddy and Lokesh, 1994) The 
similar antioxidant eflTicacies of turmenc and fluoxetine demon-
strated in our study may suggest a common mechanism of action 
With the view that antioxidant defenses are also compromised m 
stress-induced depression, it may be hypothesized that classical 
stress drugs such as fluoxetine which can reduce stress 
symptomatology, may probably also affect and act via modulation 
of endogenous antioxidant capacity Smce endogenous antiox-
idants play a cntical role m mamtaimng the integnty of the cell, 
their enhancement by fluoxetine with an efficacy similar to 
turmenc probably also accounts for the low side effects of 
fluoxetme observed chmcally (Anderson, 1999) 
In conclusion, the present study mdicates that the antioxidant 
potential of fluoxetine probably contnbutes to its therapeutic 
actions As treatment with fluoxetine ameliorates stress-induced 
oxidative damage, our study thus demonstrates that enhance-
ment of in VIVO antioxidant defenses and improvement in cel-
lular antioxidant status may be an important mechanism 
underlying the protective pharmacological effects of fluoxetine 
observed clmically m the treatment of vanous stress disorders 
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Modulation of in vivo oxidative status by exogenous 
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,„ Abstract -5 
Physical and psychological stressors not only enhance activity of the hypothalamo-pituitary-adrcnocortical axis, but also 
cause oxidative damage by inducing an imbalance between the in vivo pro-oxidant and antioxidant status. The involvement of 
adrenal steroid stress hormones in oxidative damage associated with these stressors has not been extensively investigated. 
Therefore, this study was designed to probe any direct role of glucocorticoids on induction of oxidative processes by 
comparing the effects of low, intermediate and h i ^ doses of exogenously administered corticosterone, without other applied 
2^  stressots, on a wide range of key components of the antioxidant defence system. The data presented here indicate a substantial -^^ 
decline in antioxidant defences by actions of corticosterone, evidenced by coordinate decreases in die activities in the brain, 
liver and heart of free-radical scavenging enzymes superoxide dismutase (SOD), Catalase (CAT), glutathione S-transferase 
(GST) and glutathione reductase (GR), as well as the non-enzymatic antioxidants glutathione (GSH) and serum urate. Also, 
lipid peroxidation and protein carbonyl contents, oxidative stress markers, were found to be significantly increased in brain, 
liver and heart. The compromised in vivo antioxidant status was strikingly analogous to the deleterious effects of restraint 
.Q stress, indicating a direct effect of stress hormones on induction of oxidative damage during physical or psychological stress. v;^  
A dose-dependent decrease of SOD and CAT, and increase in protein oxidation was observed between the high (40 mg/kg) 
and low (10 mg/kg) doses of corticosterone. The findings have fundamental implications for oxidative stress as a major 
pathological mechanism in the maladaptation to chronic stress. Thus, the study suggests that stress hormones have a causal 
role in impacting oxidative processes induced during the adaptive response. This may hold important implications for 
pharmacological interventions targeting cellular antioxidants as a promising strategy for protecting against oxidative insults in 
-, various psychiatric and non-psychiacric conditions induced by physical or psychological stress. 
vO 
40 95 
Introduction for the role of oxidative processes in physical and 
IM 
psychological stress comes from an accumulating 
. , . , . , number of rodent studies demonstrating increased 
oxidative biochemisiry m the adaptive response to ^^^^.^^ ^^^^^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^^^^ ^ ^ ^^^^.^ 
^ stress (reviewed by Melov 2002; Pardon 2007). It has ^ ^ ^ ^ ^ ^ ^^ ^ ^^^^ ^f ^ ^ ^ ^ ^ ^ ( K a ^ j ^ ^ ^ K a ^ 
been demonstrated that increased protection from 2003; Singal et al. 2005). A robust increase in basal 
oxidaave stress plays a key role m mamtaining oxidative stress has been consistendy reported by 
homeostasis and enhancing resistance to environmen- investigators employing restraint or immobilization 
tal stress in animal models (invertebrate and rodent), stress, as evidenced by increases in levels of oxidant 
_^ with a resultant increase in their longevity as observed species, such as NO over a 21-day period (Madrigal , „,. 
following antioxidant treatment (Winter 1998; Bonilla et al. 2001), with a resultant accumulation of the 
et al. 2002; Wu et al. 2002). Furthermore, evidence oxidative stress marker, lipid peroxidation (Liu et al. 
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1996; Hu et al. 2000; Olivenza et al. 2000; Madrigal 
et al. 2001; Abidin et al. 2004; Fontella et al. 2005; 
Perez-Nievas et al. 2007). Studies in our laboratory 
have also demonstrated a restraint stress-induced 
! IT decline in the primary endogenous antioxidant 
defenses, both enzymatic and non-enzymatic, in the 
brain and other target organs for stress such as liver 
(Zaidi et al. 2005; Zafir and Banu 2007) with a 
consequent increase of oxidative stress. Together, 
120 these investigations corroborate the emerging associ-
ation of oxidative stress in the maladaptive con-
sequences of chronic stress. 
The restraint stress paradigm reliably increases 
secretion of the adrenal steroid hormone, corticoster-
\2> one, due to HPA axis activation (Abidin et al. 2004). 
Glucocorticoids (corticosterone in rodents) are the 
central effectors of this stress response and promote 
adaptation. Conversely, persistently the elevated levels 
of glucocorticoids during chronic stress have dama-
1 ?o ging consequences, especially in the brain Qoels et al. 
2007). Exposure to 21 days of exogenous corticoster-
one or restraint stress results in dendritic atrophy of 
hippocampal neurons and impairment in related 
cognitive functions over the same time-period 
\:-i (Magarinos et al. 1998; Walesiuk et al. 2006). 
Administration of corticosterone is similar to the 
effects of restraint stress indicating that corticosterone 
mediates neuronal loss and neurodegeneration during 
chronic stress exposure (Watanabe et al. 1992; 
141} Manikandan et al. 2006), and associated cognitive 
impairment. A study on chronic emotional stress in 
rodents was not conclusive about whether glucocorti-
coids or other stress factors contribute to oxidative 
damage (Fontella et al. 2005), however, after acute 
145 immobilization stress, it was found that cortico-
sterone levels are specific predictors of oxidative 
damage to the brain (Perez-Nievas et al. 2007). Thus, 
in extension of these findings, we attempted to further 
investigate the contribution of chronic restraint stress 
i5(i and different oral doses of this hormone to oxidant 
produaion by an indirect approach, i.e. the con-
sequent response of endogenous antioxidant defences 
toward chronic exposure to exogenous corticosterone. 
The doses of corticosterone administered and the 
153 experimental regime were based on preliminary pilot 
studies carried out in our laboratory and the available 
literature, which showed that subcutaneous corticos-
terone doses at 40 mg/kg significantly enhanced in vivo 
circulating corticosterone levels, causing significant 
160 physiological changes such as substantial weight loss. 
Furthermore, a dose-dependent induction of depress-
ive behaviour in rodents was obtained using these 
doses (Johnson et al. 2006). The oral route was found 
equally efficacious to chronic subcutaneous adminis-
165 tration of corticosterone in causing neuronal damage 
after 21 days (Magarinos et al. 1998). With the possi-
bility, the oxidative stress is a significant pathophysio-
logical finding in major depression (Bilici et al. 2001; 
Michel et al. 2007). The present study was 
undertaken to evaluate the effects of exogenous 
corticosterone on antioxidant status within the same 
time-fi-ame as previous relevant studies. 
Among other causative factors, oxidative stress is i^ t) 
implicated in stress-induced brain damage in several 
neurological and psychiatric diseases such as stress-
induced depression (Bilici et al. 2001; Michel et al. 
2007). The neurotoxic damage exerted by 21 days of 
chronic restraint stress has been related to decreased i75 
expression of the gene encoding for glutathione 
S-transferase (GST), an important antioxidant 
enzyme (Cohen et al. 2006), which fiirther supports 
the role of oxidative stress in stress-induced neuro-
pathology. Thus, the effect of exogenous corticoster- i«'i 
one was evaluated on brain antioxidant enzyme 
activities and non-enzymatic levels, as well as the 
pathological markers of oxidative stress, lipid peroxi-
dation and protein carbonyl production. Since the 
association of stress with several non-psychiatric 
conditions is well documented, notably cardiovascular 
disease and cancer (Kugaya et al. 2000; Black and 
Garbun 2002; Mazza et al. 2007), we also investigated 
antioxidant defences in the liver and heart, the 
important peripheral target organs susceptible to 
stress-induced pathologies. To determine the con-
tributory role of stress hormones in oxidative 
processes, the effects of oral corticosterone adminis-
tration were compared with a parallel group of rats 
subjerted to restraint stress and to untreated non-
stressed controls. Moreover, to assess any possible 
dose-dependent effects, the different corticosterone 
doses were also compared with each other. 
Materials and methods 
Subjects 
Thirty male Swiss Albino rats weighing 1 0 0 - 1 2 5 g 
were used in the present study. T h e rats were housed 
(3 per cage; 6 per group) in standard laboratory 
conditions (25 ± 5°C; 5 5 % humidity) and natural 
12 h light/dark cycle (lights on 07:00 h, lights off 
19:00 h) , having free access to standard pellet chow 
(Ashirwad Industries, Chandigarh, India) and drink- 21U 
ing water ad libitum. T h e experimental protocol 
outlined below was followed during the light phase 
of the natural cycle and was in strict accordance with 
regulations and prescribed animal ethical procedures 
outlined by the Institutional Research Committee. 215 
Experimental protocol 
All rats were acclimated to laboratory conditions and 
handled daily for a week prior to experimental 220 
manipulations. In this period, rats were randomly 
assigned to weight-matched groups of six rats each, 
receiving either restraint stress or corticosterone 
185 
lit) 
195 
im 
205 
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treatment according to the experimental regimen 
presented below. Two types of controls were run in the 
present study, one imtreated non-stressed group and 
another vehicle-treated non-stressed. As there were no 
significant differences between the two groups in the 
antioxidant and oxidative parameters assayed, for 
further comparison purposes untreated non-stressed 
rats were used as controls (n = 6). 
Corticosterone treatments. A solution of corticosterone 
(Himedla, India) was prepared in 0.9% physiological 
saline (with absolute ethanol to the final concentration 
of 2.5%) and administered orally by gavage to three 
2H groups of rats (n= 6 in each group) at 10, 20 and 
40 mg corticosterone/kg body weight per day for 
21 days. 
: J( Restramt stress. Another group of rats (n = 6) was 
subjected to restraint stress at random times for 4h 
each day during the experimental period of 21 days, 
within the light period of the light/dark cycle. Restraint 
stress was performed by immobilizing rats in wire 
245 mesh restrainers, as described elseniiere (Zaiir and 
Banu 2007). 
Collection of serum and preparation of tissue homogenaus 
isi) At the end of the experimental period, all rats were 
killed imder ether anaesthesia in the light phase 
(between 08:00 and 10:00 4 h after the last restraint or 
corticosterone treatment. Blood samples were col-
lected by cardiac puncture for the separation of serum. 
255 The brain, liver and heart were rapidly removed, 
washed in ice-cold sterile physiological saline (0.9%) 
and a 10% homogenate (0.1 M. sodium phosphate 
buffer pH 7.4) was prepared. Cellular debris was 
removed by centrifugation at 10,000^ (4°C, 15min) 
2Mi and supematants were utilized for analysis. 
Biochemical parameters 
The following antioxidant enzyme activities were 
26 •) assayed according to the standardized, sensitive and 
rapid procedures specific for the substrate used in the 
assay medium xmder optimal conditions of tempera-
ture, pH and wavelength measurement during the 
time in which the reaction rate is linearly enhanced: 
Superoxide dismutase (SOD: E.C. 1.15.1.1). SOD 
activity was assayed by monitoring the inhibition of 
auto-oxidadon of pjrogallol (0.05 M Tris succinate 
buffer, pH 8.2) at 420 nm. One enzyme unit is defined 
as the amount of enzyme required to cause 50% 
inhibition of the rate of pyrogallol auto-oxidation 
(Marklund and Marklund 1974). 
Stress, corticosterone and oxidative status 3 
Catalase (CAT: 1.11.1.6). CAT activity was measured 
in 0.05 M phosphate buffer (pH 7.0) by following the 
decrease in absorbance at 240 nm due to 
decomposition of 30 mM hydrogen peroxide 
(H2O2). One enzyme unit is defined as the amount 
of enzyme decomposing 1 ji,M H2O2 per minute at 
25°C (Aebi 1984). 
Glutathione S-transferase (GST: E.C. 2.5.1.18). GST 
activity was assayed in 0.2 M phosphate buffer (pH 
6.5) after adding 1 mM 1-chloro 2, 4 dinitrobenzene 
(CDNB) and 1 mM GSH in the reaction mixture and 
following the increase of absorbance at 340 nm due to 
formation of the CDNB-GSH conjugate. One imit of 
enzyme activity is defined as the amoimt of enzyme 
catalysing the formation of 1 pM produa per min 
under the specific assay conditions (Habig et al. 1974). 
Enzyme activity was expressed as \mits per mg of protein 
(molar extinction coefficient = 9.6 X lO^M/cm). 
Glutathione reductase (GR: E.C. 1.8.1.7). GR activity 
was assayed by monitoring the oxidation of 0.1 mM 
NADPH as a decrease in absorbance at 340 nm due to 
NADPH-dependent reduction of 1.0 mM oxidized 
glutathione disulphide to glutathione by the catalytic 
action of GR (0.1 M phosphate buffer, pH 7.6). One 
unit of enzyme activity is defined as the amoimt of 
enzyme catalysing the 1 jxM NADPH per min under 
assay conditions (Carlberg and Mannervik 1975). 
Enzyme activity was calculated using a molar 
extinction coefficient of 6.22 X lO'^M/cm and 
expressed as units per milligram of protein. 
The following non-enzymatic antioxidants were 
estimated: 
Glutathione content (GSH)- Concentrations of GSH 
were determined in tissue homogenates using the 
classical thiol reagent 5, 5'-dithiobis-2-nitrobenzoic 
acid (DTNB) (0.1 M phosphate buffer, pH 7.4). The 
yellow colour developed by the reaction of GSH with 
DTNB was read at 412 nm QoUow et al. 1974). 
Urate. Serum urate levels were estimated using a 
specific commercial kit (Span Diagnostics Ltd, Surat, 
India), based on the principle that uric acid in an 
alkaline medium reduces phosphotungstic acid to 
"tungsten blue" which is measurable spectrophoto-
metncally at TlOnm. 
The following markers of oxidative stress were 
determined: 
Lipid peroxidation aldehydic product, malondialdehyde 
(MDA). Lipid peroxidation was assessed in tissues 
: N ( ) 
:«-> 
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'm 
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and serum by determining MDA (a thiobarbituric acid 
reactive species: TEARS) spectrophotometrically 
(Beuge and Aust 1978). The pink chromogen 
formed by MDA-TBA complex was detected at 
' 'i 535 nm and quantified using an extinction coefficient 
of 1.56 X lO'M/cm. 
Protein carborvjil content. Oxidative damage to proteins 
3.11) was determined spectrophotometrically at 370 nm by the 
quantification of carbonyl groups based on dieir reaction 
with the labelling agent 2,4-dinitrophenylhydrazine 
(DNPH), following protein precipitation with 20% 
richloroacetic acid (Levine et al. 1990). 
exposure significantly decreased CAT activity in the 
brain [^ 4,25 = 15.26, P < 0.001], liver [F^^s = 32.84, 
P < 0.001], heart [^4,25 = 25.53, P < 0.001] and 
serum [i<'4_25 = 16.46, P < 0.001], compared with 
controls. The decline in CAT activity after restraint 
stress was similar to that induced by any 
corticosterone dose. A significant dose-dependent 
effect of corticosterone on CAT activity was foimd in 
brain [F2.15 = 7.31, P< 0.01], Uver [P'2,15 = 20.82, 
P < 0.001], heart [Fj.is = 12.67, P < 0 . 0 5 ] and 
serum [Fa.u = 5.94, P < 0.001]. Significantly lower 
CAT activities were found in rats receiving 40 mg/kg 
corticosterone as compared to those administered 
10 mg/kg. 
395 
355 
X«) 
365 
37{l 
375 
'SD 
385 
Protein estimation. Protein content was estimated by 
the method of Lowry et al. (1951) using bovine serum 
albumin as standard. 
Statistical evaluation 
Data are expressed as group mean ± SEM (n = 6 rats 
per group) and were analysed by one-way ANOVA, 
followed by Tvkeypost hoc test for comparisons among 
treatment groups. Another ANOVA was similarly 
performed taking only the three groups receiving 
corticosterone treatments to fiirther examine a 
possible dose-response relationship. P values less 
than 0.05 were considered statistically significant. 
Results 
Effea of different doses of corticosterone and stress 
on antioxidant enzyme activities 
SOD. There was a significant decrease in SOD activity 
after chronic exogenous administration of all doses of 
corticosterone and chronic exposure to restraint stress 
in the brain [^4,25 = 48.32, P < 0.001], liver 
[^4,25 = 21.13, P < 0.001], heart [^4,25 = 62.07, 
P< 0.001] and serum [F4,25 = 56.79, F < 0.001] in 
comparison to controls (Figure lA, Table I). The 
restraint stress-induced decrease of SOD activity was 
not different fi:om the decrease caused by any dose of 
corticosterone. Comparison among the three 
corticosterone doses showed a significant dose effect 
in SOD activity in brain [Fz.is = 10.73, P< 0.01], 
heart [Fa.is = 14.34, F < 0 . 0 1 ] and serum 
[F2,i5 = 21.20, F < 0.001]. A dose-dependent effect 
on SOD activity was observed between the highest 
dose of 40 mg/kg corticosterone compared with the 
lowest dose of 10 mg/kg, but not the intermediate dose 
of 20 mg/kg. The decrease in liver SOD activity was 
not significantiy dose-related. 
CAT. As shown in Figure IB and Table I, 
corticosterone treatments and restraint stress 
GST. GST activity is shown in Figure IC and Table I. 
GST activity was significantiy less than in controls 
after exogenous corticosterone and after restraint 
stress in brain [F4,25 = 27.64, F < 0.001], liver 10^  
[F4,25 = 41.31, F< '0 .001] , heart [F4.25 = 21.54, 
F < 0.001] and serum [F4,25 = 27.70, F < 0.001]. 
Restraint stress and corticosterone administration had 
similar effects in decreasing GST activity. A significant 
dose-related effect of corticosterone in reducing GST 41 u 
activity was evident in brain [F2,i5 = 9.03, P < 0.01], 
heart [F2,i5 = 9.20, F < 0 . 0 1 ] and serum 
[^2,15 = 13-71j P < 0 . 0 0 1 ] i corticosterone at 
40 mg/kg decreased GST activity to a significantiy 
greater extent than 10 mg/kg. Significant dose-related 415 
effects of corticosterone on GST activity were not 
foimd for the liver. 
GR. GR activity is presented in Figure 1D. All doses of 420 
exogenous corticosterone as well as exposure to 
restraint stress significantiy decreased GR activity in 
brain [F4,25 = 15.03, P < 0.001], Uver [F4,25 = 27.73, 
P < 0.001] and hean [F4,25 = 6.68, P < 0.05] relative 
to controls. Restraint stress and corticosterone 42.5 
decreased GR activity similarly. A significant dose-
related effect of corticosterone in reducing GR activity 
was found in brain [F2,i5 = 8.74, P < 0.02], with the 
highest dose (40 mg/kg) being significantiy more 
effective than the lowest dose (10 mg/kg). However, 430 
dose-related effects did not reach statistical 
significance in other tissues. 
Effect of different doses of corticosterone and stress . 
on non-enzymatic antioxidant concentrations 
GSH. Alterations in GSH by corticosterone or stress 
are depicted in Figure 2A. GSH content was 
significantiy reduced versus controls by all doses of 
corticosterone and restraint stress in brain 440 
[F4.25 = 33.38, F < 0.001], liver [F4,25 = 42.32, 
F < 0.001] and heart [F4,25 = 40.16, F < 0 . 0 5 ] . 
There were no significant differences between 
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Figure 1 Effect of different doses of chronic coracosterone adminisiraaon (10,20 and 40 mg/kg CORT, p o for 21 days) or chronic restraint 
stress (4h/day for 21 days) on antioxidant enzyme activities (A) superoxide disfflutase (SOD), (B) catalase (CAT), (C) glutathione S-
mnsferase (GST) and (D) glutathione reductase (GR) in bram, liver and heart of experimental rats All doses of CORT as well as restraint 
stress caused significant decreases m anooxidant enzyme activities compared with controls The effects of CORTwere not statistically different 
from restiamt 40 mg/kg CORT decreased all antioxidant enzyme activines to a sigmficantly greater extent than 10 mg/kg m brain A similar 
dose-related response was evident for enzymes in other tissues, except SOD and GST m liver, and GR m hver and heart Values shown for each 
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Table I Effect of different doses of chronic corticosterone administrauon (10,20 and 40 mg/kg CORT, p o for 21 days) and chronic restraint 
stress (4 h/day for 21 days) on serum levels of antioxidant defences and oxidative stress markers 
Group SOD (U/mg protein) CAT (U/mg protein) GST (U/mg protein) Urate (mg/dl) MDA(nmol/mg protein) 
Control 
Restraint stress 
CORT 10 mg/kg 
CORT 20 mg/kg 
CORT 40 mg/kg 
19 11 2: 0 89 
9 90* ± 0 71 
13 20* t 1 08 
10 51*2:0 45 
8 04*# s 0 33 
1 18 ± 0 13 
0 53* = 0 10 
0 66* i 0 02 
0 61* ± 0 05 
0 38*# ± 0 06 
0 ISr 001 
0 09* r 0 02 
0 12* ± 0 01 
0 10* ± 0 01 
0 06*# ± 0 01 
3 29 ± 0 37 
1 76* ± 0 33 
2 14*± 0 14 
1 69* ± 0 17 
1 28*# ± 0 14 
0 15 ± 0 02 
0 37* ± 0 05 
0 34* ± 0 03 
0 41* ± 0 03 
0 43* ± 0 03 
p^() SOD superoxide dismutase, CAT catalase, GST glutathione S-transfcrase, MDA malondialdehyde Values shown for each group are the 
mean ± SEM (n = 6) *P < 0 05 for all groups as compared to controls, # P < 0 05 for 20 mg/1^ CORT and 40 mg/kg CORT as compared to 
10 mg/kg CORT (Tukey post hoc test) 
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Figure 2 Effect of different doses of chrome comcosterone administration (10,20 and 40mg/kg CORT, p o for 21 days) or chronic restramt 
stress (4 h/day for 21 days) on (A) glutathione (GSH) levels, (B) hpid perojadanon (malondialdehyde, MDA) and (C) protem carbonyl 
contents m bram, Uver and heart of experimental rats All doses of CORT and restramt stress significantly decreased GSH concentrations and 
significantly mcreased lipid peroxidation and protem carbonyl contents compared with controls The effects of CORT were not sigmficantly 
different bom restnunL 40 mg/kg CORT decreased GSH level to a sigmficantly greater extent than 10 mg/kg m bram, and increased protein 
carbonyl contents more effectively m all tissues Values shown for each group are the mean ± SEM (n = 6) 
*P < 0 05 as compared to controls, # P < 0 05 as compared to 10 mg/kg CORT (Tukey post hoc test) 
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Figure 3. Effect of chronic corticosterone administration (10,20 and 40 mg/kg CORT, p.o. for 21 days) or chronic restraint stress (4 h/day 
for 21 days) on body weight of lats, measured every 7 days. All doses of CORT and restraint stress significantly decreased body weight 
compared to controls. The effects of CORT were not statistically different from restraint. Values are group mean I SEM (n = 6). *P < 0.05 as 
compared to controls (Tukcy pon hoc test). 
restraint stress and corticosterone for decreased GSH 
levels. In the brain, significant differences in GSH 
levels were observed among corticosterone doses 
[^ 2,15 = 10.58, P < 0.01]. Corticosterone at 40 mg/kg 
was more effective than 10 mg/kg. No such dose-
related effects were foimd for other tissues. 
Urate. In comparison to control rats, administration of 
corticosterone significantly decreased sertun urate 
concentration [F4,25 = 30.74, P < 0.001; Table I\. 
Restraint stress induced a similar decrease in serum 
urate to corticosterone administration. Corticosterone 
had dose-dependent effects on serum urate 
concentration [Fj.is = 21.60, P< 0.001]. 
Effea of different doses of corticosterone and stress 
on other oxidative stress markers 
Lipid peroxidation. Exogenous corticosterone and 
restraint stress significantly increased concentrations 
of the aldehydic product of lipid peroxidation, i.e. 
malondialdehyde (MDA) (Figure 2B and Table I) in 
the brain [^ ='4,25 = 29.51, P < 0.001], liver 
[F4,25 = 10.10, P < 0.001], heart [F4,25 = 10.91, 
P< 0.001], and serum [^ 4,25 = 3.91, F < 0 . 0 1 ] , as 
compared to controls. There were no significant 
corticosterone dose-related effects. The increase in 
MDA levels by exposure to restraint stress was similar 
to that after corticosterone treatment. 
Protein carbonyl production. Corticosterone and 
restraint stress significantly enhanced protein 
carbonyl contents (Figure 2C) in the brain 
[^4,25 = 109.95, P < 0.001], liver [^ 4^ 25 = 34.38, 
P < 0.001] and heart [5*^5 = 36.10, P < 0.001] as 
compared to untreated controls. Effect of 
corticosterone was significantly dose-related in brain 
[^2,15 = 9.58, P < 0 . 0 1 ] , liver [F2.15 = 11-73, 
P < 0.001] and heart [Fz.is = 4.55, P < 0 . 0 5 ] ; 
corticosterone at 40 mg/kg was more effective than 
10 mg/kg. 
Effect of different doses of corticosterone and stress 
on body weight 
Figure 3 shows treatment effects on body weights. In 
contrast to controls, all doses of exogenous corticos-
terone significantly decreased body weight over the 
treatment period of 21 days, as did chronic exposure 
to restraint stress. Loss of weight due to corticosterone 
treatment, or restraint, was evident from the first week 
onward and remained significant thereafter [day 7: 
F4^5 = 26.41, P < 0.001; day 14: F4,25 = 63.66, 
P < 0.001 and day 21: F4,25 = 77.80, P < 0.001]. 
Discussion 
To date, few studies have investigated direa corre-
lations between the induction of oxidative damage 
under stress and the magnitude of exposure to stress 
hormones. Important findings in the available 
literature come fi'om the work of Perez-Nievas and 
coworkers (Perez-Nievas et al. 2007). They have 
demonstrated that the increase in the levels of 
circulating corticosterone after acute icnmobilization 
is directly proportional to the increase in oxidative 
mediators, thereby predicting the degree of stress-
induced brain damage imder these conditions. These 
findings suggest that the response of counter-acting 
antioxidant enzymes may be overwhelmed upon 
further increases in oxidative stress with chronic 
stress, although this was not verified in that study. 
In this regard, past studies have demonstrated that 
exposure for 3 dajrs to exogenous glucocorticoids 
decreased brain SOD and CAT activities (Mcintosh 
et al. 1998a, b), and in vitro, it was also shown that 
corticosterone reduces GPx activity (Patel et al. 
2002). The present work was carried out to extend 
725 
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these fmdings. The objective was to investigate a 
possible direct contribution of stress hormones to 
oxidative processes, by chronic administration of 
exogenous corticosterone in the absence of other 
"'"1 applied stressors. In summary, the main outcome of 
this approach was a coordinate decline in a wide 
range of enzymatic and non-enzymatic antioxidant 
defence components in response to all doses of 
corticosterone employed. Our results confirm that the 
7S0 effects of chronically administered corticosterone on 
induction of oxidative stress are similar to that 
induced by a moderate physical and psychological 
stressor (restraint stress; Fontella et al. 2005; Zafir and 
Banu 2007). The diminished antioxidant status was 
-\s evident not only in the brain of experimental rats, but 
also in imponant peripheral target organs for stress, 
such as liver and heart. In all organs studied, a dose-
related effect of corticosterone was found for the most 
important antioxidant enzymes, SOD and CAT; a 
"•xi similar dose-related effect of corticosterone was found 
for these enzymes in the circulation, and on protein 
oxidation in the organs. 
During the stress response, essential catabolism is 
increased by glucocorticoids, which are the principal 
795 effectors of these adaptive changes. However, continu-
ous stress-enhanced metabolism is associated with the 
increased production of oxidant species that ultimately 
increase oxidative stress to a damaging extent (Liu and 
Mori 1999). A prolonged stress response mediated by 
8(1)) glucocorticoids can also have negative effects on 
important cellular adaptations in the brain, thereby 
causing neuronal loss and suppressing neurogenesis 
dtiring chronic exposure to stress Qoels et al. 2007). 
The importance of altered structure-fimction relation-
'Mi^ ships is evident firom behavioural aberrations such as 
impaired cognitive function related to neuronal 
atrophy in the relevant brain region (for e.g. 
hippocampus; Manikandan et al. 2006). Of further 
significance is the observation that increased oxidative 
s J CI stress has also been foimd to occur in these key areas of 
the brain after chronic stress, contributing to and 
exacerbating neurodegeneration in stress-related dis-
orders, such as volume reduction in the brain of 
depressed patients due to morphological changes 
»I5 (Michel et al. 2007). The impact of stress hormones 
on brain function is thus significandy related to chronic 
stress-induced oxidative processes. In this context, it is 
also notable that accumulating evidence now impli-
cates oxidative stress in the adaptive stress response. 
x20 It is increasingly being established in various animal 
models that an inability to balance oxidant-antiox-
idant interactions is accompanies greater susceptibility 
to various types of stress (Winter 1998; Bonilla et al. 
2002). Combating oxidative stress is thus relevant to 
X25 maintaining homeostasis, and is linked to protection 
from the deleterious consequences of stress. 
Besides the brain, a response to stress is also 
manifested in peripheral organ systems and is 
associated with oxidative stress in these organs as 
well (Hu et al. 2000; Kaushik and Kaur 2003). 
Consistent with this view, and apparent in the present 
work, the restraint stress model has been shown to 
reliably produce robust increases in basal oxidative '^ ji.' 
stress in different organs by various investigators as 
well as previous work in our laboratory (Liu et al. 
1996; Madrigal et al. 2001; Zafir and Banu 2007). 
To clarify the causal versus consequential role of stress 
hormones in stress-related oxidative processes, we S'.'i 
studied the effect of chronic administration of 
corticosterone in the absence of other applied 
stressors. Importantly, we observed that the maimer 
by which exogenous corticosterone compromised 
in vivo antioxidant status in experimental rats was S4ii 
strikingly analogous to the deleterious effects of 
restraint stress, indicating a likely direct effect of glu-
cocorticoid hormones on the induction of oxidative 
stress during physical and psychological stress. 
Efficient cellular antioxidant mechanisms serve to s;^ 
counterbalance the potential deleterious effects of 
ROS and reduce oxidative stress. In spite of this, the 
brain is very sensitive to oxidative damage due to its 
much greater oxygen requirements that enhance 
oxidant production (Cui et al. 2004). A significant 850 
decline in the activities of both of the important 
antioxidant enzymes SOD and CAT by exogenous 
corticosterone signifies enhanced vulnerability toward 
the primary ROS, superoxide anion (dismutated by 
SOD) and hydrogen peroxide (metabolised by CAT). 5^5 
The damaging effects of both of these species is 
especially manifested in their interaction to generate 
hydroxy! radicals, the most destructive ROS to cellular 
integrity, causing widespread damage to all macro-
molecules, including proteins, nucleic acids, and lipids 86<) 
(Ctii et al. 2004). Adding to this extensive cellular 
oxidative damage, corticosterone also significandy 
depleted serum urate, a major circulating non-
enzymatic antioxidant molecule that functions in the 
aqueous phase as a scavenging/chain-breaking anti- 865 
oxidant. Moreover, treatment with all doses of 
exogenous corticosterone was foimd to significandy 
reduce levels of the major non-enzymatic thiol 
antioxidant GSH, together with decreasing activities 
of the GSH-metabolising enzymes, GST and GR. S'O 
This GSH system has multifunctional roles in 
combating oxidative stress via direct scavenging of 
free radicals, detoxification of electrophilic com-
pounds, modulation of cellular redox status and 
thiol-disulphide status of proteins, and regulation of S7s 
cell signalling and repair pathways (Cnubben et al. 
2001). Thus, an aberration in this critical second line 
of cellular defence against ROS further intensifies 
oxidative stress by corticosterone. This is supported 
by recent findings that 21 days of daily restraint stress $80 
significandy decreased the gene expression of Gstp2, 
wiiich codes for GST (Cohen et al. 2006). These 
authors related this downregulation to increased 
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oxidative stress observed upon chronic exposure to 
restraint, accounting, in part, for the structural and 
functional damage to the brain in this condition. 
Drawing a parallel from our results, it may possibly be 
8S5 inferred that such stress-induced oxidative and 
neurotoxic damage during physical and psychological 
stress could be directly mediated by glucocorticoids. 
Reduction in GSH level is also a signalling event in 
apoptosis (Sato et al. 1995), while a major neuronal 
891) defence mechanism against apoptotic cell death is 
upregulation of SOD (Greenlimd et al. 1995). Thus, 
an overall corticosterone-induced decline in not only 
SOD activity and GSH level, but also in the activities 
of other enzymes working in conjxmction with them 
sy? (CAT, GST and GR) may strongly promote neurode-
generation, as evidenced by atrophy of brain regions 
observed in stress-induced depression (Michel et al. 
2007). A dose-related response of all these endogen-
ous antioxidants toward corticosterone in the brain 
>>K! might thus be related to the previously demonstrated 
dose-dependent effects of corticosterone in eliciting 
depressive behaviour in rodents (Johnson et al. 2006). 
Although such a relation needs to be fiirther 
investigated, however, it is supported by a growing 
yxi body of evidence for oxidative stress as a major 
pathological finding in depression (Bilici et al. 2001; 
Michel et al. 2007). The results of the present study on 
the effect of exogenous corticosterone in decreasing 
antioxidant defences correlates well with the earlier 
910 finding where enhancement of oxidative stress in bran 
could be predicted by endogenous plasma corticos-
terone levels (Perez-Nievas et al. 2007). Therefore, 
the data presented here indicating a substantial 
decline in key components of the antioxidant defence 
')15 system by corticosterone, parallel to the effects of 
restraint stress, point to a key role of glucocorticoids in 
initiating stress-induced oxidative damage. 
This is further corroborated by the observed 
amplification in markers of oxidative stress, peroxi-
920 dation and protein oxidation, by corticosterone 
treatment. These secondary effects of oxidative stress 
have particularly great potential to affect several 
aspects of brain fimction, due to the high content of 
oxidisable polyunsaturated fatty acids in the brain. 
92.') Peroxidation of lipids has disruptive potential by 
altering membrane viscosity, fluidity, permeability, 
and impairing the functions of membrane transport 
proteins and ion chaimels, thereby adversely affecting 
electrical potential and controlled transport of 
'AiO metabolites across membrane (Mattson 1998; 
Cui et al. 2004). Protein oxidation directiy affects 
the structure of the cell, enzymatic processes such as 
metabolism, and also cell signalling pathways, as well 
as inducing the accumulation of oxidized proteins and 
935 enhancing cellular dysfunction (Stadtman 2000). In 
the present study a significant dose-related effect of 
exogenous corticosterone on lipid peroxidation was 
not observed as reported by Perez-Nievas et al. (2007). 
However, a dose-dependent increase in another 
marker of oxidative stress, protein carbonyl content, 
was observed in all organs. This apparently signifies 
the impaa of stress in disrupting homeostasis at the 
cellular level, due to the critical involvement of "^ o 
proteins in maintaining all vital intracellular functions. 
This finding is important because protein oxidation 
events are linked to the pathology of several diseases as 
well as aging processes (Stadtman and Levine 2000). 
Thus the present study is also of interest in relation 945 
to the role of oxidative stress as a crucial link between 
stress and the development of disease, including 
associations foimd between psychiatric and non-
psychiatric conditions, particularly cancers and cardi-
ovascular disease (Mazza et al. 2007). For example, v50 
psychological stress is a recognized major risk factor 
for cardiovascular disease (Wittstein et al. 2005). It is 
possible that insufficiencies in the antioxidant system 
imposed by stress hormones, as evidenced by our 
present results, may underlie stress-induced degen- v55 
erative diseases affecting various organs and their 
physiological fimctions. Our finding thus also corro-
borates the involvement of oxidative stress in 
physiological damage exerted on major organ systems 
during exposure to chronic stress, as a putative ''w) 
mechanism for stress-induced disease. In this regard, a 
corticosterone dose-related response was especially 
evident in the brain, denoting greater vulnerability to 
oxidative stress during chronic phjfsical and psycho-
logical stress. The dose-related effect of corticosterone 965 
in the heart was foimd for SOD, CAT and GST, while 
in the liver, only CAT activity was affeaed in this 
manner. This result could be interpreted in a general 
way to mean that the heart is more susceptible to the 
adverse effects of stress-induced oxidative damage 970 
than the liver, and thus partially account for the stress-
induced onset of cardiovascular disease. Therefore, 
pharmacological interventions targeting cellular anti-
oxidants may be a promising stress management 
strategy for protecting against stress-induced disease. 97.'> 
Indeed, animal studies show that negative conse-
quences of stress are amenable to improvement by 
antioxidant intervention acting through various path-
wa)?s to enhance resistance to stress (Winter 1998; 
Bonilla et al. 2002, Pardon et al. 2004). 9S0 
Finally, oxidative damage induced by corticosterone 
was found to be associated with decreased body 
weight, an "orgaruc correlate of stress effects" 
(Sapolsky et al. 2000). The present study confirms 
previous reports of substantial weight loss during 9K5 
exposure to repeated stress, and decreased body 
weight gain due to administration of glucocorticoids 
(Magarinos et al. 1998; Johnson et al. 2006). 
In conclusion, to the best of our knowledge, this is 
the first comprehensive study that has evaluated and 990 
clearly demonstrated damaging changes in oxidative 
status in vital organs of experimental rats, specifically 
brain, liver and heart, following chronic glucocorti-
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cioid treaonent. The finding that similar changes 
resulted from chronic restraint stress suggests that 
glucocorticoids have a causal role in impacting 
oxidative processes during the adaptive response to 
y')5 chronic physical and psychological stress. 
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